Alternating pressure (active) air surfaces for preventing pressure ulcers

DOI: 10.1002/14651858.CD013620.pub2

Document Version
Final published version

Link to publication record in Manchester Research Explorer

Citation for published version (APA):

Published in:
Cochrane Database of Systematic Reviews

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Alternating pressure (active) air surfaces for preventing pressure ulcers

Editors: Cochrane Wounds Group

Contact Person: Chunhu Shi (chunhu.shi@manchester.ac.uk)

Division of Nursing, Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, Greater Manchester, M13 9PL, UK


[1] Division of Nursing, Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

[2] Division of Population Health, Health Services Research & Primary Care, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

[3] Nursing Research Institute, St Vincent's Health Australia (Sydney) and Australian Catholic University (ACU), School of Nursing, Midwifery and Paramedicine, Australian Catholic University, Darlinghurst, Australia

[4] Nursing Research Institute, St Vincent’s Health Australia Sydney, St Vincent’s Hospital Melbourne & Australian Catholic University, Fitzroy, Melbourne, Australia

Citation


Dates
Abstract

Background

Pressure ulcers (also known as pressure injuries, pressure sores, decubitus ulcers and bed sores) are localised injuries to the skin or underlying soft tissue, or both, caused by unrelieved pressure, shear or friction. Alternating pressure (active) air surfaces are widely used with the aim of preventing pressure ulcers.

Objectives

To assess the effects of alternating pressure (active) air surfaces (beds, mattresses or overlays) compared with any support surface on the incidence of pressure ulcers in any population in any setting.

Search methods

In November 2019, we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE (including In-Process & Other Non-Indexed Citations); Ovid Embase and EBSCO CINAHL Plus. We also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta-analyses and health technology reports to identify additional studies. There were no restrictions with respect to language, date of publication or study setting.

Selection criteria

We included randomised controlled trials that allocated participants of any age to alternating pressure (active) air beds, overlays or mattresses. Comparators were any beds, overlays or mattresses.

Data collection and analysis

At least two review authors independently assessed studies using predetermined inclusion criteria. We carried out data extraction, 'Risk of bias' assessment using the Cochrane 'Risk of bias' tool, and the certainty of the evidence assessment according to Grading of Recommendations, Assessment, Development and Evaluations methodology.

Main results

We included 32 studies (9058 participants) in the review. Most studies were small
(median study sample size: 83 participants). The average age of participants ranged from 37.2 to 87.0 years (median: 69.1 years). Participants were largely from acute care settings (including accident and emergency departments). We synthesised data for six comparisons in the review: alternating pressure (active) air surfaces versus: foam surfaces, reactive air surfaces, reactive water surfaces, reactive fibre surfaces, reactive gel surfaces used in the operating room followed by foam surfaces used on the ward bed, and another type of alternating pressure air surface. Of the 32 included studies, 25 (78.1%) presented findings which were considered at high overall risk of bias.

**Primary outcome: pressure ulcer incidence**

Alternating pressure (active) air surfaces may reduce the proportion of participants developing a new pressure ulcer compared with foam surfaces (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.34 to 1.17; \( I^2 = 63\% \); 4 studies, 2247 participants; low-certainty evidence). Alternating pressure (active) air surfaces applied on both operating tables and hospital beds may reduce the proportion of people developing a new pressure ulcer compared with reactive gel surfaces used on operating tables followed by foam surfaces applied on hospital beds (RR 0.22, 95% CI 0.06 to 0.76; \( I^2 = 0\% \); 2 studies, 415 participants; low-certainty evidence).

It is uncertain whether there is a difference in the proportion of people developing new pressure ulcers between alternating pressure (active) air surfaces and the following surfaces, as all these comparisons have very low-certainty evidence: (1) reactive water surfaces; (2) reactive fibre surfaces; and (3) reactive air surfaces.

The comparisons between different types of alternating pressure air surfaces are presented narratively. Overall, all comparisons suggest little to no difference between these surfaces in pressure ulcer incidence (7 studies, 2833 participants; low-certainty evidence).

Included studies have data on time to pressure ulcer incidence for three comparisons. When time to pressure ulcer development is considered using a hazard ratio (HR), it is uncertain whether there is a difference in the risk of developing new pressure ulcers, over 90 days’ follow-up, between alternating pressure (active) air surfaces and foam surfaces (HR 0.41, 95% CI 0.10 to 1.64; \( I^2 = 86\% \); 2 studies, 2105 participants; very low-certainty evidence). For the comparison with reactive air surfaces, there is low-certainty evidence that people treated with alternating pressure (active) air surfaces may have a higher risk of developing an incident pressure ulcer than those treated with reactive air surfaces over 14 days' follow-up (HR 2.25, 95% CI 1.05 to 4.83; 1 study, 308 participants). Neither of the two studies with time to ulcer incidence data suggested a difference in the risk of developing an incident pressure ulcer over 60 days' follow-up between different types of alternating pressure air surfaces.

**Secondary outcomes**

The included studies have data on (1) support-surface-associated patient comfort for comparisons involving foam surfaces, reactive air surfaces, reactive fibre surfaces and alternating pressure (active) air surfaces; (2) adverse events for comparisons involving foam surfaces, reactive gel surfaces and alternating pressure (active) air surfaces; and (3) health-related quality of life outcomes for the comparison involving foam surfaces. However, all these outcomes and comparisons have low or very low-certainty evidence and it is uncertain whether there are any differences in these
outcomes.

Included studies have data on cost effectiveness for two comparisons. Moderate-certainty evidence suggests that alternating pressure (active) air surfaces are probably more cost-effective than foam surfaces (1 study, 2029 participants) and that alternating pressure (active) air mattresses are probably more cost-effective than overlay versions of this technology for people in acute care settings (1 study, 1971 participants).

**Authors' conclusions**

Current evidence is uncertain about the difference in pressure ulcer incidence between using alternating pressure (active) air surfaces and other surfaces (reactive water surfaces, reactive fibre surfaces and reactive air surfaces). Alternating pressure (active) air surfaces may reduce pressure ulcer risk compared with foam surfaces and reactive gel surfaces used on operating tables followed by foam surfaces applied on hospital beds. People using alternating pressure (active) air surfaces may be more likely to develop new pressure ulcers over 14 days' follow-up than those treated with reactive air surfaces in the nursing home setting; but as the result is sensitive to the choice of outcome measure it should be interpreted cautiously. Alternating pressure (active) air surfaces are probably more cost-effective than reactive foam surfaces in preventing new pressure ulcers.

Future studies should include time-to-event outcomes and assessment of adverse events and trial-level cost-effectiveness. Further review using network meta-analysis will add to the findings reported here.

**Plain language summary**

Do beds, mattresses and mattress toppers with air-filled surfaces that regularly redistribute pressure under the body prevent pressure ulcers?

**Key messages**

Beds, mattresses and mattress toppers that regularly redistribute pressure under the body may reduce the chance of pressure ulcers developing when compared with surfaces that:

- apply a constant pressure to the skin; and
- are made of foam or gel.

However, they may increase the risk of pressure ulcers developing among nursing home residents when compared with air surfaces that apply constant pressure.

More research is needed to strengthen the evidence that compares air-filled and other surfaces. Future studies should focus on effects that are important to decision-makers, including:
- whether and when pressure ulcers develop;  
- unwanted effects; and  
- costs.

**What are pressure ulcers?**

Pressure ulcers are also known as pressure sores or bed sores. They are wounds to the skin and underlying tissue caused by prolonged pressure or rubbing. They often occur on bony parts of the body, such as heels, elbows, hips and the bottom of the spine. People who have mobility problems or who lie in bed for long periods are at risk of developing pressure ulcers.

**What did we want to find out?**

There are beds, mattresses and mattress toppers specifically designed for people at risk of pressure ulcers. These can be made of a range of materials (such as foam, air cells or water bags) and are divided into two groups:

- reactive (static) surfaces that apply a constant pressure to the skin, unless a person moves or is repositioned; and  
- active (alternating pressure) surfaces that regularly redistribute the pressure under the body.

We wanted to find out if active, air-filled surfaces:

- prevent pressure ulcers;  
- are comfortable and improve people’s quality of life;  
- have health benefits that outweigh their costs (cost-effectiveness); and  
- have any unwanted effects.

**What did we do?**

We searched the medical literature for studies that evaluated the effects of beds, mattresses and mattress toppers with an active, air-filled surface. We compared and summarised their results, and rated our confidence in the evidence, based on factors such as study methods and sizes.

**What did we find?**

We found 32 studies (9058 people, average age: 69 years) that lasted between three and 180 days (average: 14 days). The studies compared active, air-filled surfaces with:

- foam, fibre, water-filled or gel surfaces; and  
- other air-filled surfaces.

**Pressure ulcer prevention**

The evidence suggests that active, air-filled surfaces may reduce the risk of pressure ulcers developing when compared with:

- foam surfaces;  
- gel surfaces used on operating tables followed by foam surfaces used on hospitals beds, for people who undergo surgery.

However, active, air-filled surfaces may increase the risk of pressure ulcers developing when compared with reactive air surfaces (1 study, 308 nursing home
residents, duration: 14 days).

It is unclear if active air-filled surfaces prevent pressure ulcers compared with surfaces other than reactive foam, gel or air-filled surfaces.

The type of active, air-filled surface used may make little to no difference for preventing pressure ulcers.

**Other effects**

Active, air-filled surfaces are probably more cost-effective than foam. Mattresses with an active, air-filled surface are probably more cost-effective than mattress toppers with the same surface.

We did not find sufficiently robust and clear evidence to determine how active, air-filled surfaces affect comfort, quality of life and unwanted effects.

**What limited our confidence in the evidence?**

Most studies were small (83 people on average) and more than two-thirds of them (25) used methods likely to introduce errors in their results.

**How up-to-date is this review?**

The evidence in this Cochrane Review is current to November 2019.

---

**Summary of findings**

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Risk with foam surfaces</th>
<th>Risk with alternating pressure (active) air surfaces</th>
<th>Relative effect (95% CI)</th>
<th>Nº of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of participants developing a new pressure ulcer Follow-up: median 90 days</td>
<td>Study population</td>
<td>RR 0.63 (0.34 to 1.17)</td>
<td>104 per 1,000 (35 to 122)</td>
<td>2247 (4 RCTs)</td>
<td>⊕⊕⊝⊝ Lowa,b</td>
<td>Alternating pressure (active) air surfaces may reduce the proportion of participants developing a new pressure ulcer compared with foam surfaces.</td>
<td></td>
</tr>
<tr>
<td>Outcome</td>
<td>Study population</td>
<td>HR (95% CI)</td>
<td>N (RCTs)</td>
<td>GRADE</td>
<td>Comment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-----------------</td>
<td>-------------</td>
<td>---------</td>
<td>-------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to pressure ulcer development</td>
<td></td>
<td>0.41 (0.10 to 1.64)</td>
<td>2105 (2 RCTs)</td>
<td>Very low</td>
<td>It is uncertain if there is any difference in the risk of developing a new pressure ulcer at any time point up to 90 days when alternating pressure (active) air surfaces are compared with foam surfaces.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support surface-associated patient comfort</td>
<td>Sauvage 2017</td>
<td>-</td>
<td>76 (1 RCT)</td>
<td>Very low</td>
<td>It is uncertain if there is any difference in support surface-associated patient comfort between alternating pressure (active) air surfaces and foam surfaces.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All reported adverse events</td>
<td>Nixon 2019 and Sauvage 2017</td>
<td>-</td>
<td>2181 (3 RCTs)</td>
<td>Very low</td>
<td>It is uncertain if there is any difference in all reported adverse events between alternating pressure (active) air surfaces and foam surfaces.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health-related quality of life (90-day EQ-5D-5L, expressed as utility values ranging from −1 to 1 with 1 representing perfect health, 0 representing death, and −1 representing worse than death)</td>
<td>The mean health-related quality of life (90-day EQ-5D-5L) was 0.52.</td>
<td>MD 0.00 (0.05 lower to 0.05 higher)</td>
<td>267 (1 RCT)</td>
<td>Low</td>
<td>It is unclear if there is a difference in health-related quality of life measured using EQ-5D-5L at 90-day follow-up between alternating pressure (active) air surfaces and foam surfaces.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health-related quality of life (90-day PU-QoL-UI, expressed as utility values ranging from −1 to 1 with 1 representing perfect health, 0 representing death, and −1 representing worse than death)</td>
<td>The mean health-related quality of life (90-day PU-QoL-UI) was 0.50.</td>
<td>MD 0.00 (0.03 lower to 0.03 higher)</td>
<td>233 (1 RCT)</td>
<td>Low</td>
<td>It is unclear if there is a difference in health-related quality of life measured using PU-QoL-UI at 90-day follow-up between alternating pressure (active) air surfaces and foam surfaces.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
utility values ranging from −1 to 1 with 1 representing perfect health, 0 representing death, and −1 representing worse than death) Follow-up: 90 days

Cost-effectiveness Follow-up: 90 days

| Cost-effectiveness ratio (ICER) = GBP −101699 and Net Monetary Benefit (NMB) = GBP −2114 in the probabilistic analysis, meaning alternating pressure (active) air surfaces has lower costs and higher quality-adjusted life-year (QALY) values. Alternating pressure (active) air surfaces had a 99% probability of being cost-effective at a threshold of GBP 20,000 and alternating pressure (active) air surfaces dominated reactive foam surfaces. | 1 RCT | Moderate |

Alternating pressure (active) air surfaces are probably cost-effective compared with reactive foam surfaces.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; RR: risk ratio; HR: hazard ratio; MD: mean difference

GRADE Working Group grades of evidence

**High certainty**: we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty**: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty**: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

**Very low certainty**: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

aDowngraded once for risk of bias (2 studies with about 50% of weight in the analysis had either 1 domain other than performance bias at high risk of bias or all domains at unclear risk of bias; 2 studies with about 50% of weight in the analysis had domains other than performance bias at unclear risk of bias).

bDowngraded once for moderate imprecision because, even though the optimal information size (OIS) was met, the wide confidence interval crossed RR = 0.75.

cDowngraded once for high risk of bias in 1 study with 40% of analysis weight but low risk of bias in domains other than performance bias in another study.

dDowngraded twice for substantial inconsistency ($I^2 = 86\%$; $\chi^2$ test $P = 0.009$; point estimates and confidence intervals largely vary between studies).

eDowngraded twice for high risk of detection bias.

fDowngraded once for imprecision due to small sample size.

gDowngraded once for unclear risk of bias in 2 studies with about half weight.

hDowngraded twice for substantial inconsistency.

iDowngraded twice for substantial imprecision due to small sample size.

jDowngraded once for imprecision for the EQ-5D-5L outcome of the relevant study.
## Summary of findings 2

### Alternating pressure (active) air surfaces compared with reactive air surfaces for pressure ulcer prevention

**Patient or population:** pressure ulcer prevention  
**Setting:** any care setting  
**Intervention:** alternating pressure (active) air surfaces  
**Comparison:** reactive air surfaces

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects * (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
</table>
| **Proportion of participants developing a new pressure ulcer**  
Follow-up: median 14 days  
Risk with reactive air surfaces | Study population | RR 1.61 (0.90 to 2.88) | 1648 (6 RCTs) | ☺☺☺☺ Very low<sup>a,b</sup> | It is uncertain if the proportion of people developing a new pressure ulcer is decreased or increased when alternating pressure (active) air surfaces are compared with reactive air surfaces.  
Risk with alternating pressure (active) air surfaces | 22 per 1,000 (20 to 64) | 36 per 1,000 (20 to 64) | |
| **Time to pressure ulcer development**  
Follow-up: 14 days  
Risk with reactive air surfaces | Study population | HR 2.25 (1.05 to 4.83) | 308 (1 RCT) | ☺☺☺ Low<sup>c</sup> | People treated with alternating pressure (active) air surfaces may have a higher risk of developing an incident pressure ulcer than those treated with reactive air surfaces at any time within 14 days.  
Risk with alternating pressure (active) air surfaces | 52 per 1,000 (54 to 227) | 113 per 1,000 (54 to 227) | |
| **Support surface-associated patient comfort**  
Follow-up: median 11 days  
Three studies appeared to report equivalent comfort between their study arms (Cavicchioli 2007; Jiang 2014; Price 1999) whilst Finnegan 2008 seemed to suggest that the use of alternating pressure (active) air surfaces was associated with better comfort than reactive air surfaces. | - | - | 1364 (4 RCTs) | ☺☺☺☺ Very low<sup>d,e</sup> | It is uncertain if there is any difference in support surface-associated patient comfort between alternating pressure (active) air surfaces and reactive air surfaces.  
Included studies did not report this outcome. |
### Summary of findings 3

**Alternating pressure (active) air surfaces compared with reactive water-filled surfaces for pressure ulcer prevention**

Patient or population: pressure ulcer prevention  
Setting: any care setting  
Intervention: alternating pressure (active) air surfaces  
Comparison: reactive water-filled surfaces

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects * (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No. of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Proportion of participants developing a new pressure ulcer  
Follow-up: median 10 days | Risk with reactive water-filled surfaces  
Study population | RR 1.21 (0.52 to 2.83) | 358 (2 RCTs) | ☹☹☹☹ Very low | It is uncertain if the proportion of people developing a new pressure ulcer is decreased or increased when alternating pressure (active) air surfaces are compared with reactive water surfaces.  
52 per 1,000  
63 per 1,000 (27 to 148) | Risk with alternating pressure (active) air surfaces |  |  |  | |
**Time to pressure ulcer development**

Included studies did not report this outcome.

**Support surface-associated patient comfort**

Included studies did not report this outcome.

**All reported adverse events**

Included studies did not report this outcome.

**Health-related quality of life**

Included studies did not report this outcome.

**Cost effectiveness**

Included studies did not report this outcome.

**GRADE Working Group grades of evidence**

- **High certainty**: we are very confident that the true effect lies close to that of the estimate of the effect.
- **Moderate certainty**: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- **Low certainty**: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
- **Very low certainty**: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of the effect.

*a* Downgraded twice for high risk of detection bias in 1 study with more than 60% analysis weight and unclear overall risk of bias in another study.

*b* Downgraded twice for substantial imprecision as the OIS was not met and the confidence interval was very wide and crossed RRs = 0.75 and 1.25.

---

**Summary of findings 4**

**Alternating pressure (active) air surfaces compared with reactive fibre surfaces for pressure ulcer prevention**

**Patient or population:** pressure ulcer prevention  
**Setting:** acute care setting  
**Intervention:** alternating pressure (active) air surfaces  
**Comparison:** reactive fibre surfaces

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects</th>
<th>Risk with reactive fibre surfaces</th>
<th>Risk with alternating pressure (active) air surfaces</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Proportion of participants developing a new pressure ulcer  
Follow-up: range 17.7 days to 3 months. | Study population | Risk with reactive fibre surfaces  
424 per 1,000 | Risk with alternating pressure (active) air surfaces  
381 per 1,000 (288 to 504) | RR 0.90 (0.68 to 1.19) | 285 (3 RCTs) | ⊕ ⊝ ⊝ ⊝ Very low | It is uncertain if the proportion of people developing a new pressure ulcer is decreased or increased when alternating pressure (active) air surfaces are compared with reactive fibre surfaces. |
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Anticipated absolute effects (95% CI)</th>
<th>Relative effect</th>
<th>Number of participants</th>
<th>Certainty of the effect</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to pressure ulcer development</td>
<td>Included studies did not report this outcome.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support surface-associated patient comfort</td>
<td>19 dropouts among 93 people using alternating pressure (active) air surfaces; and 17 of 94 using reactive fibre surfaces with discomfort as the reason given.</td>
<td>-</td>
<td>187 (1 RCT)</td>
<td>⊕⊕⊕⊕ Very low</td>
<td>It is uncertain if there is any difference in support surface-associated patient comfort between alternating pressure (active) air surfaces and reactive fibre surfaces.</td>
</tr>
<tr>
<td>All reported adverse events</td>
<td>Included studies did not report this outcome.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health-related quality of life</td>
<td>Included studies did not report this outcome.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost effectiveness</td>
<td>Included studies did not report this outcome.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).*

CI: confidence interval; RR: risk ratio

**GRADE Working Group grades of evidence**

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

a Downgraded twice for high risk of bias in domains other than performance bias in 2 studies with more than 80% of analysis weight.

b Downgraded once for imprecision as the OIS was not met.

c Downgraded once for indirectness as the outcome measured (i.e. dropouts due to discomfort) was not directly relevant to comfort.

d Downgraded once for high overall risk of bias.

Summary of findings 5

**Alternating pressure (active) air surfaces on operating tables and subsequently on ward beds compared with reactive gel surfaces on operating tables followed by foam surfaces on ward beds for pressure ulcer prevention**

Alternating pressure (active) air surfaces on operating tables and subsequently on ward beds compared with reactive gel surfaces on operating tables followed by foam surfaces on ward beds for pressure ulcer prevention

Patient or population: pressure ulcer prevention

Setting: operating room

Intervention: alternating pressure (active) air surfaces on operating tables and subsequently on ward beds

Comparison: reactive gel surfaces on operating tables followed by foam surfaces on ward beds

Outcomes | Anticipated absolute effects (95% CI) | Relative effect | Number of participants | Certainty of the effect | Comments |
|---------|--------------------------------------|----------------|------------------------|-------------------------|----------|
### Risk with reactive gel surfaces used on operating tables followed by foam surfaces applied on hospital beds

| Study population | RR 0.22 (0.06 to 0.76) | 415 (2 RCTs) | ⊕⊕⊝⊝ Low

Alternating pressure (active) air surfaces applied on both operating tables and hospital beds may reduce the proportion of people developing a new pressure ulcer compared with reactive gel surfaces used on operating tables followed by foam surfaces applied on hospital beds.

### Time to pressure ulcer development

Included studies did not report this outcome.

### Support surface-associated patient comfort

Included studies did not report this outcome.

### All reported adverse events

Approximately 1/2 of the participants in each group reported adverse events. No difference in adverse events between groups was reported. None of the adverse events were related to the mattresses assigned.

- 198 (1 RCT)

It is uncertain if there is any difference in all reported adverse events between alternating pressure (active) air surfaces applied on both operating tables and hospital beds and reactive gel surfaces used on operating tables followed by foam surfaces applied on hospital beds.

### Health-related quality of life

Included studies did not report this outcome.

### Cost effectiveness

Included studies did not report this outcome.
The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 

<table>
<thead>
<tr>
<th>CI: confidence interval; RR: risk ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GRADE Working Group grades of evidence</strong></td>
</tr>
<tr>
<td><strong>High certainty:</strong> we are very confident that the true effect lies close to that of the estimate of the effect.</td>
</tr>
<tr>
<td><strong>Moderate certainty:</strong> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.</td>
</tr>
<tr>
<td><strong>Low certainty:</strong> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.</td>
</tr>
<tr>
<td><strong>Very low certainty:</strong> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of the effect.</td>
</tr>
</tbody>
</table>

iad Downgraded once for risk of bias (1 study with 36% of analysis weight was at high risk of attrition bias whilst the other study was at unclear risk of bias for more than 1 domain other than performance bias).

bDowngraded once for imprecision as, despite the fact that the OIS was met, the 95% CI crossed RR = 0.75.

cDowngraded once for unclear risk of bias in more than 1 domain other than performance bias.

dDowngraded twice for imprecision due to small sample size.

---

**Background**

**Description of the condition**

Pressure ulcers (also known as pressure injuries, pressure sores, decubitus ulcers and bed sores) are localised injuries to the skin or underlying soft tissue, or both, caused by unrelieved pressure, shear or friction (**NPIAP 2016**). Pressure ulcer severity is generally classified using the National Pressure Injury Advisory Panel (NPIAP) system (**NPIAP 2016**).

- **Stage 1:** intact skin with a local appearance of non-blanchable erythema.
- **Stage 2:** partial-thickness skin loss with exposed dermis.
- **Stage 3:** full-thickness skin loss.
- **Stage 4:** full-thickness skin and tissue loss with visible fascia, muscle, tendon, ligament, cartilage or bone.
- **Unstageable pressure injury:** full-thickness skin and tissue loss that is obscured by slough or eschar so that the severity of injury cannot be confirmed.
- **A deep tissue pressure injury:** local injury of persistent, non-blanchable deep red, maroon, purple discolouration or epidermal separation revealing a dark wound bed or blood-filled blister.

These above stages of pressure ulcer are consistent with those described in another commonly used system: the International Classification of Diseases for Mortality and Morbidity Statistics of the **World Health Organization 2019**.

Pressure ulcers are relatively common, complex wounds affecting people across different care settings. A systematic review found that prevalence estimates for people affected by pressure ulcers in communities of the UK, USA, Ireland, and Sweden ranged from 5.6 to 2300 per 10,000 depending on the nature of the population surveyed (**Cullum 2016**). A subsequent cross-sectional survey of people receiving community health services in one city in the UK estimated that 1.8 people...
per 10,000 have a pressure ulcer (Gray 2018).

Pressure ulcers confer a heavy burden in terms of personal impact and health service resource use. Having a pressure ulcer may impair physical, social and psychological activities (Gorecki 2009). Ulceration impairs health-related quality of life (Essex 2009); can result in longer institution stays (Theisen 2012); and increases the risk of systemic infection (Espejo 2018). There are also substantial impacts on health systems. A 2015 systematic review of 14 studies across a range of care settings in Europe and North America, showed that pressure ulcer-related treatment costs ranged between EUR 1.71 and EUR 470.49 per person, per day (Demarré 2015). In the UK, the annual average National Health Service cost attributable to managing one person with a pressure ulcer in the community was estimated to be GBP 1400 for a Stage 1 pressure ulcer and more than GBP 8500 for more severe stages (2015/2016 prices; Guest 2018). In Australia, the annual cost of treating pressure ulcers was estimated to be AUD 983 million (95% confidence interval (CI) 815 to 1151 million) at 2012/2013 prices (Nguyen 2015). The serious consequences of pressure ulceration have led to an intensive focus on their prevention.

**Description of the intervention**

Pressure ulcers are considered largely preventable. Support surfaces are specialised medical devices designed to relieve or redistribute pressure on the body, or both, in order to prevent pressure ulcers (NPIAP S3I 2007). Types of support surface include, but are not limited to, integrated bed systems, mattresses and overlays (NPIAP S3I 2007).

Classification of support surface type can now be based on the NPIAP Support Surface Standards Initiative (S3I) terms and definitions related to support surfaces (NPIAP S3I 2007). According to the NPIAP S3I terms and definitions support surfaces may:

- be powered (i.e. require electrical power to function) or non-powered;
- passively redistribute body weight (i.e. reactive pressure redistribution), or mechanically alternate the pressure on the body to reduce the duration of pressure (i.e. active pressure redistribution);
- be made of a range of materials including but not limited to: air-cells, foam materials, fibre materials, gel materials, sheepskin for medical use, and water-bags;
- be constructed of air-filled cells that have small holes on the surface for blowing out air to dry skin (i.e. low-air-loss feature) or have fluid-like characteristics via forcing filtered air through ceramic beads (i.e. air-fluidised feature), or have neither of these features.

Full details of support surface classifications are listed in Appendix 1. A widely used type of support surface is the alternating pressure (active) air bed, mattress or overlay (traditionally termed alternating pressure, or dynamic air bed, mattress or overlay). Examples of types of alternating pressure air beds, mattresses or overlays include:

- powered active air mattresses (e.g. Nimbus II, MicroPulse, large-celled ripple);
- powered active low-air-loss mattresses;
- powered hybrid system air mattresses (e.g. TheraPulse);
- powered hybrid system low-air-loss mattresses.

These mattresses are made of air-cells that intermittently inflate and deflate via electrically powered pumps (Clark 2011; NPIAP S3I 2007). Additionally, these active, alternating pressure air mattresses can have an integrated reactive element to create so-called 'hybrid' mattresses (Fletcher 2015). Alternating pressure (active) air mattresses can have low-air-loss features designed to influence the microclimate environment by keeping the skin dry (since moisture is thought to potentially increase friction on skin and increase the risk of skin damage) (Clark 2011; Wounds International 2010).

**How the intervention might work**

Support surfaces that can prevent pressure ulceration aim to redistribute pressure beneath the body, facilitating blood flow to tissues and preventing skin and soft tissue distortion (Wounds International 2010). Active support surfaces (e.g. alternating pressure (active) air bed, mattress or overlay) achieve pressure redistribution by frequently changing the points of contact between the surface and body, reducing the duration of the pressure applied to specific anatomical sites (Clark 2011; NPIAP S3I 2007). This contrasts with the mode of action of reactive support surfaces, which is more passive and includes immersion (i.e. 'sinking' of the body into a support surface) and envelopment (i.e. conforming of a support surface to the irregularities of the body). These devices distribute the pressure over a greater area, thereby reducing the magnitude of the pressure at specific sites (Clark 2011).

**Why it is important to do this review**

Support surfaces are widely used for pressure ulcer prevention and are the focus of recommendations in international and national guidelines (EPUAP/NPIAP/PPPIA 2019; NICE 2014). Since the publication of the Cochrane Review, 'Support surfaces for pressure ulcer prevention' (McInnes 2015), there has been a substantial increase in the number of relevant randomised controlled trials (RCTs) published; recognition of the NPIAP S3I 2007 terms and definitions related to support surfaces; and new Cochrane methodological requirements, such as the use of GRADE assessments (Guyatt 2008). These developments mean that it is important to update the evidence base.

In considering this evidence update, we took into account the size and complexity of 'Support surfaces for pressure ulcer prevention' (McInnes 2015), which included all support surface types. An alternative approach is to split the review into multiple new titles, each with a narrower focus. We consulted on this splitting option via an international survey in August 2019. The potential new titles suggested were based on clinical use, the new terms and definitions related to support surfaces (NPIAP S3I 2007), a relevant network meta-analysis (Shi 2018a), and current clinical practice guidelines (EPUAP/NPIAP/PPPIA 2019; NICE 2014). We received responses from 29 health professionals involved in pressure ulcer prevention activity in several countries (Australia, Belgium, China, Italy, the Netherlands and the UK). In total, 83% of respondents supported splitting the review into suggested titles and 17% were unsure (no respondent voted against splitting). The new review titles are:

- Alternating pressure (active) air surfaces for preventing pressure ulcers;
Foam surfaces for preventing pressure ulcers; Reactive air surfaces for preventing pressure ulcers; and Alternative reactive support surfaces (non-foam and non-air-filled) for preventing pressure ulcers.

We will bring the results of these new reviews together in an overview with a network meta-analysis (Salanti 2012), in order to compare simultaneously all support surfaces and to rank them based on the probabilities of each being the most effective for preventing pressure ulcers.

This particular review compares alternating pressure (active) air beds, mattresses or overlays with any surface.

### Objectives

To assess the effects of alternating pressure (active) air surfaces (beds, mattresses or overlays) compared with any support surface on the incidence of pressure ulcers in any population in any setting.

### Methods

#### Criteria for considering studies for this review

**Types of studies**

We included published and unpublished RCTs (including multi-arm studies, cluster-RCTs and cross-over trials), regardless of the language in which they were reported. We also included RCTs with particular designs (factorial design, n-of-1 trial design (i.e. a randomised controlled cross-over trial in a single participant)). We excluded studies using quasi-random allocation methods (e.g. alternation).

**Types of participants**

We included studies in any populations, including those defined as being at risk of ulceration, as well as those with existing pressure ulcers at baseline (when the study measured pressure ulcer incidence).

**Types of interventions**

This review focused on alternating pressure (active) air beds or mattresses in general. Eligible studies included a specific bed, overlay or mattress with active pressure redistribution (or alternating pressure) capabilities. These included, but were not limited to, specific active mattresses identified in Shi 2018a; namely:

- powered active air mattresses (also known as alternating pressure air mattresses); or
- powered active low-air-loss mattresses (also known as dynamic low-air-loss mattresses); or
- powered hybrid system air mattresses (e.g. Softform Premier Active air mattresses); or
- powered hybrid system low-air-loss mattresses (e.g. TheraPulse ATP mattresses).

In this review, we considered hybrid mattresses to be systems that incorporate both active and reactive pressure redistribution modes in a single unit and could apply either of the two modes as required by the user. For those using such hybrid mattresses, potential pressure ulcer risk reduction may result from both modes being used interchangeably over time, rather than being the result of constantly applying a single mode.

We included studies where two or more support surfaces were used sequentially over time or in combination, where the support surface(s) of interest were included in one of the study arms.

We included studies comparing eligible alternating pressure (active) air beds, overlays or mattresses with any comparator defined as a support surface. Comparators could be:

- non-alternating pressure (active) air surfaces, including: reactive air surfaces (e.g. static air overlays, dry flotation mattresses, air-fluidised bed), foam mattresses, and non-foam and non-air-filled surfaces (e.g. reactive gel surfaces such as a gel pad used on an operating table, reactive fibre surfaces such as Silicore fibre overlay, reactive water surfaces, reactive sheepskin surfaces such as Australian Medical Sheepskins overlay); or
- a different type of alternating pressure (active) air surface.

We included studies in which co-interventions (e.g. repositioning) were delivered, provided that co-interventions between a study’s arms were the same (i.e. interventions randomised were the only systematic difference).

**Types of outcome measures**

We considered the primary and secondary outcomes described below. If a study was otherwise eligible (i.e. eligible study design, participants and interventions) but did not report any review-relevant outcomes, we contacted the study authors where possible to clarify whether they measured a relevant outcome but did not report it. We placed the study in 'Studies awaiting classification' if we could not establish whether it measured an outcome or not. We excluded the study if the study authors confirmed that they did not measure any review-relevant outcomes.

For a study that measured an outcome at multiple time points, we considered outcome measures at three months as the primary interest of this review (Schoonhoven 2007), regardless of the time points specified as being of primary interest by the study. If the study did not report three-month outcome measures, we considered those closest to three months in this review. Where a study only reported a single time point, we considered these data in this review. Where the study did not specify a time point for their outcome measurement, we assumed this was the final duration of follow-up noted.

**Primary outcomes**

Our primary outcome was pressure ulcer incidence. We recorded two outcome measures (the proportion of participants developing a new pressure ulcer; and time to pressure ulcer development) where available. However, we considered the
proportion of participants developing a new pressure ulcer as the primary outcome for this review. Time to pressure ulcer development was our preferred measure; however, we did not expect it to be reported in many studies. We extracted and analysed time-to-event data but focused on the binary outcome in our conclusions. We accepted authors' definitions of an incident ulcer regardless of which pressure ulcer severity classification was used to measure or grade new pressure ulcers. We also considered the outcome of pressure ulcer incidence irrespective of whether studies report ulcers by stages or as a non-stratified value.

We did not consider subjective outcome measures (e.g. 'better' or 'worse' skin condition) as measures of pressure ulcer incidence.

Secondary outcomes

- **Support-surface-associated patient comfort.** We considered patient comfort outcome data in this review only if the evaluation of patient comfort was pre-planned and was systematically conducted across all participants in the same way in a study. The definition and measurement of this outcome varied from one study to another; for example, the proportion of participants who report comfort, or comfort measured by a scale with continuous (categorical) numbers. We planned to include these data with different measurements in separate meta-analyses when possible.

- **All reported adverse events** (measured using surveys or questionnaires, other data capture process or visual analogue scale). We included data where study authors specified a clear method for collecting adverse event data. Where available, we extracted data on all serious and all non-serious adverse events as an outcome. We recorded where it was clear that events were reported at the participant level or whether multiple events per person were reported, in which case appropriate adjustments were required for data clustering (Peryer 2019). We considered the assessment of any event in general defined as adverse by participants, health professionals, or both.

- **Health-related quality of life** (measured using a standardised generic questionnaire such as EQ-5D (Herdman 2011), 36-item Short Form (SF-36; Ware 1992), or pressure ulcer-specific questionnaires such as the PURPOSE Pressure Ulcer Quality of Life (PU-QOL) questionnaire (Gorecki 2013), at noted time points). We did not include ad hoc measures of quality of life or qualitative interviews of quality of life because these measures were unlikely to be validated.

- **Cost-effectiveness:** within-trial cost-effectiveness analysis comparing mean differences in effects with mean cost differences between the two arms: we extracted data on incremental mean cost per incremental gain in benefit (incremental cost-effectiveness ratio (ICER)). We also considered other measures of relative cost-effectiveness (e.g. net monetary benefit, net health benefit).

Search methods for identification of studies

Electronic searches

We searched the following electronic databases to identify reports of relevant clinical...
trials:
- the Cochrane Wounds Specialised Register (searched 14 November 2019);
- the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 10) in the Cochrane Library (searched 14 November 2019);
- Ovid MEDLINE including In-Process & Other Non-Indexed Citations (1946 to 14 November 2019);
- Ovid Embase (1974 to 14 November 2019);
- EBSCO CINAHL Plus (Cumulative Index to Nursing and Allied Health Literature; 1937 to 14 November 2019).

The search strategies for the Cochrane Wounds Specialised Register, CENTRAL, Ovid MEDLINE, Ovid Embase and EBSCO CINAHL Plus can be found in Appendix 2. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision) (Lefebvre 2019). We combined the Embase search with the Ovid Embase filter developed by the UK Cochrane Centre (Lefebvre 2019). We combined the CINAHL Plus search with the trial filter developed by Glanville 2019. There were no restrictions with respect to language, date of publication or study setting.

We also searched the following clinical trials registries:
- US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (clinicaltrials.gov) (searched 20 November 2019);

Search strategies for clinical trial registries can be found in Appendix 2.

**Searching other resources**

For previous versions of McInnes 2015, the review authors of McInnes 2015 contacted experts in the field of wound care to enquire about potentially relevant, ongoing and recently published studies. In addition, the review authors of McInnes 2015 contacted manufacturers of support surfaces for details of any studies manufacturers were conducting. This approach did not yield any additional studies; therefore, we did not repeat it for this review.

We identified other potentially eligible studies or ancillary publications by searching the reference lists of retrieved included studies, as well as relevant systematic reviews, meta-analyses and health technology assessment reports.

When necessary, we contacted authors of key papers and abstracts to request further information about their trials.

We did not perform a separate search for adverse effects of interventions used. We considered adverse effects described in included studies only.

**Data collection and analysis**

We carried out data collection and analysis according to the methods stated in the
published protocol (Shi 2020), which were based on the *Cochrane Handbook for Systematic Reviews of Interventions* (Li 2019). Changes from the protocol or previous published versions of the review are documented in *Differences between protocol and review*.

### Selection of studies

One review author re-checked the RCTs included in McInnes 2015 for eligibility (CS). Two review authors (CS and A JB, or JCD) independently assessed the titles and abstracts of the new search results for relevance using Rayyan (Ouzzani 2016) (*Differences between protocol and review*) and then independently inspected the full-text of all potentially eligible studies. The two review authors (CS and A JB, or JCD) resolved disagreements through discussion and by involving a third review author if necessary.

### Data extraction and management

One review author checked data from the studies included in McInnes 2015 and extracted additional data where necessary (CS). A second review author or researcher (SR, A JB, EM, Zhenmi Liu, Gill Norman, or Melanie Stephens) checked any new data extracted.

For new included studies, one review author (CS) independently extracted data and another review author or researcher (SR, A JB, EM, Zhenmi Liu, Gill Norman, or Melanie Stephens) checked all data (*Differences between protocol and review*). We resolved any disagreements through discussion and, if necessary, with the involvement of another review author. Where necessary, we contacted the authors of included studies to clarify data.

We extracted these data using a pre-prepared data extraction form:

- basic characteristics of studies (first author, publication type, publication year, and country);
- funding sources;
- care setting;
- characteristics of participants (trial eligibility criteria, average age in each arm or in a study, proportions of participants by gender, and participants' baseline skin status);
- support surfaces being compared (including their descriptions);
- details on any co-interventions;
- follow-up duration;
- the number of participants enrolled;
- the number of participants randomised to each arm;
- the number of participants analysed;
- participant withdrawals with reasons;
- the number of participants developing new ulcers (by ulcer stages where possible);
- time to pressure ulceration outcome data;
• patient support-surface-associated comfort;
• adverse event outcome data;
• health-related quality of life outcome data; and
• cost-effectiveness outcome data.

We (CS and NC) classified specific support surfaces in the included studies into intervention groups using the NPIAP S3I terms and definitions related to support surface (NPIAP S3I 2007). Therefore, to accurately assign specific support surfaces to intervention groups, we extracted full descriptions of support surfaces from included studies, and when necessary, supplemented the information with that from external sources such as other publications about the same support surface, manufacturers’ or product websites, and expert clinical opinion (Shi 2018b). If we were unable to define or classify any of the specific support surfaces evaluated in an included study, we extracted available data and reported these as additional data outside the main review results.

Assessment of risk of bias in included studies

Two review authors or researchers (CS and SR, AJB, EM, Zhenmi Liu, Gill Norman, or Melanie Stephens) independently assessed the risk of bias of each included study using the Cochrane 'Risk of bias' tool (see Appendix 3). This tool has seven specific domains: sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete data (attrition bias), selective outcome reporting (reporting bias), and other issues (Higgins 2017). We assessed performance bias, detection bias, and attrition bias for each of the review outcomes separately (Higgins 2017). We noted that it is often impossible to blind participants and personnel in device trials. In this case, performance bias may be introduced if knowledge of treatment allocation results in deviations from intended interventions, differential use of co-interventions or care between groups not specified in the study protocol that may influence outcomes. We attempted to understand if, and how, included studies compensated for challenges in blinding; for example, implementing strict protocols to maximise consistency of co-interventions between groups to reduce the risk of performance bias. We also noted that pressure ulcer incidence is a subjective outcome. Compared with blinded assessment, non-blinded assessment of subjective outcomes tends to be associated with more optimistic effect estimates of experimental interventions in RCTs (Hróbjartsson 2012). Therefore, we judged non-blinded outcome assessment as being at high risk of detection bias. In this review, we included the issues of differential diagnostic activity and unit of analysis under the domain of 'other issues'. For example, unit of analysis issues occurred where a cluster-randomised trial had been undertaken but analysed at the individual level in the study report.

For the studies included in McInnes 2015, one review author (CS) checked the 'Risk of bias' judgements and, where necessary, updated them. A second review author or researcher (SR, AJB, EM, Zhenmi Liu, Gill Norman, or Melanie Stephens) checked any updated judgement. We assigned each 'Risk of bias' domain a judgement of high, low, or unclear risk of bias. We resolved any discrepancy through discussion and by involving another review author where necessary. Where possible, useful and feasible, when a lack of reported information resulted in a judgement of unclear risk of bias, we planned to contact study authors for clarification.
We present our assessment of risk of bias for the proportion of participants developing a new pressure ulcer outcome using two 'Risk of bias' summary figures. One is a summary of bias for each item across all studies, and the second shows a cross-tabulation of each study by all of the 'Risk of bias' items.

Once we had given our judgements for all 'Risk of bias' domains, we judged the overall risk of bias for each outcome across studies as:

- low risk of bias, if we judged all domains to be at low risk of bias;
- unclear risk of bias, if we judged one or more domains to be at unclear risk of bias and other domains were at low risk of bias but no domain was at high risk of bias; or
- high risk of bias, as long as we judged one or more domains as being at high risk of bias, or all domains had unclear 'Risk of bias' judgements, as this could substantially reduce confidence in the result.

We resolved any discrepancy between review authors through discussion and by involving another review author where necessary.

For studies using cluster randomisation, we planned to consider the risk of bias in relation to recruitment bias, baseline imbalance, loss of clusters, incorrect analysis and comparability with individually randomised studies (Eldridge 2019; Higgins 2019; Appendix 3). However, we did not include any studies with a cluster design.

Measures of treatment effect

For meta-analysis of pressure ulcer incidence data, we present the risk ratio (RR) with its 95% confidence interval (CI). For continuous outcome data, we present the mean difference (MD) with 95% CIs for studies that use the same assessment scale. If studies reporting continuous data used different assessment scales, we planned to report the standardised mean difference (SMD) with 95% CIs. However, this was not undertaken in the review.

For time-to-event data (time to pressure ulcer development), we present the hazard ratio (HR) with its 95% CI. If included studies reporting time-to-event data did not report an HR, then, when feasible, we estimated this using other reported outcomes, such as numbers of events, through employing available statistical methods (Parmar 1998; Tierney 2007).

Unit of analysis issues

We noted whether studies presented outcomes at the level of cluster (e.g. ward, research site) or at the level of participants. We also recorded whether the same participant was reported as having multiple pressure ulcers.

Unit of analysis issues may occur if studies randomise at the cluster level but the incidence of pressure ulcers is observed and data are presented and analysed at the level of participants (clustered data). We noted whether data regarding participants within a cluster were (incorrectly) treated as independent within a study, or were analysed using within-cluster analysis methods. If clustered data were incorrectly analysed, we recorded this as part of the 'Risk of bias' assessment.

If a cluster-RCT was not correctly analysed, where possible, we planned to use available information (see below) to adjust for clustering ourselves, in accordance with guidance in the Cochrane Handbook for Systematic Reviews of Interventions...
(Higgins 2019):
- the number of clusters randomly assigned to each intervention; or the average (mean) number of participants per cluster;
- outcome data ignoring the cluster design for the total number of participants; and
- estimate of the intra-cluster (or intra-class) correlation coefficient (ICC).

However, we did not adjust for clustering for the two studies with an n-of-1 trial design because they did not report sufficient information to facilitate this.

**Cross-over trials**
For cross-over trials, we only considered outcome data at the first intervention phase (i.e. prior to cross-over) as eligible.

**Studies with multiple treatment groups**
If a study had more than two eligible study arms, where appropriate, we combined results across these arms to make single pair-wise comparisons (Higgins 2019).

**Dealing with missing data**
Data are commonly missing from study reports. Reasons for missing data could be the exclusion of participants after randomisation, withdrawal of participants from a study, or loss to follow-up. The exclusion of these data from analysis may break the randomisation and potentially introduces bias.

Where there were missing data and where relevant we contacted study authors to pose specific queries about these data. In the absence of other information, for pressure ulcer incidence we assumed that participants with missing data did not develop new pressure ulcers for the main analysis (i.e. we added missing data to the denominator but not the numerator). We examined the impact of this assumption through undertaking a sensitivity analysis (see Sensitivity analysis).

Note that when a study did not specify the number of randomised participants prior to dropout, we used the available number of participants as the number randomised.

**Assessment of heterogeneity**
Assessing heterogeneity can be a complex, multifaceted process. Firstly, we considered clinical and methodological heterogeneity; that is, the extent to which the included studies varied in terms of participant, intervention, outcome and other characteristics including duration of follow-up, clinical settings, and overall study-level 'Risk of bias' judgement (Deeks 2019). In terms of the duration of follow-up, in order to assess the relevant heterogeneity, we recorded and classed assessment of outcome measures from:
- up to eight weeks as short-term;
- more than eight weeks to 16 weeks as medium-term; and
- more than 16 weeks as long-term.

We supplemented this assessment of clinical and methodological heterogeneity with information regarding statistical heterogeneity, assessed using the Chi² test. We
considered a P value less than 0.10 to indicate statistically significant heterogeneity given that the Chi$^2$ test has low power, particularly in the case where studies included in a meta-analysis have small sample size. We carried out this statistical assessment in conjunction with the I$^2$ statistic (Higgins 2003), and the use of prediction intervals for random-effects meta-analyses (Borenstein 2017; Riley 2011).

The I$^2$ statistic is the percentage of total variation across studies due to heterogeneity rather than chance (Higgins 2003). Very broadly, we considered that I$^2$ values of 25% or less may indicate a low level of heterogeneity and values of 75% or more may indicate very high heterogeneity (Higgins 2003). For random-effects models, where the meta-analysis had more than 10 included studies and no clear funnel plot asymmetry, we also planned to present 95% prediction intervals (Deeks 2019). We planned to calculate prediction intervals following methods proposed by Borenstein 2017.

Random-effects analyses produce an average treatment effect, with 95% confidence intervals indicating where the true population average value is likely to lie. Prediction intervals quantify variation away from this average due to between-study heterogeneity. The interval conveys where a future study treatment effect estimate is likely to fall based on the data analysed to date (Riley 2011). Prediction intervals are always wider than confidence intervals (Riley 2011).

It is important to note that prediction intervals will reflect heterogeneity of any source, including from methodological issues as well as clinical variation. For this reason, some authors have suggested that prediction intervals are best calculated for studies at low risk of bias, to ensure intervals that have meaningful clinical interpretation (Riley 2011). We had planned to calculate prediction intervals for all studies to assess heterogeneity and then to explore the impact of risk of bias in subgroup analysis as detailed below. However, we did not calculate any prediction intervals because all conducted meta-analyses contained fewer than 10 studies.

**Assessment of reporting biases**

We followed the systematic framework recommended by Page 2019 to assess risk of bias due to missing results (non-reporting bias) in the meta-analysis of pressure ulcer incidence data. To make an overall judgement about risk of bias due to missing results, we:

- identified whether pressure ulcer incidence data were unavailable by comparing the details of outcomes in trials registers, protocols or statistical analysis plans, if available, with reported results. If the above information sources were unavailable, we compared outcomes in the conference abstracts or in the methods section of the publication, or both, with the reported results. If we found non-reporting of study results, we then judged whether the non-reporting was associated with the nature of findings by using the 'Outcome Reporting Bias In Trials' (ORBIT) system (Kirkham 2018);
- assessed the influence of definitely missing pressure ulcer incidence data on meta-analysis; and
- assessed the likelihood of bias where a study had been conducted but not reported in any form. For this assessment, we considered whether the literature search was comprehensive and planned to produce a funnel plot for meta-analysis for seeking more evidence about the extent of missing results,
provided there were at least 10 included studies (Peters 2008; Salanti 2014).

However, we did not produce a funnel plot for any meta-analysis because all analyses in this review had fewer than 10 included studies.

Data synthesis

We summarised the included studies narratively and synthesised data using meta-analysis where applicable. We structured comparisons according to type of comparator and then by outcomes ordered by follow-up period.

We considered clinical and methodological heterogeneity and undertook pooling when studies appeared appropriately similar in terms of participants, support surfaces and outcome type. Where statistical synthesis of data from more than one study was not possible or considered inappropriate, we conducted a narrative review of eligible studies.

Once the decision to pool was made, we used a random-effects model, which estimated an underlying average treatment effect from studies. Conducting meta-analysis with a fixed-effect model in the presence of even minor heterogeneity may provide overly narrow confidence intervals. We used the Chi² test and I² statistic to quantify heterogeneity but not to guide choice of model for meta-analysis (Borenstein 2009). We exercised caution when meta-analysed data were at risk of small study effects because use of a random-effects model may be unsuitable here. In this case, or where there were other reasons to question the choice of a fixed-effect or random-effects model, we assessed the impact of the approach using sensitivity analyses to compare results from alternate models (Thompson 1999).

We performed meta-analyses largely using Review Manager 5.4 (Review Manager 2020). We presented data using forest plots where possible. For dichotomous outcomes, we presented the summary estimate as an RR with 95% CI. Where continuous outcomes were measured, we presented an MD with 95% CI. We planned to report SMD estimates where studies measured the same outcome using different methods. For time-to-event data, we presented the summary estimates as HRs and 95% CIs.

Subgroup analysis and investigation of heterogeneity

Investigation of heterogeneity

When important heterogeneity occurred, we planned to follow these steps, proposed by Cipriani 2013, to investigate further:

- check the data extraction and data entry for errors and possible outlying studies;
- if outliers existed, perform sensitivity analysis by removing them; and
- if heterogeneity was still present, we planned to perform subgroup analyses for study-level characteristics (see below) in order to explain heterogeneity as far as possible. However, we did not undertake any subgroup analysis because meta-analyses in this review included fewer than 10 studies.

Subgroup analysis

We investigated heterogeneity using the methods described in the Cochrane
**Handbook for Systematic Reviews of Interventions (Deeks 2019).** We planned to perform subgroup analyses for binary and categorical factors (or meta-regression for continuous factors) to determine whether the size of treatment effects was influenced by these four study-level characteristics:

- risk of bias (binary: low or unclear risk of bias; and high risk of bias; Schulz 1995);
- settings (categorical: acute care and other hospital settings; long-term care settings; operating theatre setting; and intensive care unit);
- baseline skin status (categorical: participants at risk, mixed skin status or non-reporting; non-blanchable erythema; existing ulcers of Stage 2 or serious; Shi 2018c); and
- follow-up duration (continuous).

We did not perform subgroup analysis/meta-regression when the number of studies included in the meta-analysis was not reasonable (i.e. fewer than 10).

We planned to compare subgroup findings using the ‘Test for Subgroup Differences’ in Review Manager 5.4 (Review Manager 2020).

**Sensitivity analysis**

We assessed the robustness of meta-analysis of pressure ulcer incidence data through doing sensitivity analyses as follows.

- Impact of considering specific alternating pressure (active) air surfaces as different surfaces rather than as a general group. We undertook a sensitivity analysis to examine whether disentangling specific alternating pressure (active) air surfaces that were listed in *Types of interventions* from alternating pressure (active) air surface as a single intervention affected the meta-analysis results.

- Impact of the selection of pressure ulcer incidence outcome measure. The proportion of participants developing a new pressure ulcer was the primary outcome measure for this review but we also analysed time to pressure ulcer development, where data were available.

- Impact of missing data. The primary analysis assumed that participants with missing data did not develop new pressure ulcers. We also analysed pressure ulcer incidence by only including data for the participants for whom we had endpoint data (complete cases). We noted that when a study only had complete case data (i.e. missing data or the numbers of participants randomised were not reported), complete case data were considered in the related main analysis (*Differences between protocol and review*).

- Impact of altering the effects model used. We used a random-effects model for the main analysis, followed by a fixed-effect analysis.

**Summary of findings and assessment of the certainty of the evidence**

We presented the main, pooled results of the review in 'Summary of findings' tables. These tables present key information concerning the certainty of evidence, the magnitude of the effects of the interventions examined and the sum of available data for the main outcomes (Schünemann 2019). These tables also include an overall
grading of the certainty of the evidence associated with each of the main outcomes that we assessed using the GRADE approach via GRADEpro GDT software. The GRADE approach defines the certainty of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest.

The GRADE assessment involves consideration of five factors: within-trial risk of bias, directness of evidence, heterogeneity, precision of effect estimates, and risk of publication bias (Schünemann 2019). The certainty of evidence can be assessed as being: high, moderate, low or very low. RCT evidence has the potential to be high certainty. We did not downgrade the certainty of evidence for the risk of bias factor in a specific circumstance. That is if the blinding of participants and personnel was the only domain resulting in our judgement of overall high risk of bias for the included studies; however for these studies it was impossible to blind participants and personnel.

When downgrading for imprecision, we followed the methods described in Guyatt 2011: either considering both the optimal information size (OIS) and the 95% CI of each meta-analysis if they were estimable; or considering the sample size, the number of events and other effectiveness indicators if the calculation of OIS and undertaking a meta-analysis were not applicable. Where necessary, we used the GRADE 'default' minimum important difference values (RR = 1.25 and 0.75) as the thresholds to judge if a 95% CI was wide (imprecise) so as to include the possibility of clinically important harm and benefit (Guyatt 2011).

We presented a separate 'Summary of findings' table for all but one comparison evaluated in this review. The exception was the comparison of alternating pressure (active) air surfaces versus another type of alternating pressure (active) air surfaces; see Differences between protocol and review. We presented these outcomes in the 'Summary of findings' tables:

- proportion of participants developing a new pressure ulcer;
- time to pressure ulcer development;
- support-surface-associated patient comfort;
- all reported adverse events;
- health-related quality of life; and
- cost-effectiveness.

We prioritised the time points and method of outcome measurement specified in Types of outcome measures for presentation in ‘Summary of findings’ tables’. Where we did not pool data for some outcomes within a comparison, we conducted a GRADE assessment for each of these outcomes and presented these assessments in a narrative format in 'Summary of findings' tables (Differences between protocol and review).

**Results**

**Description of studies**

See Characteristics of included studies; Characteristics of excluded studies;
Characteristics of studies awaiting classification; and Characteristics of ongoing studies.

Results of the search

The electronic searches identified 1624 records, including 1164 from electronic databases and 460 from trial registries. We excluded 218 duplicate records and screened 1406 records, of which 233 were identified as potentially eligible and obtained as full-text. Following full-text screening, we considered 54 records of 31 studies eligible for inclusion in this review (Andersen 1982; Aronovitch 1999; Ballard 1997; Beeckman 2019; Bliss 1967; Bliss 1995; Cavicchioli 2007; Conine 1990; Daechsel 1985; Demarre 2012; Finnegan 2008; Gray 2008; Grindley 1996; Hampton 1997; Jiang 2014; Laurent 1998; Malbrain 2010; Nixon 2006; Nixon 2019; Phillips 1999; Price 1999; Pring 1998; Rosenthal 2003; Russell 2000; Sanada 2003; Sauvage 2017; Sideranko 1992; Stapleton 1986; Taylor 1999; Theaker 2005; Whitney 1984).

From other resources, we identified Rafter 2011 by scanning the reference lists of the 14 systematic reviews or meta-analyses that were identified via the electronic searches (Chou 2013; Huang 2013; McGinnis 2011; McInnes 2015; McInnes 2018; Mistiaen 2010; De Oliveira 2017; Rae 2018; Reddy 2006; Reddy 2008; Serraes 2018; Shi 2018a; Smith 2013; Yao 2018), as well as the clinical practice guidelines listed in Searching other resources.

In total, we included 32 studies in the review, of which one was a conference abstract (Laurent 1998). See Figure 1.

Included studies

Types of studies

Of the 32 included RCTs, 26 had a parallel group design: four studies with three arms and 22 with two arms. Six studies had particular design features:

- two studies applied cross-over design (Ballard 1997; Grindley 1996);
- one study had a $2 \times 2$ factorial design (Laurent 1998), containing the comparison of alternating pressure (active) air surfaces versus standard hospital surfaces in an intensive care unit (ICU);
- one study appeared to be a multi-arm, multi-stage trial design with eight arms, of which seven were randomised and eligible for this review (Bliss 1995);
- two studies used a series of n-of-1 trial design (i.e. a randomised controlled crossover trial in a single participant) (Phillips 1999; Pring 1998).

Of the 32 included studies, 10 were conducted at more than one research site (Ballard 1997; Beeckman 2019; Cavicchioli 2007; Demarre 2012; Gray 2008; Jiang 2014; Nixon 2006; Nixon 2019; Rosenthal 2003; Sauvage 2017). Except for Jiang 2014 in China and Sanada 2003 in Japan, all of the included studies were conducted in high-income and upper-middle-income economies in Europe and North America, including Belgium, Canada, Denmark, France, Italy, the UK and the USA.

Of the 30 studies that clearly stated duration of follow-up, the median was 14 days (range: 3 to 180 days).
Types of participants

Age and sex at baseline

Of the 32 studies, 31 enrolled a total of 9058 participants (median study sample size: 83 participants, or the number of individual trials comprising a series of n-of-1 trials; range: 10 to 2029) whilst one (Hampton 1997) did not specify the number of participants. The average participant age was specified for 29 studies and ranged between 37.2 and 87.0 years (median: 69.1 years). The sex of the participants was specified for 26 studies; within these, 3654 (44.4%) of participants were male and 4571 (55.6%) were female.

Skin status at baseline

Of the 32 studies, 27 (8620 participants) recruited people at risk of having a new ulcer with risk assessed largely using the Waterlow, Norton or Braden scales. In 18 of these studies, 3812 (44.2%) participants were free of pressure ulcers at baseline; in nine studies, 4808 (55.8%) participants with superficial ulcers were enrolled (Bliss 1967; Bliss 1995; Cavicchioli 2007; Grindley 1996; Malbrain 2010; Nixon 2006; Nixon 2019; Rafter 2011; Whitney 1984). Two studies did not specify the skin status at baseline (Hampton 1997; Laurent 1998); one study stated that their participants had no risk of developing a pressure ulcer (Ballard 1997); and two studies recruited people with severe full-thickness pressure ulcers alone (Finnegan 2008; Rosenthal 2003).

Care settings

Participants were from a variety of settings, including:

- a mixture of secondary and community in-patient facilities (Nixon 2019),
- intensive care units (Malbrain 2010; Sideranko 1992; Theaker 2005), and
- community and long-term care settings (including hospice, community, nursing homes, extended care facilities, rehabilitation wards, long-term facilities and geriatric units) (Ballard 1997; Beeckman 2019; Conine 1990; Daechsel 1985; Grindley 1996; Phillips 1999; Pring 1998; Rosenthal 2003; Sauvage 2017).

Types of interventions

The studies investigated a wide range of alternating pressure (active) air surfaces with alternating pressure cycle periods ranging from 7.5 to 30 minutes. Of these studies, Sanada 2003 included two types of alternating pressure (active) air surfaces. Hybrid systems with alternating pressure (active) and continuously static (reactive) capabilities were used in five studies (Gray 2008; Hampton 1997; Rafter 2011; Taylor 1999; Theaker 2005). Alternating pressure (active) air surfaces with low air loss features were used in two studies (Rosenthal 2003; Theaker 2005). Three studies (Andersen 1982; Conine 1990; Daechsel 1985) did not specify the type (or cycle time) of the alternating pressure (active) air surfaces they used.

Full details of alternating pressure (active) air surfaces and comparators are listed in
Appendix 4 and in results below. Four studies used comparator group surfaces defined by study authors as 'standard hospital surfaces' that could not be classified further using the NPIAP S3I support surface terms and definitions (Andersen 1982; Bliss 1967; Laurent 1998; Sanada 2003). Of these four studies, Sanada 2003 reported use of a 'standard hospital surface' made of polyester (Paracare®) whilst the remaining three studies did not specify the type of surface they referred to as standard hospital surfaces.

Twelve studies specified co-interventions they applied (e.g. repositioning, cushions) (Beeckman 2019; Bliss 1967; Conine 1990; Daechsel 1985; Finnegan 2008; Gray 2008; Jiang 2014; Malbrain 2010; Price 1999; Rosenthal 2003; Sanada 2003; Whitney 1984). All twelve stated or indicated that the same co-interventions were applied in all study groups.

Funding sources

Of the 32 included studies, 18 specified the details of funding sources. Eleven studies were completely or partly funded by industry or received mattresses under evaluation from industries (Aronovitch 1999; Ballard 1997; Beeckman 2019; Bliss 1995; Daechsel 1985; Finnegan 2008; Grindley 1996; Price 1999; Rafter 2011; Russell 2000; Theaker 2005), and seven studies were supported by public funding (Bliss 1967; Conine 1990; Demarre 2012; Jiang 2014; Nixon 2006; Nixon 2019; Stapleton 1986).

Excluded studies

We excluded 140 studies (with 165 records). The main reasons for these 140 exclusions were: irrelevant and ineligible interventions (53 studies); ineligible study design (e.g. non-RCT, reviews, commentary articles; 52 studies); studies focused on the treatment rather than prevention of pressure ulcers (20 studies); incorrect randomisation and non-randomised methods (eight studies); studies with ineligible outcomes (four studies); clinical trials that were withdrawn (two studies; NCT02634892; NCT02735135); and ineligible participants (healthy subjects; one study). We also identified eight duplicates in screening full texts (see Figure 1).

Ongoing studies

We did not identify any ongoing studies.

Studies awaiting classification

There were six studies (six records) about which we could not make eligibility decisions. We were unable to determine whether Gardner 2008 measured one or more outcomes relevant to this review. We could not obtain the full-text of five studies (in part due to more limited access to intra-library loans during the COVID-19 period) despite extensive efforts made (Chaloner 2000; Henn 2004; Knight 1999; Mastrangelo 2010b; Melland 1998).

Risk of bias in included studies

We summarise 'Risk of bias' assessments for the primary outcome of this review in Figure 2 and Figure 3. We judged seven of the 32 studies as having an unclear overall risk of bias for the primary outcome (Gray 2008; Grindley 1996; Jiang 2014; Malbrain 2010; Rosenthal...
We judged all the remaining 25 studies as having findings at a high overall risk of bias, of which two had an unclear risk of bias judgements for all domains (Hampton 1997; Stapleton 1986) and 23 had one or more domains with a high risk of bias judgement (Andersen 1982; Aronovitch 1999; Ballard 1997; Beeckman 2019; Bliss 1967; Bliss 1995; Cavicchioli 2007; Conine 1990; Daechsel 1985; Demarre 2012; Finnegan 2008; Laurent 1998; Nixon 2006; Nixon 2019; Phillips 1999; Price 1999; Pring 1998; Rafter 2011; Russell 2000; Sanada 2003; Sauvage 2017; Theaker 2005; Whitney 1984). Of these 23 studies, 15 had a high risk of bias judgement for the primary outcome in domains of blinding of participants and personnel, blinding of outcome assessment, or both (Andersen 1982; Beeckman 2019; Daechsel 1985; Demarre 2012; Finnegan 2008; Laurent 1998; Nixon 2006; Nixon 2019; Price 1999; Pring 1998; Rafter 2011; Russell 2000; Sauvage 2017; Theaker 2005; Whitney 1984).

**Publication bias**

We ran a comprehensive search and were able to locate one eligible study, Rafter 2011, from other resources and one conference abstract, Laurent 1998. We considered the risk of having missed published reports to be low. We were unable to assess for the risk of non-publication of studies with negative findings as we could not present funnel plots given the small number of included studies in each analysis.

**Effects of interventions**

See Summary of findings table 1; Summary of findings table 2; Summary of findings table 3; Summary of findings table 4; Summary of findings table 5.

Unless otherwise stated, random-effects analysis was used throughout. Each pooled result presented is an average effect, rather than a common effect and should be interpreted as such.

We have not reported data from the four studies with comparator group surfaces that we could not classify in the main body of the results (Andersen 1982; Bliss 1967; Laurent 1998; Sanada 2003). For completeness, we summarise the results of these studies in Appendix 5.

We performed data analyses for the following comparisons and outcomes. Where applicable, we performed pre-specified sensitivity analyses as noted in Sensitivity analysis.

**Comparison 1: Alternating pressure (active) air surfaces versus foam surfaces (six studies, 2427 participants)**

One study, Bliss 1995, randomised participants to three types of foam mattresses (in three individual trial arms) which we combined into a single study arm for analysis against the relevant comparison, which was a type of alternating pressure (active) air surface. However, this study and Whitney 1984 (in total 180 participants) reported no outcomes directly relevant to this review and so none of their data were analysable. Rosenthal 2003 evaluated an alternating pressure (active) air surface with a low-air-loss feature. The remaining studies compared a standard alternating pressure (active) air surface with a foam surface comparison.

**Primary outcomes**
Proportion of participants developing a new pressure ulcer (median follow-up duration 90 days, minimum 30 days, maximum 6 months or unspecified)

Four studies (2247 participants) reported data for this outcome and the data from these studies were pooled (Nixon 2019; Rosenthal 2003; Sauvage 2017; Stapleton 1986). Alternating pressure (active) air surfaces (83/1125 (7.4%)) may reduce the proportion of participants developing pressure ulcers compared with foam surfaces (117/1122 (10.4%)); however, this is low-certainty evidence. The RR was 0.63 (95% CI 0.34 to 1.17; $I^2 = 63\%$; Analysis 1.1). Evidence certainty was downgraded once for risk of bias (two studies contributing 50% weight in the meta-analysis had either one domain other than performance bias at high risk of bias, or all domains at unclear risk of bias; two studies contributing 50% of weight in the meta-analysis had domains other than performance bias at low or unclear risk of bias), and once for imprecision as, despite the fact that the optimal information size (OIS) was met, the wide confidence interval crossed RR = 0.75.

Subgroup analysis

We considered the studies included in Analysis 1.1 heterogeneous in terms of all pre-specified subgroup factors (overall 'risk of bias', care settings, skin status at baseline, and follow-up) and there was some indication of statistical heterogeneity ($\chi^2$ test $P$ value = 0.07; $\tau^2 = 0.18$; $I^2 = 63\%$). We noticed that, of the four studies, Sauvage 2017 reported a greater treatment effect than the other three. Once the extreme value was removed (Sauvage 2017), $I^2$ went from 63% to 0%, but the overall estimate remained consistent with the main analysis (RR 0.79, 95% CI 0.60 to 1.03; $\chi^2$ test $P$ value = 0.83; $\tau^2 = 0.00$; $I^2 = 0\%$). Of the four studies, Sauvage 2017 differed from the others in terms of care settings: Sauvage 2017 was conducted at long-term care settings whilst the others were at acute care settings. However, as noted in Subgroup analysis and investigation of heterogeneity, because there were fewer than 10 studies, we did not undertake a subgroup analysis.

Sensitivity analyses

We performed sensitivity analyses for the following factors but did not use complete case data for a sensitivity analysis because the four included studies did not report missing data.

- **Sensitivity analysis deconstructing different types of alternating pressure (active) air surfaces into single groups**. Splitting the class of alternating pressure (active) air surfaces resulted in two independent analyses: (1) alternating pressure (active) air surfaces compared with foam surfaces (Nixon 2019; Sauvage 2017; Stapleton 1986); and (2) alternating pressure (active) low-air-loss surfaces compared with foam surfaces (Rosenthal 2003). There were insufficient data to show whether results were consistent across these subgroups.

- **Sensitivity analysis with fixed-effect (rather than random-effects) model**. The use of a fixed-effect model resulted in a RR of 0.71 (95% CI 0.55 to 0.93; $I^2 = 63\%$). The results suggest that the effect size of our outcome of interest is sensitive to the type of effect model chosen.

- **Post hoc sensitivity analysis using pressure ulcer incidence data from Nixon 2019 only**. In Analysis 1.1, Nixon 2019 was the largest study (with data for 2029 participants) and was the only study having all domains other than
performance bias at low risk of bias for this outcome. Using pressure ulcer incidence data from Nixon 2019 made little difference to the pooled effect estimate (RR 0.78, 95% CI 0.57 to 1.05; $I^2 = 0\%$).

- **Sensitivity analysis with time to pressure ulcer development as pressure ulcer incidence measure (median follow-up duration 60 days, minimum 30 days, maximum 90 days)**. Two studies (2105 participants) reported this outcome measure (Nixon 2019; Sauvage 2017), and the data from these were pooled. Analysis 1.2 resulted in a HR of 0.41 (95% CI 0.10 to 1.64; $I^2 = 86\%$) which was consistent with the main analysis. It is uncertain whether there is a difference in the risk of developing a new pressure ulcer, over 60 days’ follow-up, between alternating pressure (active) air surfaces and foam surfaces. Evidence is of very low certainty, downgraded once for high risk of bias in one study with 40% of analysis weight, twice for substantial inconsistency, and once for imprecision.

### Secondary outcomes

#### Support-surface-associated patient comfort (follow-up duration 30 days)

Only Sauvage 2017 (76 participants) reported this outcome, defined by the study authors as the perception of patient comfort and measured using a satisfaction questionnaire. Sauvage 2017 reported no significant difference in the overall satisfaction between study groups ($P = 0.21$); no other information was reported. We are uncertain whether there is any difference between alternating pressure (active) air surfaces and foam surfaces in patient comfort responses. Evidence is of very low certainty, downgraded twice for high risk of detection bias, and once for imprecision.

#### All reported adverse events (median follow-up duration 90 days, minimum 30 days, maximum 6 months)

Three studies (2181 participants) reported this outcome (Nixon 2019; Rosenthal 2003; Sauvage 2017). We did not pool these data as the definitions of adverse events varied between studies (Table 1). It is uncertain if there is any difference in adverse events between alternating pressure (active) air surfaces and foam surfaces. Evidence is of very low certainty, downgraded once for unclear risk of bias in two studies with about half weight, and twice for inconsistency.

#### Health-related quality of life (follow-up duration 90 days)

Only Nixon 2019 (2029 participants) reported health-related quality of life, measured using the EQ-5D-5L (with 267 participants only) and PU-QoL-UI (with 233 participants only). It is unclear if there is a difference in health-related quality of life (measured using either the EQ-5D-5L or PU-QoL-UI) at 90 days follow-up between alternating pressure (active) air surfaces and foam surfaces (low-certainty evidence). Nixon 2019 reported a MD in the 90-day EQ-5D-5L of 0.00 (95% CI -0.05 to 0.05) between 118 participants using alternating pressure (active) air surfaces and 149 using foam surfaces; and a MD in 90-day PU-QoL-UI of 0.00 (95% CI -0.03 to 0.03) between 107 participants using alternating pressure (active) air surfaces and 126 using foam surfaces (Analysis 1.3). Evidence certainty was downgraded twice for imprecision due to small sample sizes for this outcome.

#### Cost-effectiveness (follow-up duration 90 days)

Only Nixon 2019 (2029 participants) reported the incremental cost per quality-
adjusted life-years (QALYs) gained based on within-trial analyses. Moderate-certainty evidence suggests that alternating pressure (active) air surfaces have a 99% probability of being cost-effective at a threshold of GBP 20,000 compared with reactive foam surfaces. Evidence certainty was downgraded once for imprecision for the EQ-5D-5L outcome from which QALY scores were calculated.

**Comparison 2: Alternating pressure (active) air surfaces versus reactive air surfaces (seven studies, 1728 participants)**

Seven studies made this comparison (Beeckman 2019; Cavicchioli 2007; Finnegans 2008; Jiang 2014; Malbrain 2010; Price 1999; Sideranko 1992).

**Primary outcomes**

Proportion of participants developing a new pressure ulcer (median follow-up duration 14 days, minimum 5 days, maximum 15 days)

Six studies (1648 participants) reported this outcome (Beeckman 2019; Cavicchioli 2007; Finnegans 2008; Jiang 2014; Malbrain 2010; Sideranko 1992) and the data from these were pooled. It is uncertain whether there is a difference in the proportion of participants developing a new ulcer between alternating pressure (active) air surfaces (32/799 (4.0%)) and reactive air surfaces (19/849 (2.2%)). The RR was 1.61 (95% CI 0.90 to 2.88; $I^2 = 3$%; Analysis 2.1). Evidence is of very low certainty, downgraded twice for high risk of bias in domains other than performance bias for three studies contributing over 54% weight in the meta-analysis, and once for imprecision as, despite the fact that the OIS was met, the wide confidence interval crossed RR = 1.25.

**Subgroup analysis**

We considered the studies in Analysis 2.1 heterogeneous in terms of care settings, skin status at baseline, and overall 'risk of bias'. However, we did not perform any pre-specified subgroup analysis because, as noted in Subgroup analysis and investigation of heterogeneity, the number of included studies was fewer than 10, meaning it would be difficult to meaningfully interpret the results.

**Sensitivity analyses**

- **Sensitivity analysis with complete case data**. This resulted in a RR of 1.62 (95% CI 0.90 to 2.89; $I^2 = 3$%). The evidence was consistent with the main analysis Analysis 2.1.

- **Sensitivity analysis with fixed-effect (rather than random-effects) model**. The use of a fixed-effect model resulted in a RR of 1.72 (95% CI 1.00 to 2.97; $I^2 = 3$%) so this was consistent with the main analysis.

- **Sensitivity analysis with time to pressure ulcer development as pressure ulcer incidence measure** (follow-up duration of 14 days). Only Beeckman 2019 (308 participants) reported this outcome. Low-certainty evidence suggests that people treated with alternating pressure (active) air surfaces may be at more risk of developing an incident pressure ulcer over 14 days' follow-up than those treated with reactive air surfaces in a nursing home setting (HR 2.25; 95% CI 1.05 to 4.83; Analysis 2.2). The results are sensitive to the choice of format for the primary outcome measure so the main analysis results should be interpreted cautiously. Evidence certainty is low, downgraded twice for high risk
of detection bias.

Secondary outcomes

Support-surface-associated patient comfort (median follow-up duration 11 days, minimum 5 days, maximum 14 days)

Four studies (1364 participants) reported this outcome (Cavicchioli 2007; Finnegan 2008; Jiang 2014; Price 1999). The four studies report a range of different measures for this outcome and they cannot be pooled (see Table 2). We are uncertain about any difference in patient comfort responses between alternating pressure (active) air surfaces and reactive air surfaces. Evidence is of very low certainty, downgraded once for high overall risk of bias in three small studies but unclear risk of bias in one large study, and twice for substantial inconsistency.

All reported adverse events

Not reported.

Health-related quality of life

Not reported.

Cost-effectiveness

Not reported.

Comparison 3: Alternating pressure (active) air surfaces versus reactive water surfaces (three studies, 414 participants)

Three studies compared alternating pressure (active) air surfaces with reactive water surfaces (Andersen 1982; Bliss 1995; Sideranko 1992). Of these, Bliss 1995 (56 participants) reported the outcome of the numbers of treatment sessions in which pressure ulcers developed or worsened, which we considered not directly relevant to this review.

Primary outcomes

Proportion of participants developing a new pressure ulcer (median follow-up duration 10.0 days, minimum 10.0 days, maximum 17.7 days)

We pooled available data from two studies (358 participants; Andersen 1982; Sideranko 1992). It is uncertain whether there is a difference in the proportion of participants developing a new pressure ulcer between alternating pressure (active) air surfaces (12/186 (6.5%)) compared with reactive water surfaces (9/172 (5.2%)). The RR was 1.21 (95% CI 0.52 to 2.83; I² = 0%; Analysis 3.1). Evidence is of very low certainty, downgraded twice for high risk of detection bias in one study contributing over 60% weight in the meta-analysis and unclear overall risk of bias in another study, and twice for substantial imprecision as the OIS was not met and the confidence interval was very wide and crossed RRs = 0.75 and 1.25.

The included studies did not report data on time to pressure ulcer incidence.

Subgroup analysis

We considered studies heterogeneous in terms of care setting, and overall 'risk of bias'. However, we did not perform any pre-specified subgroup analysis because, as noted in Subgroup analysis and investigation of heterogeneity, the number of
included studies was fewer than 10, meaning it would be difficult to meaningfully interpret the results.

**Sensitivity analyses**

- **Sensitivity analysis with fixed-effect (rather than random-effects) model**.
  The use of a fixed-effect model resulted in a RR of 1.21 (95% CI 0.53 to 2.78; $I^2 = 0\%$). The evidence remained consistent with the main analysis Analysis 3.1 (Appendix 6).

**Secondary outcomes**

None reported.

**Comparison 4: Alternating pressure (active) air surfaces versus reactive fibre surfaces (four studies, 384 participants)**

Four studies made this comparison (Bliss 1995; Conine 1990; Daechsel 1985; Stapleton 1986). Of these, Bliss 1995 randomised participants into two types of fibre-filled surfaces (in two individual study arms) that we combined into a single study arm. Bliss 1995 reported the outcome of the numbers of treatment sessions in which pressure ulcers developed or worsened, which we considered not directly relevant to this review.

**Primary outcomes**

**Proportion of participants developing a new pressure ulcer (minimum follow-up duration 17.7 days, maximum three months or unspecified)**

All four studies (384 participants) reported this outcome (Bliss 1995; Conine 1990; Daechsel 1985; Stapleton 1986).

We pooled the data from three studies (285 participants). It is uncertain whether there is a difference in the proportion of participants developing a new pressure ulcer between alternating pressure (active) air surfaces (54/141 (38.3%)) and reactive fibre surfaces (61/144 (42.4%)). The RR was 0.90 (95% CI 0.68 to 1.19; $I^2 = 0\%$; Analysis 4.1). Evidence is of very low certainty, downgraded twice for high risk of bias in domains other than performance bias in two studies contributing over 80% weight to the meta-analysis, and once for imprecision as the OIS was not met.

The included studies did not report data on time to pressure ulcer incidence.

**Subgroup analysis**

We considered these studies heterogeneous in terms of care settings, participants' average age and skin status at baseline. However, we did not perform any pre-specified subgroup analysis because, as noted in *Subgroup analysis and investigation of heterogeneity*, the number of included studies was fewer than 10, meaning it would be difficult to meaningfully interpret the results.

**Sensitivity analyses**

- **Sensitivity analysis using complete case data**. This resulted in a RR of 0.93 (95% CI 0.72 to 1.20; $I^2 = 0\%$). The evidence is consistent with the main analysis Analysis 4.1 (Appendix 6).

- **Sensitivity analysis with fixed-effect (rather than random-effects) model**.
The use of a fixed-effect model resulted in a RR of 0.90 (95% CI 0.68 to 1.20; I² = 0%) and this remained consistent with the main analysis Analysis 4.1 (Appendix 6).

Secondary outcomes

Support-surface-associated patient comfort (follow-up duration of three months)

Only Conine 1990 (187 participants) reported this outcome. We are uncertain about any difference between alternating pressure (active) air surfaces and reactive fibre surfaces in patient comfort responses. Conine 1990 reported 19 dropouts among 93 people using alternating pressure (active) air surfaces; and 17 of 94 using reactive fibre surfaces. The reason for dropout was given as discomfort. Evidence is of very low certainty, downgraded once for high overall risk of bias for this outcome, once for indirectness, and once for imprecision.

All reported adverse events using allocated support surfaces

Not reported.

Health-related quality of life

Not reported.

Cost-effectiveness

Not reported.

Comparison 5: Alternating pressure (active) air surfaces on operating tables and subsequently on postoperative ward beds versus reactive gel surfaces used on operating tables followed by foam surfaces on postoperative ward beds (two studies, 415 participants)

Two studies (415 participants) were included in this comparison (Aronovitch 1999; Russell 2000).

Primary outcomes

Proportion of participants developing a new pressure ulcer (follow-up duration of seven days)

Both studies (415 participants) reported this outcome and these data were pooled (Aronovitch 1999; Russell 2000). Alternating pressure (active) air surfaces applied on both operating tables and hospital beds (3/210 (1.4%)) may reduce the proportion of people developing a new pressure ulcer compared with reactive gel surfaces used on operating tables followed by foam surfaces applied on hospital beds (14/205 (6.8%)); however, this is low-certainty evidence. The RR is 0.22 (95% CI 0.06 to 0.76; I² = 0%; Analysis 5.1). Evidence certainty was downgraded once for risk of bias (one study contributing 36% of weight to the meta-analysis was at high risk of attrition bias whilst the other study was at unclear risk of bias for more than one domain other than performance bias) and once for imprecision as, despite the fact that the OIS was met, the 95% CI crossed RR = 0.75.

The included studies did not report data on time to pressure ulcer incidence.

Subgroup analysis
We considered both studies similar in terms of care settings, follow-up duration, overall risk of bias, participant characteristics and interventions: statistical heterogeneity was low (Chi² test P value = 0.55; Tau² = 0.00; I² = 0%). Because the number of included studies was less than 10, we did not undertake a subgroup analysis.

Sensitivity analyses

- **Sensitivity analysis with fixed-effect (rather than random-effects) model.** The use of a fixed-effect model resulted in a RR of 0.21 (95% CI 0.06 to 0.72; I² = 0%) and this remained consistent with the main analysis Analysis 5.1 (Appendix 6).

Secondary outcomes

Support-surface-associated patient comfort

None reported.

All reported adverse events (follow-up duration of seven days)

Only Russell 2000 (198 participants) reported this outcome. It is uncertain if there is a difference between alternating pressure (active) air surfaces and the alternative in adverse events. The study authors claimed that approximately one half of people in each group reported one or more types of adverse events, with no difference between groups reported. The study authors also noted that no adverse events were considered to be related to the mattresses assigned. Evidence is of very low certainty, downgraded once for unclear risk of bias in more than one domain other than performance bias, and twice for imprecision due to small sample size.

Health-related quality of life

Not reported.

Cost-effectiveness

Not reported.

Comparison 6: Comparison between two types of alternating pressure (active) air surfaces (ten studies, 2868 participants)

We included 10 studies (2868 participants) that compared two or more different types of alternating pressure (active) air surfaces (Ballard 1997; Demarre 2012; Gray 2008; Grindley 1996; Hampton 1997; Nixon 2006; Pring 1998; Rafter 2011; Taylor 1999; Theaker 2005). Specifically, three studies included an alternating pressure (active) air surface with a hybrid (active/reactive) function (Gray 2008; Hampton 1997; Taylor 1999); Rafter 2011 and Theaker 2005 compared two types of alternating pressure (active) air surface that could both be classed as hybrid air surfaces, and one type of hybrid air surface used in Theaker 2005 also had a low-air-loss feature. The remaining five studies compared different types of standard alternating pressure (active) air surfaces.

We did not pool data from the 10 studies as such comparisons are not meaningful beyond the individual study level. We summarise study findings narratively below with key outcome data presented in Table 2 and Table 3.
Primary outcomes

Proportion of participants developing a new pressure ulcer (median follow-up period one month, minimum 10.5 days, maximum six months)

Seven studies (2833 participants) reported this outcome with no study showing a difference in the proportion of people with incident pressure ulcers between different types of alternating pressure (active) air surfaces (Demarre 2012; Gray 2008; Hampton 1997; Nixon 2006; Rafter 2011; Taylor 1999; Theaker 2005). See Table 3. These study findings were considered to be of low certainty overall, downgraded once for risk of bias as two small studies were at high risk of bias in domains other than performance bias and all the remaining five studies were at unclear risk of bias in at least one domain other than performance bias, and once for imprecision as the number of events was relatively low and the 95% CIs in each study included both benefits and harms as well as no effect.

Two studies (2581 participants) reported time to pressure ulcer development (Demarre 2012; Nixon 2006; follow-up period 14 and 60 days). Neither of these studies suggested a difference in the risk of developing an incident pressure ulcer over 60 days' follow-up between these support surfaces. This is consistent with the pressure ulcer risk finding. Evidence is of low certainty, downgraded once for unclear risk of bias in domains other than performance bias in both included studies, and once for imprecision as the 95% CIs of both studies included both benefits and harms as well as no effect.

Secondary outcomes

Support-surface-associated patient comfort (median follow-up duration 10.5 days, minimum 3 days, maximum 60 days)

Seven studies (2705 participants) reported this outcome (Ballard 1997; Demarre 2012; Grindley 1996; Nixon 2006; Pring 1998; Rafter 2011; Taylor 1999). The studies reported a range of different measures and outcome data cannot be easily interpreted (see Table 2). We are uncertain if there is a difference in support-surface-associated patient comfort between different types of alternating pressure (active) air surfaces. Evidence is of very low certainty, downgraded once for risk of bias (three small studies with a high risk of bias judgement for at least one domain other than performance bias, and all the rest having an unclear judgement for at least one domain other than performance bias), once for inconsistency in terms of comfort results across studies, and once for strongly suspected publication bias.

All reported adverse events (median follow-up duration 60 days)

Only Nixon 2006 (1971 participants) reported this outcome for its comparison of mattress and overlay formats of alternating air (active) surfaces. We are uncertain if there is a difference in the adverse events between the two formats of alternating pressure (active) air surfaces. Nixon 2006 reported that 377 adverse events were observed among 308 participants within 60 days. However, the study authors did not report these data by study groups, although they did present surface-related adverse events by study groups (10 participants in alternating pressure air mattresses and four in alternating pressure air overlays). Evidence is of very low certainty, downgraded twice for high overall risk of bias for this outcome due to high attrition bias, and twice for imprecision due to small sample size.

Health-related quality of life
Not reported.

**Cost-effectiveness (follow-up duration median 60 days)**

Only *Nixon 2006* (1971 participants) reported this outcome using a trial-based, cost-effectiveness analysis for its comparison of mattress and overlay formats of alternating air (active) surfaces. The cost-effectiveness acceptability curve indicated that, on average, alternating pressure mattresses were associated with an 80% probability of being cost-saving compared with alternating pressure overlays. Evidence is of moderate certainty, downgraded once for an unclear risk of bias in one domain other than performance bias: *Nixon 2006* was at an unclear risk of detection bias in terms of both the health benefit (time to pressure ulcer development) and costs in the economic analysis.

In its base case analysis, *Nixon 2006* reported that alternating pressure air mattresses were associated with a delay in pressure ulcer development and lower overall costs (mean difference in total costs between overlay and mattress groups: GBP 283.60 per participant on average, 95% CI GBP 377.59 to GBP 976.79; and the mean difference in the restricted Kaplan–Meier estimates of time to pressure ulcer onset between overlay and mattress groups: –10.63 days, 95% bias-corrected CI of the difference –24.40 to 3.09 days). The analysis was from the perspective of the UK National Health Service (NHS) and Personal Social Service; but there was no cost discounting due to the time horizon being less than one year.

**Discussion**

**Summary of main results**

We report evidence from 32 RCTs on the effects of alternating pressure (active) air beds or mattresses compared with any support surface on the incidence of pressure ulcers in any setting and population. We did not analyse data reported in four studies that compared alternating pressure (active) air surfaces with 'standard hospital surfaces' that were not well described, because the term 'standard hospital surface' does not represent a single recognisable surface internationally or over time. We summarise key findings for six specific comparisons that had data analyses as follows:

- **Alternating pressure air surfaces versus foam surfaces**: alternating pressure (active) air surfaces may reduce the proportion of people developing incident pressure ulcers compared with foam surfaces (4 studies, 2247 participants; low-certainty evidence). It is uncertain whether there is any difference in the risk of developing a new pressure ulcer over 60 days' follow-up (2 studies, 2105 participants; very low-certainty evidence); in support-surface-associated patient comfort (1 study, 76 participants; very low-certainty evidence); in health-related quality of life at 90 days' follow-up (1 study, 2029 participants; low-certainty evidence); as well as in the number of all reported adverse events (3 studies, 2181 participants; very low-certainty evidence) between these types of support surfaces. We found moderate-certainty cost-effectiveness evidence that alternating pressure (active) air surfaces are probably more cost-effective than foam surfaces. Although there were negligible differences in participant-reported health utility in those allocated to alternating pressure (active) air surfaces and foam surfaces, the difference in
costs between these trial arms (with the arm of foam surfaces having higher costs) meant the cost-effectiveness finding favoured the alternating pressure (active) air surfaces (Nixon 2019).

- **Alternating pressure air surfaces versus reactive air surfaces**: it is uncertain if there is any difference between alternating pressure (active) air surfaces and reactive air surfaces in the proportion of participants developing a new pressure ulcer (6 studies, 1648 participants; very low-certainty evidence). When we considered time to pressure ulcer development as our primary outcome, we found that people using alternating pressure (active) air surfaces may be more likely to develop an incident pressure ulcer than those treated with reactive air surfaces over 14 days' follow-up in a nursing home setting (1 study, 308 participants; low-certainty evidence). For our secondary outcome, we are uncertain if there is a difference in support-surface-associated patient comfort between alternating pressure (active) air surfaces and reactive air surfaces (4 studies, 1364 participants; very low-certainty evidence).

- **Alternating pressure air surfaces versus reactive water surfaces**: it is uncertain if there is a difference in the proportion of participants developing a new pressure ulcer between alternating pressure (active) air surfaces and reactive water-filled surfaces (2 studies, 358 participants; very low-certainty evidence). We did not find data for our secondary outcomes.

- **Alternating pressure air surfaces versus reactive fibre surfaces**: it is uncertain if there is a difference in the proportion of participants developing a new pressure ulcer between alternating pressure (active) air surfaces and reactive fibre surfaces (3 studies, 285 participants; very low-certainty evidence). We also found it is uncertain if there is a difference in support surface associated patient comfort between these support surfaces (1 study, 187 participants; very low-certainty evidence).

- **Alternating pressure (active) air surfaces on operating tables and subsequently on ward beds versus reactive gel surfaces used on operating tables followed by foam surfaces on ward beds**: Alternating pressure (active) air surfaces applied on both operating tables and hospital beds may reduce the proportion of people developing a new pressure ulcer compared with reactive gel surfaces used on operating tables followed by foam surfaces applied on hospital beds (2 studies, 415 participants). However, this is low-certainty evidence. We are uncertain if there is any difference in adverse events between these support surfaces (1 study, 198 participants; very low-certainty evidence).

- **Alternating pressure air surfaces versus alternating pressure air surfaces**: we found low-certainty evidence suggesting little to no difference in the risk of developing a new pressure ulcer when treated with different forms of alternating pressure (active) air surfaces (7 studies, 2833 participants). We are uncertain whether there is any difference in support-surface-associated patient comfort and adverse effects between different forms of alternating pressure (active) air surfaces (very low-certainty evidence). There is moderate-certainty evidence that alternating pressure air mattresses are probably more cost-effective than alternating pressure air overlays.

### Overall completeness and applicability of evidence
As detailed in *Search methods for identification of studies*, we ran a comprehensive set of literature searches to maximise the relevant research included here.

Whilst use of support surfaces is relevant to adults and children, all participants in the included studies were adults (with the reported average age ranging from 37.2 to 87.0 years, median of 69.1 years). Across the included studies, more than half (55.6%) of enrolled participants were female. Almost all of the studies enrolled people who were at (high) risk of pressure ulceration (with risk assessed using a risk assessment tool (e.g. the Braden scale)), and who were ulcer-free at the time of recruitment. Nine of the included studies (with 4808 participants) did include participants with superficial pressure ulcers at baseline.

Most of the included studies were small (half had fewer than 100 participants). Nine studies enrolled more than 200 participants (*Andersen 1982*; *Aronovitch 1999*; *Beeckman 2019*; *Bliss 1995*; *Demarre 2012*; *Jiang 2014*; *Laurent 1998*; *Nixon 2006*; *Nixon 2019*), of which six studies enrolled more than 400 participants (*Andersen 1982*; *Bliss 1995*; *Demarre 2012*; *Jiang 2014*; *Nixon 2006*; *Nixon 2019*). These six trials together accounted for 73% (6624/9058) of the participants in the review.

The geographical scope of the included studies was limited. Almost all of the studies were from Europe and North America. Only one large trial was from China (*Jiang 2014*), and another one was from Japan (*Sanada 2003*).

The included studies recruited participants from a variety of care settings including: acute care settings (19 studies); community and long-term care settings (nine studies), or both (one study), and intensive care units (three studies). Whilst five of the six comparisons included studies from a variety of care settings, due to a limited number of included studies for these four comparisons, we could not perform pre-specified subgroup analysis by different care settings. Thus, for these five comparisons, we are unable to draw conclusions about potential modification of treatment effects in different care settings. An exception to this is the comparison of the alternating pressure (active) air surface on operating tables and subsequently on the ward bed with the reactive gel surface on operating tables followed by the foam surface applied on ward beds. This evidence suggests the beneficial effects of using alternating pressure (active) air surfaces on both operating tables and hospital ward beds. There were no data specifically for operating rooms.

We recognise that alternating pressure (active) air surfaces can have a range of cell sizes (e.g. large cells, small cells) and other features (e.g. being able to operate as a hybrid surface switching between active and reactive modes; low-air-loss; see *Appendix 4*). In this review, we considered all these specific types (e.g. alternating pressure (active) low-air-loss surfaces, and hybrid air surfaces) as alternating pressure (active) air surfaces because they have the same underlying mechanism of redistributing pressure activity (i.e. mechanically alternating pressure). Some health professionals have expressed an interest in the effectiveness of support surfaces defined as hybrid based on having a mixed composition of materials; for example, surfaces made from alternating pressure air cells on a foam layer as opposed to only air cells. When exploring the evidence in this way, we identified very limited evidence. Such exploration may be important for future work if deemed a clinical priority.

We did not analyse data reported in another four studies comparing alternating pressure (active) air surfaces with 'standard hospital surfaces'. Those surfaces were labelled with that term by the original study authors, and we could not define them using the *NPIAP S3I 2007* support surfaces terms and definitions. However, for
completeness of all relevant evidence, we reported the data from these studies in Appendix 5.

Another potential limitation in the included studies is the large variation in duration of follow-up (ranging from three days to 180 days, median of 14 days). This is partly because different follow-up durations are appropriate in different care settings. For example, participants staying in acute care settings are more likely to be discharged after a short-term hospital stay, whilst those staying at community and long-term care settings will typically stay for longer. The short median duration of follow-up may contribute to an under-estimation of pressure ulcer incidence across study groups of the included studies because most pressure ulcers would occur in the first two to four weeks after hospital admission (Schoonhoven 2007), and some incident pressure ulcers may have been missed in these studies.

Quality of the evidence

We implemented the GRADE approach for assessing the certainty of the evidence and found that most included evidence from our 19 meta-analyses or syntheses across six comparisons was of low and very low certainty. Downgrading of evidence was largely due to the high risk of bias of findings and imprecision due to small study sizes in terms of participants or event numbers, or both. There was also some inconsistency across studies and publication bias for some comparisons.

Limitations in study design

We downgraded once or twice for study limitations for almost all evidence. We assessed risk of bias according to seven domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, selective outcome reporting, incomplete follow-up, and other potential biases. Of the 32 studies, we judged 25 as being at high overall risk of bias, and only seven at unclear overall risk of bias. The prevalence of high overall risk of bias is partly due to the non-blinding of participants and personnel for most of comparisons. We acknowledged that such blinding of participants and personnel is impractical for almost all comparisons. Therefore, we did not downgrade certainty of evidence for studies at high overall risk of bias solely due to the possible presence of performance bias.

Ten studies were also at high risk of bias due to unblinded outcome assessment. Unblinded assessment has been found to exaggerate odds ratios (from subjective binary outcomes) by, on average, 36% (Hróbjartsson 2012). The outcome assessment of pressure ulcer incidence is subjective and blinded assessment - whilst operationally challenging - can be undertaken; for example, through masked adjudication of photographs of pressure areas (Baumgarten 2009). Therefore, we considered unblinded pressure ulcer incidence assessment could substantially bias effect estimates in the included studies and downgraded the certainty of evidence for detection bias on a study-by-study basis.

Indirectness of evidence

In general, we considered that the participants, interventions, and outcomes in the included studies were within the scope of the published review protocol and there was no indirectness. Therefore, we did not downgrade for indirectness, with the exception of one piece of included evidence: the evidence for support-surface-
associated patient comfort outcome in the comparison of alternating pressure (active) air surfaces versus reactive fibre surfaces. In the only included study for this outcome, the reason for dropout was considered as discomfort. Therefore, the evidence may not be directly relevant to the comfort outcome of this review.

**Inconsistency of results and unexplained heterogeneity**

Statistical heterogeneity was low for most of the evidence syntheses (15/19) we performed and we did not downgrade for inconsistency for these pieces of evidence. The low statistical heterogeneity was partly because eight of the 19 syntheses included only one study. One of the 19 meta-analyses suggested some heterogeneity ($I^2 = 63\%$ in Analysis 1.1). However, we did not downgrade for inconsistency for this because our additional exploratory analyses suggested the heterogeneity could be well explained by excluding a study with an extreme value. We downgraded for inconsistency for the rest (four) of the meta-analyses or narrative syntheses. None of these four analyses included more than seven studies. Despite the fact that we found heterogeneity in terms of overall risk of bias, care settings, outcome measurement methods, or follow-up durations between their included studies, we investigated their heterogeneity using subgroup analysis and we considered their heterogeneity (inconsistency) unexplained.

We have to note that, although we planned to calculate prediction intervals to understand the implications of heterogeneity, all analyses included a small number (up to seven) of included studies which was fewer than the 10 needed for this calculation.

**Imprecision of results**

We downgraded once or twice for imprecision for most comparisons. Study sample sizes were small in most cases (median sample size: 83; range: 10 to 2029) with often small numbers of events and wide associated confidence intervals around effect estimates. Confidence intervals often crossed the line of null effect and RRs = 0.75 and/or 1.25, thus meaning we could not discern whether the true population effect was likely to be beneficial or harmful.

**Publication bias**

We did not downgrade the certainty of evidence for publication bias in almost all meta-analyses. This is because (1) we have confidence in the comprehensiveness of our literature searches; and (2) we did not find any clear evidence of non-reporting bias of study results. Although we planned to perform funnel plots for meta-analysis to visually inspect for publication bias, there was no analysis including more than ten studies.

**Potential biases in the review process**

We followed pre-specified methods to review evidence in order to prevent potential bias in the review process. For example, we ran comprehensive electronic searches, searched trials registries, and checked the references of systematic reviews identified by the electronic searches.

This review also has limitations. Firstly, some included studies may have considered co-interventions as 'usual care' but did not fully describe them. We assumed that all
studies had provided co-interventions equally to participants in their study groups if there was nothing to indicate that this was not the case. Secondly, we did not implement pre-specified subgroup analysis, as mentioned above, mainly because no analysis included more than ten studies. Thirdly, we included a factorial design study - Laurent 1998 - in this review but did not consider the potential interaction between interventions. Fourthly, only Nixon 2019 reported HRs and CIs related to time-to-event data. The remaining HRs and CIs we used in related analyses were calculated using the methods described in Tierney 2007. We recognised that those calculated data (and associated meta-analyses) might be inaccurate. We noted that almost all time-to-event data analyses using the HRs and CIs we calculated appeared (or tended) to agree with associated binary data analyses as we expected. Fifthly, four studies described their controls as 'standard hospital surfaces' but did not specify the construction materials of these surfaces. Although we made efforts to collect information on these surfaces, we were not able to classify them. Traditionally, 'standard hospital surfaces' meant foam surfaces, but we felt adopting that assumption was unwarranted. Further classification of these surfaces might change the results of some comparisons; for example, alternating pressure (active) air surfaces versus foam surfaces. Finally, we were not able to pre-specify the comparisons included in this review. This is because specific support surfaces applied could only be known and defined once eligible studies were included. However, we pre-planned to use the NPIAP S3I 2007 support surface terms and definitions to define specific support surfaces in order to avoid any potential bias.

**Agreements and disagreements with other studies or reviews**

To our knowledge, among the 14 systematic reviews or meta-analyses we identified in electronic searches for this review (Chou 2013; Huang 2013; McGinnis 2011; McInnes 2015; McInnes 2018; Mistiaen 2010; De Oliveira 2017; Rae 2018; Reddy 2006; Reddy 2008; Serraes 2018; Shi 2018a; Smith 2013; Yao 2018), two recent comprehensive reviews include alternating pressure (active) air surfaces evidence: Shi 2018a, and the Cochrane Review 'Support surfaces for pressure ulcer prevention' (McInnes 2015).

This review differs from Shi 2018a in how specific alternating pressure (active) air surfaces are classified. In this review, we consider them as a single generic group, whereas Shi 2018a considered alternating pressure (active) low-air-loss surfaces, hybrid air surfaces and generic alternating pressure (active) air surfaces as separate groups.

Additionally, Shi 2018a grouped some interventions under the term 'standard hospital surfaces' but concluded that the types of surfaces labelled in this way varied over time, and by setting. In this review, we made great efforts to define surfaces where these surfaces were described as a 'standard hospital surface' in the included studies to ensure they were placed in the correct comparisons. This re-definition allowed us to define the 'conventional management' used in Aronovitch 1999 and Russell 2000 as reactive gel surfaces followed by foam surfaces, rather than standard hospital surfaces. We classified 'standard hospital surfaces' used in other studies as undefined surfaces.

Shi 2018a reported moderate-certainty evidence favouring alternating pressure (active) air surfaces. The reasons above may explain some of the inconsistency
between the reviews but, importantly, **Shi 2018a** was a network meta-analysis. **Shi 2018a** indicated an evidence gap around the comparison alternating pressure (active) air surfaces versus foam surfaces, and expected to tackle this gap by including a large, then ongoing study - **Nixon 2019** - in data analysis. This review did include this study, but this still resulted in some uncertain evidence with the use of pairwise meta-analysis methods. Further planned review work using network meta-analysis will add to the findings reported here.

The Cochrane Review **McInnes 2015** grouped a variety of reactive surfaces ('Silicore overlay', a 'water mattress', a 'foam pad', and 'static air mattresses') into 'constant low-pressure devices', concluding that it was unclear whether alternating pressure (active) air surfaces impacted on incident pressure ulceration compared with these constant low-pressure devices. The conclusions of **McInnes 2015** are generally consistent with our review but our review adds more granular findings to the evidence base. By using the NPIAP S3I terms for support surfaces, our review differentiated reactive surfaces from each other, and presents separate analyses for each.

## Authors' conclusions

### Implications for practice

Current evidence is uncertain about the difference in pressure ulcer incidence between alternating pressure (active) air surfaces and other surfaces: reactive water surfaces, reactive fibre surfaces and reactive air surfaces. People using alternating pressure (active) air surfaces may reduce pressure ulcer incidence compared with those using foam surfaces. Also, alternating pressure (active) air surfaces applied on both operating tables and hospital beds may reduce pressure ulcer incidence compared with reactive gel surfaces used on operating tables followed by foam surfaces applied on hospital beds. However, people using alternating pressure (active) air surfaces may be more likely to develop an incident pressure ulcer than those treated with reactive air surfaces over 14 days’ follow-up in a nursing home setting. Alternating pressure (active) air mattresses are probably more cost-effective than overlay versions of this technology for people in acute care settings. Alternating pressure (active) air surfaces are probably more cost-effective than foam surfaces for people in community and acute care settings.

### Implications for research

Given the large number of different support surfaces available, future studies should prioritise which support surfaces to evaluate on the basis of the priorities of decision-makers. For example, alternating pressure air surfaces versus reactive air surfaces may be a high priority for future evaluation. All interventions used should be clearly described using the current classification system, and researchers should avoid the use of generic terms such as 'standard hospital surfaces'. Limitations in included studies are largely due to small sample size and sub-optimal RCT design. The incidence of pressure ulcers can be low in certain settings and this needs to be considered in sample size calculations and when considering the feasibility of trial conduct. Under-recruitment or over-estimation of event rates that then fail to occur, or both, can lead to imprecision and less robust effect estimates.

Future studies should also consider carefully the choice of outcomes they report. Time-to-event data for pressure ulcer incidence should be used in studies. Careful and consistent assessment and reporting of adverse events needs to be undertaken to generate
meaningful data that can be compared between studies. Likewise, patient comfort is an important outcome but poorly defined and reported, and this needs to be considered in future research studies. Further studies should aim to collect and report health-related quality of life using validated measures. Finally, future studies should nest cost-effectiveness analysis in their conduct where possible.

Any future studies must be undertaken to the highest standard possible. Whilst it is challenging to avoid the risk of performance bias in trials of support surfaces as blinding of participants and personnel is seldom possible, stringent protocols - for example, in terms of encouraging consistent care and blinded decision-making - can help to minimise the risk. It is also important to fully describe co-interventions (e.g. repositioning) and ensure protocols mandate balanced use of these across trial arms. The risk of detection bias can also be minimised with the use of digital photography and adjudicators of the photographs being masked to support surfaces (Baumgarten 2009). Follow-up periods should be for as long as possible and clinically relevant in different settings. Where possible and useful, data collection after discharge from acute settings may be considered.

Acknowledgements

The authors are grateful to the following peer reviewers who provided feedback on both the protocol and the review: Julie Bruce and Zena Moore. Thanks are also due to Denise Mitchell for copy-editing the protocol, to Jess Sharp for additional copy-edit feedback, to Faith Armitage for copy-editing the review and to Nicole Pitcher for writing the Plain Language Summary.

We also would like to thank Zhenmi Liu, Gill Norman and Melanie Stephens for double-checking data extraction and risk of bias assessment for this review and Cochrane Musculoskeletal, Oral, Skin and Sensory Network Editors Peter Tugwell and Jennifer Hilgart for feedback and final approval of the review for publication.

Data and analyses

<table>
<thead>
<tr>
<th>Comparison 1</th>
<th>Alternating pressure (active) air surfaces compared with reactive foam surfaces</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outcome or subgroup title</strong></td>
<td><strong>No. of studies</strong></td>
</tr>
<tr>
<td>1.1 Proportion of participants developing a new pressure ulcer</td>
<td>4</td>
</tr>
<tr>
<td>1.2 Time to pressure ulcer development</td>
<td>2</td>
</tr>
<tr>
<td>1.3 Health-related quality of life</td>
<td>1</td>
</tr>
<tr>
<td>Outcome or subgroup title</td>
<td>No. of studies</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>1.3.1 90-day EQ-5D-5L</td>
<td>1</td>
</tr>
<tr>
<td>1.3.2 90-day PU-QoL-UI</td>
<td>1</td>
</tr>
</tbody>
</table>

**Comparison 2**

**Alternating pressure (active) air surfaces compared with reactive air surfaces**

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 Proportion of participants developing a new pressure ulcer</td>
<td>6</td>
<td>1648</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>1.61 [0.90, 2.88]</td>
</tr>
<tr>
<td>2.2 Time to pressure ulcer development</td>
<td>1</td>
<td></td>
<td>Hazard Ratio (IV, Random, 95% CI)</td>
<td>2.25 [1.05, 4.83]</td>
</tr>
</tbody>
</table>

**Comparison 3**

**Alternating pressure (active) air surfaces compared with reactive water surfaces**

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 Proportion of participants developing a new pressure ulcer</td>
<td>2</td>
<td>358</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>1.21 [0.52, 2.83]</td>
</tr>
</tbody>
</table>

**Comparison 4**

**Alternating pressure (active) air surfaces compared with reactive fibre surfaces**

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
</table>
### Outcome or subgroup title

<table>
<thead>
<tr>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 Proportion of participants developing a new pressure ulcer</td>
<td>3</td>
<td>285</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
</tr>
</tbody>
</table>

### Comparison 5

**Alternating pressure (active) air surfaces on operating tables and subsequently on ward beds compared with reactive gel surfaces on operating tables followed by foam surfaces on ward beds**

<table>
<thead>
<tr>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1 Proportion of participants developing a new pressure ulcer</td>
<td>2</td>
<td>415</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
</tr>
</tbody>
</table>

### History

Protocol first published: Issue 5, 2020
Review first published: Issue 5, 2021

### Contributions of authors

Chunhu Shi: conceived the review; designed the review; coordinated the review; extracted data; analysed or interpreted data; undertook quality assessment; performed statistical analysis; produced the first draft of the review; contributed to writing or editing the review; wrote to study authors/experts/companies; approved the final review prior to publication; is guarantor of the review.

Jo Dumville: conceived the review; designed the review; coordinated the review; analysed or interpreted data; checked quality assessment; checked quality of statistical analysis; produced the first draft of the review; contributed to writing or editing the review; advised on the review; secured funding; performed previous work that was the foundation of the current review; approved the final review prior to publication.

Nicky Cullum: conceived the review; designed the review; checked quality of data extraction; contributed to writing or editing the review; advised on the review; secured funding.
funding; performed previous work that was the foundation of the current review; approved the final review prior to publication.

Sarah Rhodes: conceived the review; designed the review; checked quality of data extraction; checked quality assessment; checked quality of statistical analysis; contributed to writing or editing the review; advised on the review; approved the final review prior to publication.

Asmara Jammali-Blasi: checked quality of data extraction; checked quality assessment; contributed to writing or editing the review; performed previous work that was the foundation of the current review; approved the final review prior to publication.

Elizabeth McInnes: conceived the review; designed the review; coordinated the review; checked quality of data extraction; checked quality assessment; contributed to writing or editing the review; advised on the review; performed previous work that was the foundation of the current review; approved the final review prior to publication.

Contributions of the editorial base

Gill Norman (Editor): edited the protocol; advised on methodology, interpretation and content; approved the final protocol prior to publication.

Gill Rizzello (Managing Editor): coordinated the editorial process; advised on content; edited the protocol and the review.

Sophie Bishop (Information Specialist): designed the search strategy and edited the search methods section.

Tom Patterson (Editorial Assistant): edited the reference section of the protocol and the review.

Declarations of interest

Chunhu Shi: I received research funding from the National Institute for Health Research (NIHR; Research for Patient Benefit, Evidence synthesis for pressure ulcer prevention and treatment, PB-PG-1217-20006). I received support from the Tissue Viability Society to attend conferences unrelated to this work. The Doctoral Scholar Awards Scholarship and Doctoral Academy Conference Support Fund (University of Manchester) also supported a PhD and conference attendance respectively; both were unrelated to this work.

Jo Dumville: I am the Chief Investigator on a National Institute for Health Research grant that funded the conduct of this review (Research for Patient Benefit, Evidence synthesis for pressure ulcer prevention and treatment, PB-PG-1217-20006). This research was co-funded by the NIHR Manchester Biomedical Research Centre and partly funded by the National Institute of Health Research Applied Research Collaboration Greater Manchester.

Nicky Cullum: I am Co-investigator on a National Institute for Health Research grant that funded the conduct of this review (Research for Patient Benefit, Evidence synthesis for pressure ulcer prevention and treatment, PB-PG-1217-20006). This
research was co-funded by the National Institute of Health Research Manchester Biomedical Research Centre, and partly funded by the National Institute of Health Research Applied Research Collaboration Greater Manchester.

My previous and current employers received research grant funding from the NHS Research and Development Programme, and subsequently the NIHR, for previous versions of this review. The funders had no role in the conduct of the review. My previous employer received research grant funding from the NIHR for an RCT comparing different alternating pressure air surfaces for pressure ulcer prevention. This RCT (for which I was the Chief Investigator) is included in this review. I played no part in the data extraction or risk of bias assessment for this study (Nixon 2006).

Sarah Rhodes: my salary is funded from three National Institute of Health Research grants and a grant from Greater Manchester Cancer.

Asmara Jammali-Blasi: none known.

Elizabeth McInnes: none known.

Sources of support

Internal sources

- Division of Nursing, Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK

External sources

- National Institute for Health Research, UK
  This project is funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-1217-20006). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

- NIHR Manchester Biomedical Research Centre (BRC), UK
  This research was co-funded by the NIHR Manchester BRC. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

- National Institute for Health Research (NIHR), UK
  This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Wounds. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

- National Institute for Health Research Applied Research Collaboration (ARC), Greater Manchester, UK
  Nicky Cullum and Jo Dumville’s work on this project was partially funded by the National Institute for Health Research Applied Research Collaboration Greater Manchester. The views expressed in this publication are those of the authors and not necessarily those of the National Institute for Health Research or the...
Department of Health and Social Care.

Differences between protocol and review

- Two review authors independently assessed the titles and abstracts of the new search results for relevance using Rayyan rather than using Covidence.
- For new included studies, one review author independently extracted data and another review author checked all data, rather than two review authors independently carrying out data extraction.
- When a study only had complete case data, we considered complete case data in the related main analysis (i.e. assuming no missing data issue). This was not pre-planned.
- We presented separate 'Summary of findings' tables for five of the six comparisons evaluated in this review. We did not present the table for the comparison between different types of alternating pressure (active) air surfaces.
- Where we did not pool data, we conducted a GRADE assessment and presented these assessments in a narrative format in 'Summary of findings' tables. This was not previously planned.

Characteristics of studies

Characteristics of included studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study characteristics</th>
<th>Andersen 1982</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study objective:</td>
<td>to observe &quot;the development of pressure sores in risk-patients nursed on these mattresses [water-mattresses and alternating pressure air-mattresses and compare] the results with a similar group of patients nursed on ordinary hospital mattresses&quot;</td>
</tr>
<tr>
<td>Study design:</td>
<td>randomised controlled trial</td>
</tr>
<tr>
<td>Study grouping:</td>
<td>parallel group</td>
</tr>
<tr>
<td>Duration of follow-up:</td>
<td>10 days</td>
</tr>
<tr>
<td>Number of arms:</td>
<td>3</td>
</tr>
<tr>
<td>Single centre or multi-site:</td>
<td>single centre</td>
</tr>
<tr>
<td>Study start date and end date:</td>
<td>not described</td>
</tr>
<tr>
<td>Setting:</td>
<td>hospital</td>
</tr>
<tr>
<td>Baseline characteristics</td>
<td></td>
</tr>
<tr>
<td>Inclusion criteria:</td>
<td>patients with acute conditions and a risk score of 2 or more (i.e. at risk)</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
<td>&quot;those who already had pressure sores&quot;</td>
</tr>
<tr>
<td>Sex (M:F):</td>
<td>60:101 in control; 73:93 in air; 73:82 in water</td>
</tr>
<tr>
<td>Age (years):</td>
<td>distribution of participants' ages described</td>
</tr>
</tbody>
</table>
Baseline skin status: all at risk according to the risk score used by the authors; free of ulcers.

Group difference: no difference between groups according to age, sex, body weight or risk score.

Total number of participants: not described; n = 482 available.

Unit of analysis: individuals.

Unit of randomisation (per patient): individuals.

Interventions

**Alternating-pressure air-mattress**
- **Description of interventions**: "2 metres long and consists of longitudinal air tubes connected in two separate series ... Each of the two series is inflated and deflated alternately by an electrically driven pump, providing sufficient air-pressure to support the patient ... for about 5 minutes. The mattress is placed on top of an ordinary hospital mattress."
- **NPUAP S3I classification**: powered, alternating pressure (active) air surface.
- **Co-interventions**: not described.
- **Number of participants randomised**: not described; 166 available.
- **Number of participants analysed**: n = 166.

**Water mattress**
- **Description of interventions**: "a box-shaped container 200 by 90 by 15 cm ... filled with lukewarm water and placed on top of a hospital mattress ... to keep the patient afloat."
- **NPUAP S3I classification**: non-powered, reactive water-filled surface.
- **Co-interventions**: not described.
- **Number of participants randomised**: not described; 155 available.
- **Number of participants analysed**: n = 155.

**Ordinary hospital mattresses**
- **Description of interventions**: not described.
- **NPUAP S3I classification**: standard hospital surface.
- **Co-interventions**: not described.
- **Number of participants randomised**: not described; 161 available.
- **Number of participants analysed**: n = 161.

Outcomes

**Proportion of participants developing a new pressure ulcer**
- **Outcome type**: binary.
- **Time points**: 10 days.
- **Reporting**: partially reported.
- **Measurement method (e.g. scale, self-reporting)**: researchers-assessed; ulcer classification system not described.
- **Definition (including ulcer stage)**: using bullae, black necrosis and skin defect as evidence of pressure sores; stage of ulcer not described.
- **Dropouts**: not described.
- **Notes (e.g. other results reported)**: 21 patients in control versus 7 patients in water-mattress versus 7 patients in air-mattress.

**Time to pressure ulcer development**
- **Reporting**: not reported.
Support-surface-associated patient comfort
- **Reporting**: not reported

All reported adverse events using allocated support surfaces
- **Reporting**: not reported

Health-related quality of life (HRQOL)
- **Reporting**: not reported

Cost-effectiveness
- **Reporting**: not reported
- **Notes**: water-mattress price GBP (pounds sterling) 20; alternating-pressure air-mattress price GBP 200

Outcomes that are not considered in this review but reported in trials:
1. "opinions on mattresses" described as "the acceptability of the mattress" and rated as the numbers of staff satisfied and the numbers of patients satisfied with different mattresses.

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias)    | Unclear risk       | Quote: "Six hundred patients at risk for pressure sores were randomised in either a control group or one of two experimental groups ... They were allotted to one of the three groups ..."  
Comment: method of randomisation was not reported |
| Allocation concealment (selection bias)        | Unclear risk       | Comment: no information provided                                                                                                                                                          |
| Blinding of participants and personnel (performance bias) All outcomes | Unclear risk       | **Outcome group: primary outcome (i.e. the only outcome)**                                                                                                                                   
Comment: no information provided                                                                                                                                 |
| Blinding of outcome assessment (detection bias) All outcomes | High risk          | **Outcome group: primary outcome (i.e. the only outcome)**                                                                                                                                   
Quote: "One of us [note: study's authors] assessed the condition of the skin ..."  
Comment: appears to have no blinding, and the pressure ulcer incidence outcome measurement is likely to be influenced by lack of blinding. |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk       | **Outcome group: primary outcome (i.e. the only outcome)**                                                                                                                                   
Quote: "Six hundred patients at risk for pressure sores were randomised ..."  
Quote: "Among the 600 risk-patients ... 118 dropped out during the first 24 hours before the first dermatologic inspection. This did not impair randomization."  
Quote: "The groups remained comparable throughout the 10-day study period"  
Comment: unclear risk of bias was judged because authors claimed that randomisation was not impaired though the proportion of missing data was high and no reasons for missing data were provided. |
| Selective reporting (reporting bias)           | Low risk           | Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified. |
Other bias | Low risk | Comment: the study appears to be free of other sources of bias.

### Aronovitch 1999

#### Study characteristics

**Study objective**: 
"... to determine the efficacy and safety of the experimental system (study group), in comparison with conventional management (control group), for the prevention of pressure ulcers in the operative and postoperative settings"

**Study design**: randomised controlled trial

**Study grouping**: parallel group

**Duration of follow-up**: 7 days

**Number of arms**: 2

**Single centre or multi-site**: single centre

**Study start date and end date**: March 1997 to February 1998

**Setting**: tertiary care facility (operating theatre and wards)

#### Baseline characteristics

**Inclusion criteria**: "18 years of age or older undergoing a scheduled surgery with general anesthesia for at least 4 hours (actual operative time of 3 hours or more)"

**Exclusion criteria**: patients "participated in a clinical trial within 30 days of the baseline visit ... or had a pressure ulcer at the baseline visit"

**Sex (M:F)**: 79:31 in experimental system; 77:27 in conventional management

**Age (years)**: mean 63.5 (SD 11.9) in experimental system; 64.7 (11.8) in conventional management

**Baseline skin status**: Modified Knoll scale score - on average less than 4 (range 0 to 13; a score of 12 or higher = at risk of pressure ulcer development) in both groups; and those with pressure ulcers at baseline excluded

**Group difference**: no difference

**Total number of participants**: 217 patients

**Unit of analysis**: individuals

**Unit of randomisation (per patient)**: groups of individuals by weeks

#### Intervention characteristics

**Experimental management**

- **Description of interventions**: "using the MicroPulse System (MicroPulse, Inc., Portage, Mich) both during then after surgery ... comprised of a thin multi-segmented pad with more than 2,500 small air-cells enclosed in a fluid-proof cover. The air-cells are arranged in rows so the patient is supported by 50% of the cells (the inflated cells) at any given time ... the cells are deflated ... a cycle time of less than 5 minutes ... until discharge from the hospital or for a maximum of 7 days post-surgery"

- **NPUAP S3I classification**: powered, alternating pressure (active) air surface

- **Co-interventions**: not described

- **Number of participants randomised**: n = 112

- **Number of participants analysed**: not described

**Conventional management**

- **Description of interventions**: "the use of an Action Pad (Action Products, Inc, Hagerstown, Md) in the operating room on top of a standard operating room pad, and a Pressure Guard II hospital replacement mattress (Span-America Medical Systems, Inc., Spartanburg, SC) on the hospital bed" (Aronovitch 1999); for operating table, Action Pad (Action Products) consisting of AKTON® Viscoelastic polymer that looks and feels like a gel
A series of PressureGuard products identified from Span-America product catalogue (www.spanamerica.com/product-catalog-new.php) and the catalogue states "... every PressureGuard model combines the effectiveness of an air flotation system with the unmatched stability and safety of a multi-component engineered foam shell"

- **NPUAP S3I classification**: non-powered, reactive gel surface; non-powered, reactive foam surface; applied sequentially
- **Co-interventions**: not described
- **Number of participants randomised**: n = 105
- **Number of participants analysed**: not described

### Outcomes

**Proportion of participants developing a new pressure ulcer**

- **Outcome type**: binary
- **Time points**: within 7 days
- **Reporting**: partially reported

**Measurement method (e.g. scale, self-reporting)**: using the recommendations of both the NPUAP and the Wound, Ostomy, and Continence Nurses Society (WOCN)

**Definition (including ulcer stage)**: the occurrence of a pressure ulcer of any stage at any time within 7 days of surgery

- **Dropouts**: not described
- **Notes (e.g. other results reported)**: data on stages of ulcers available.

**Experimental system**: one individual (not considered to be related to the study device); conventional management: 7 individuals (8.75%), one with three ulcers, two with two ulcers, and four with one ulcer (P < 0.005 between groups)

**Time to pressure ulcer development**

- **Reporting**: not reported

**Support-surface-associated patient comfort**

- **Reporting**: not reported

**All reported adverse events using allocated support surfaces**

- **Reporting**: not reported

**Health-related quality of life (HRQOL)**

- **Reporting**: not reported

**Cost-effectiveness**

- **Reporting**: not reported

**Outcomes that are not considered in this review but reported in trials**: No further outcome

### Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;Randomization was performed by week rather than by patient to decrease protocol error.&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk of bias because the methods were not clear</td>
</tr>
</tbody>
</table>
### Ballard 1997

#### Study characteristics

**Methods**

- **Study objective**: to evaluate two alternating-pressure mattresses for patient comfort and quality of sleep
- **Study design**: pilot randomised trial
- **Study grouping**: cross-over design
- **Duration of follow-up**: 3 days for each arm (so 6-day trial duration)
- **Number of arms**: 2
- **Single centre or multi-site**: 2 centres
- **Study start date and end date**: not described
- **Setting**: 2 UK nursing homes

**Participants**

- **Baseline characteristics**
  - **Inclusion criteria**: able and willing to give their informed consent; able to understand and use standardised visual rating scales and questionnaires; without any evidence of existing pressure damage
  - **Exclusion criteria**: those who were confused; acutely or terminally ill; regularly incontinent of urine or faeces; had any sensory/neurological deficiency; weighed over 150 kg; involved in a simultaneous study; unable to complete the questionnaire or visual analogue scale
- **Sex (M:F)**: overall 5:5
- **Age (years)**: overall mean 84 (range 75 to 90)
- **Baseline skin status**: no risk
- **Group difference**: not given
- **Total number of participants**: n = 10

#### Outcome group: primary outcome

**Blinding of participants and personnel (performance bias)**

- **Unclear risk**

**Blinding of outcome assessment (detection bias)**

- **Unclear risk**

**Incomplete outcome data (attrition bias)**

- **High risk**

**Selective reporting (reporting bias)**

- **Low risk**

**Other bias**

- **Low risk**

### Allocation concealment (selection bias)

- **Unclear risk**

**Comment**: no information provided

### Blinding of participants and personnel (performance bias)

**Outcome group: primary outcome**

- **Unclear risk**

**Comment**: no information provided

### Blinding of outcome assessment (detection bias)

**Outcome group: primary outcome**

- **Unclear risk**

**Quote**: "Patients were examined following surgery and daily for pressure ulcers, including number, stage (I-IV), size (area), location, and appearance."

**Comment**: insufficient information to permit judgement of low or high risk of bias.

### Incomplete outcome data (attrition bias)

**Outcome group: primary outcome**

- **High risk**

**Quote**: "Seven patients (8.75%) in the control group developed a total of 11 pressure ulcers ...

**Comment**: high risk of bias because 7 (8.75%) in control group implied 80 of 105 individuals were considered in data analysis, meaning a large proportion of missing data in the control group alone. However, the number of available cases in experimental group is not given.

### Selective reporting (reporting bias)

- **Low risk**

**Comment**: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.

### Other bias

- **Low risk**

**Comment**: the study appears to be free of other sources of bias.
Unit of analysis: individuals
Unit of randomisation (per patient): individuals

Interventions

Debut MR mattress
- **Description of interventions**: Debut MR (SSI Hill-Rom) mattress, unlike the rigid tubes of conventional alternating pressure mattresses (APMs), has a different type of cushion design incorporating 20% extra material that allows the patient to sink into the mattress, resulting in further distribution of the body weight. The 28 air cushions inflate and deflate on a one-in-four alternating cycle lasting 30 minutes... The mattress will operate in a static mode but this is recommended for transport only
- **NPUAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: not described
- **Number of participants randomised**: n = 5
- **Number of participants analysed**: n = 5

Nimbus
- **Description of interventions**: Nimbus (HNE Huntleigh) comprises a series of horizontal air-filled cells arranged in a double layer "figure of eight". The cells alternately inflate and deflate over a 10-minute cycle. Between the cells and the base sheet, a sensor pad inflates to prevent bottoming out... For the purposes of this trial the mattress was used in dynamic mode, although it can be switched to a static mode
- **NPUAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: not described
- **Number of participants randomised**: n = 5
- **Number of participants analysed**: n = 5

Outcomes

**Proportion of participants developing a new pressure ulcer**
- Not reported

**Time to pressure ulcer development**
- Not reported

**Support-surface-associated patient comfort**
- **Outcome type**: categorical
- **Time points**: 3 days
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: self-reported; measured by using a 15-point standardised questionnaire and a visual rating scale (rating from very uncomfortable to very comfortable)
- **Definition**: the level of comfort of mattresses experienced by older people
- **Dropouts**: one withdrew during the study and another person recruited
- **Notes**: "Five recruits to the study found the Debut mattress more comfortable than their normal bed, while six found the Nimbus mattress less comfortable than their normal bed"; "there was a strong preference for the Debut over the Nimbus mattress and this difference was statistically significant (Wilcoxon signed ranks exact test p = 0.019)"; "Overall 8/10 preferred the Debut mattress for both sleep quality and comfort"

All reported adverse events using allocated support surfaces
Health-related quality of life (HRQOL)
- Not reported

Cost-effectiveness
- Not reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;The recruits were randomised to sleep for three nights on either the Debut MR or the Nimbus&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk of bias because the sequence generation process is not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>Comment: high risk of bias because during the study, one withdrawal due to incompatibility with allocated mattress and another person recruited for final analysis</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>Comment: the study appears to be free of other sources of bias.</td>
</tr>
</tbody>
</table>

Beeckman 2019

Study characteristics

Methods

| Study objective: | to compare the effectiveness and cost of static air support surfaces versus alternating air pressure support surfaces in a nursing home population at high risk for pressure ulcers |
| Study design:    | randomised controlled trial |
| Study grouping:  | parallel group |
| Duration of follow-up: | 14 days |
| Number of arms:  | 2 |
| Single centre or multi-site: | multi-site |
| Study start date and end date: | April 2017 to May 2018 |
| Setting:         | nursing home |
## Participants

**Baseline characteristics**

**Inclusion criteria:**
1. High risk of developing pressure ulcer (Braden score 12 and/or Braden subscale score for mobility 2) and/or pressure ulcer category 1; (2) being bed bound (> 8 hours in bed) and/or chair bound (> 8 hours sitting in a chair); (3) aged > 65 years; and (4) use of an alternating air pressure mattress.

**Exclusion criteria:**
1. Nursing home residents with a pressure ulcer category II–IV upon admission; (2) those with an expected length of stay < 2 weeks; (3) those who received end-of-life care; or (4) those with medical contraindications for the use of static air support devices.

**Sex (M:F):** 71:237 overall; 39:115 in static air support surfaces; 32:122 in alternating air pressure surfaces.

**Age (years):** mean 87 (SD 7.6) overall; 86.9 (7.9) in static air support surfaces; 86.8 (7.3) in alternating air pressure surfaces.

**Baseline skin status:** mean Braden score 13 (SD 2.2) overall; all at risk according to the risk score used by the authors.

**Group difference:** no difference between groups.

**Total number of participants:** n = 308

**Unit of analysis:** individuals.

**Unit of randomisation (per patient):** individuals.

## Interventions

### Intervention characteristics

#### Static air support surfaces

**Description of interventions:** provided with the static air support surfaces (Repose) ... Repose mattress overlay, Repose 1 cushion and Repose 1 wedge, or Repose 1 foot protector (Frontier Medical Group, South Wales, the UK) ... consist of two urethane multidirectional stretch membranes. The inner membrane is inflated and provides static pressure redistribution throughout the tubular open cells that are oriented along the length of the device. The second membrane is formed from a multidirectional stretch, vapour-permeable material.

**NPUAP S3I classification:** non-powered, reactive air surface.

**Co-interventions:** static air-filled cushion used in 81% of participants and usual seat cushion used in the remaining 19%, static air-filled foot protectors or wedges used in 100% of participants.

**Number of participants randomised:** n = 154

**Number of participants analysed:** n = 154

#### Alternating air pressure support surfaces

**Description of interventions:** all using alternating air pressure support surfaces, with a 3 to 30 minute cycle time. However, the surfaces were not standardised to reflect current clinical practice.

**NPUAP S3I classification:** powered, alternating pressure (active) air surface.

**Co-interventions:** seat cushions used in 88% and heel protectors used in 34%.

**Number of participants randomised:** n = 154

**Number of participants analysed:** n = 154

## Outcomes

**Proportion of participants developing a new pressure ulcer**

**Outcome type:** binary.

**Time points:** 14 days.

**Reporting:** fully reported.

**Measurement method (e.g. scale, self-reporting):** graded using the International Pressure Ulcer Classification system (National Pressure Ulcer...

- **Definition (including ulcer stage):** cumulative incidence and incidence density of the participants developing a new category II-IV pressure ulcer within a 14-day observation period; that is the percentage of participants in the population at risk who developed a new pressure ulcer.

- **Dropouts:** intention-to-treat (ITT) analysis

- **Notes (e.g. other results reported):** 8 of 154 developing category II-IV pressure ulcer in static air support surfaces (6 category II; 2 category III); 18 of 154 in alternating air pressure support surfaces (15 category II; 1 category III; 2 category IV); (Chi² test P = 0.04). Ulcer incidence by areas reported also in the paper but not extracted for this review. Category II-IV ulcer incidence density 0.41/100 observed days (8 ulcers/1970 observed days) (95% CI 0.19 to 0.77) in static air surfaces; 0.89/100 observed days (18 ulcers/2013 observed days) (95% CI 0.55 to 1.39) in alternating pressure air surfaces

**Time to pressure ulcer development**

- **Outcome type:** binary
- **Time points:** 14 days
- **Reporting:** fully reported
- **Measurement method (e.g. scale, self-reporting):** graded using the International Pressure Ulcer Classification system (National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and, P.P.P.I.A., 2014).

- **Definition (including ulcer stage):** median time to develop a new ulcer

- **Dropouts:** median time to develop an ulcer 10.5 days (interquartile range (IQR) 1 to 14) in static air support surfaces; 5.4 (1 to 12) in alternating air pressure support surfaces (Mann-Whitney U test P = 0.05); probability to remain pressure ulcer-free differed between groups (log-rank X² = 4.051, df = 1, P = 0.04); Kaplan–Meier survival plot presented in Fig 2. ln(HR) 0.81 and seln(HR) 0.39 estimated by the review authors using the methods in Tierney 2007.

**Support-surface-associated patient comfort**

- **Reporting:** not reported

**All reported adverse events using allocated support surfaces**

- **Reporting:** not reported

**Health-related quality of life (HRQOL)**

- **Reporting:** not reported

**Cost-effectiveness**

- **Reporting:** not reported

- **Notes:** purchase costs of the support surfaces calculated per participant per day given the 2-year lifespan for a static air mattress and 7-year lifespan for an alternating air pressure mattresses. The average lifespan of 2 years for a static air mattress resulted in a daily cost of 0.20 euro; the average lifespan of 7 years for an alternating air pressure mattress resulted in a daily cost of 0.53 euro.

---

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>

---

Notes
<table>
<thead>
<tr>
<th>Random sequence generation (selection bias)</th>
<th>Low risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quote: &quot;The random allocation sequence was based on a computer-generated list of random numbers using an online tool (<a href="http://www.randomization.com">www.randomization.com</a>).&quot;</td>
<td></td>
</tr>
<tr>
<td>Comment: low risk of bias because of the use of a proper randomisation method.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Allocation concealment (selection bias)</th>
<th>Unclear risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quote: &quot;When the participants met the inclusion criteria and an informed consent was obtained, they received an allocation number (first available number on the computer-generated list).&quot;</td>
<td></td>
</tr>
<tr>
<td>Quote: &quot;Subsequently, a random allocation of each eligible participant was performed based on a computer-generated list of random numbers.&quot;</td>
<td></td>
</tr>
<tr>
<td>Comment: unclear risk of bias because the process of allocation is not clear for judging if concealment was properly performed and it is unclear who performed allocation.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blinding of participants and personnel (performance bias) All outcomes</th>
<th>High risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome group: all outcomes</td>
<td></td>
</tr>
<tr>
<td>Quote: &quot;The study was not blinded due to the obvious visible difference between the support surfaces (e.g. external control unit).&quot;</td>
<td></td>
</tr>
<tr>
<td>Comment: high risk of bias because of the understandable challenge of performing blinding.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blinding of outcome assessment (detection bias) All outcomes</th>
<th>High risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome group: all outcomes</td>
<td></td>
</tr>
<tr>
<td>Quote: &quot;The study was not blinded due to the obvious visible difference between the support surfaces (e.g. external control unit). Both support surface types were presented to ward nurses ...&quot;</td>
<td></td>
</tr>
<tr>
<td>Quote: &quot;During the follow-up period (days 1–14), the ward nurses collected all data&quot;</td>
<td></td>
</tr>
<tr>
<td>Quote: &quot;Researchers performed independent and unannounced skin assessments and technical controls weekly&quot;</td>
<td></td>
</tr>
<tr>
<td>Comment: high risk of bias because of the understandable challenge of performing blinding.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Incomplete outcome data (attrition bias) All outcomes</th>
<th>Low risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quote: &quot;An intention-to-treat analysis was performed.&quot;</td>
<td></td>
</tr>
<tr>
<td>Comment: low risk of bias.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>Low risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comment: the study protocol is available and it is clear that the published reports include all outcomes, including those that were pre-specified.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other bias</th>
<th>Low risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comment: the study appears to be free of other sources of bias.</td>
<td></td>
</tr>
</tbody>
</table>

### Bliss 1967

#### Study characteristics

<table>
<thead>
<tr>
<th>Study objective</th>
<th>to assess different mattresses for preventing pressure sores</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design</td>
<td>randomised controlled trial</td>
</tr>
<tr>
<td>Study grouping</td>
<td>parallel group</td>
</tr>
<tr>
<td>Duration of follow-up</td>
<td>treatment for 14 days and follow-up assessments on the 16th day</td>
</tr>
<tr>
<td>Number of arms</td>
<td>2</td>
</tr>
<tr>
<td>Single centre or multi-site</td>
<td>single centre</td>
</tr>
<tr>
<td>Study start date and end date</td>
<td>not described</td>
</tr>
<tr>
<td>Setting</td>
<td>geriatric unit</td>
</tr>
</tbody>
</table>

Cochrane Wounds Group, Shi, Shi, Dumville, Cullum, Rhodes, Jammali... https://archie.cochrane.org/sections/documents/view?version=z2105051...
Participants

Baseline characteristics

Inclusion criteria: all new patients with a Norton score of 7 or more, and all inpatients with a score 7 or more and still rising, provided they had no, or only superficial, trunk sores at the time

Exclusion criteria: patients with severe sores of the trunk

Sex (M:F): overall 27:56; large-celled ripple bed 10:32; control 17:24

Age (years): overall mean 81.2; large-celled ripple bed 80.4; control 82.1

Baseline skin status: mean baseline Norton score 10.5; free of existing severe ulcers (43 with superficial sore)

Group difference: no difference in variables except for sex distributions

Total number of participants: n = 83 (70 analysed)

Unit of analysis: individuals

Unit of randomisation (per patient): individuals

Interventions

Intervention characteristics

Large-celled ripple bed

- Description of interventions: alternating pressure mattress made of large cells (6 inches / 15 cm wide) giving a depth of 4 inches (10 cm) when inflated, consisting of transverse air cells. Consisting of 14 cells, leaving a gap of 12 inches (30 cm) to accommodate the pillow at the head of the bed. Inflated and deflated by an electrically driven pump so that the patient is supported on each series of cells in turn for about four to five minutes.

- NPUAP S3I classification: powered, alternating pressure (active) air surface

- Co-interventions: standardised care

- Number of participants randomised: n = 42

- Number of participants analysed: n = 35

Ordinary hospital mattress

- Description of interventions: ordinary hospital mattress

- NPUAP S3I classification: standard hospital surface

- Co-interventions: standardised care

- Number of participants randomised: n = 41

- Number of participants analysed: n = 35

Outcomes

Proportion of participants developing a new pressure ulcer

- Outcome type: binary

- Time points: 14 days

- Reporting: partially reported

- Measurement method (e.g. scale, self-reporting): ulcer incidence graded by the Bliss (1966) method

- Definition (including ulcer stage): incidence of trunk ulcers

- Dropouts: 4 on the ripple bed and 6 in the control group died, and 3 participants were on ripple bed mattresses that had deficiencies (e.g. the failure of motors, leaks of air cells)

- Notes (e.g. other results reported): trunk ulcers; 3 of 15 patients without existing ulcers at baseline developed new ulcers in ripple bed; 7 of 18 in control. Incident ulcer data not available for those with existing ulcers at baseline. Heel sore data not extracted due to incomplete reporting of relevant data.

Time to pressure ulcer development
- Not reported

**Support-surface-associated patient comfort**
- Not reported

**All reported adverse events using allocated support surfaces**
- Not reported
- Notes: 4 on the ripple bed and 6 in the control group died

**Health-related quality of life (HRQOL)**
- Not reported

**Cost-effectiveness**
- Not reported

**Outcomes that are not considered in this review but reported in trials:**
- Deficiencies of the ripple bed machine (n = 3)
- Ulcer changes among those with existing ulcers at baseline

### Notes

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;In order to ensure that the distribution of subjects among the various regimens was as random as possible the experimental and control treatments were arranged in a rota. As patients were admitted to the trial they were allocated to the next treatment on the rota in order&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk of bias because the sequence generation process is not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Outcome group: ulcer incidence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: no information provided</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Outcome group: ulcer incidence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quote: &quot;The record forms were all evaluated in a single session by one observer, each being masked in such a way that it was not possible to know to which patient or to which experimental regimen it referred&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: low risk of bias because the blinding of assessment is stated</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Outcome group: ulcer incidence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk of bias because 7 of 42 in ripple bed and 6 of 41 in control group were excluded from analysis</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified. However, incidence outcome data among those with existing ulcers are not available.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>Comment: the study appears to be free of other sources of bias</td>
</tr>
</tbody>
</table>
### Bliss 1995

#### Study characteristics

**Study objective**: to identify inexpensive and, if possible, non-mechanical constant low pressure overlays effective for patients at long-term risk in continuing-care wards for elderly people.

**Study design**: randomised controlled trial (a poorly designed multi-arm multi-stage trial, with re-randomisation)

**Study grouping**: parallel group

**Duration of follow-up**: not given; assessment with a mean of 17.7 days

**Number of arms**: 7 (The trial had a Vaperm as control arm but its participants were not randomised. Vaperm data were not extracted for this review.)

**Single centre or multi-site**: not specified

**Setting**: hospital

#### Baseline characteristics

**Inclusion criteria**: patients liable to pressure sores; included those who already had superficial breaks in the skin of the pressure areas

**Exclusion criteria**: patients with superficial sores > 5 cm and discoloured areas > 2 cm diameter

**Sex (M:F)**: overall 62:296 (treatment sessions rather than individuals)

**Age (years)**: mean 84.4 (range 67 to 97) large-celled Ripple bed (n = 71 treatment sessions of 34 patients); 85.2 (67 to 97) Preventix (n = 25 sessions of 20 patients); 85.6 (68 to 98) Groove (n = 66 sessions of 36 patients); 86.1 (68 to 98) Modular Propad (n = 60 sessions of 39 patients); 84.4 (68 to 93) Ardo Watersoft (n = 32 sessions of 22 patients); 85.6 (68 to 94) Spenco (n = 63 sessions of 35 patients); 84.3 (67 to 97) Surgicgoods Hollowcore (n = 41 sessions of 30 patients).

**Baseline skin status**: not given; allowed inclusion of those with superficial ulcers

**Group difference**: not given

**Total number of participants**: n = 358 sessions of 216 patients

**Unit of analysis**: treatment sessions of patients

**Unit of randomisation (per patient)**: treatment sessions of patients

#### Interventions

**Groove**

- **Description of interventions**: a contoured 10-centimetre thick foam overlay
- **NPUAP S3I classification**: non-powered, reactive foam surface; lack of information for specifying foam characteristics
- **Co-interventions**: not described
- **Number of participants randomised**: n = 66 sessions of 36 patients
- **Number of participants analysed**: n = 66 sessions of 36 patients

**Spenco**

- **Description of interventions**: one-piece cotton hollow-core fibrefill
- **NPUAP S3I classification**: non-powered, reactive fibre surface
- **Co-interventions**: not described
- **Number of participants randomised**: n = 63 sessions of 35 patients
- **Number of participants analysed**: n = 63 sessions of 35 patients

**Propad**
• **Description of interventions**: Modular Propad was an 8.5-centimetre thick foam pad with the upper surface moulded into air-ducted, rounded horizontal blocks

• **NPUAP S3I classification**: non-powered, reactive foam surface; lack of information for specifying foam characteristics

• **Co-interventions**: not described

• **Number of participants randomised**: n = 60 sessions of 39 patients

• **Number of participants analysed**: n = 60 sessions of 39 patients

**Preventix**

• **Description of interventions**: a 16-centimetre thick mat of 8-centimetre square foam modules of different densities inserted into a flexible PVC frame ... providing a variably soft, contoured, slit surface to optimise pressure distribution

• **NPUAP S3I classification**: non-powered, reactive foam surface; lack of information for specifying foam characteristics

• **Co-interventions**: not described

• **Number of participants randomised**: n = 25 sessions of 20 patients

• **Number of participants analysed**: n = 25 sessions of 20 patients

**Surgicgoods**

• **Description of interventions**: Surgicgoods Hollowcore Mattress pad was a one-piece fibrefill

• **NPUAP S3I classification**: non-powered, reactive fibre-filled surface

• **Co-interventions**: not described

• **Number of participants randomised**: n = 41 sessions of 30 patients

• **Number of participants analysed**: n = 41 sessions of 30 patients

**Watersoft**

• **Description of interventions**: Ardo Watersoft consisting of three 4-centimetre deep, partly-filled water cushions with stabilising baffles

• **NPUAP S3I classification**: non-powered, reactive water-filled surface

• **Co-interventions**: not described

• **Number of participants randomised**: n = 32 sessions of 22 patients

• **Number of participants analysed**: n = 32 sessions of 22 patients

**Large-celled Ripple bed**

• **Description of interventions**: consisting of 14 horizontal cells 10 cm in diameter in the centre, connected in 2 alternating series powered by a small pump which caused them to inflate and deflate reciprocally underneath the patient every 10 minutes, thus continually changing the supporting points of pressure.

• **NPUAP S3I classification**: powered, alternating pressure (active) air surface

• **Co-interventions**: not described

• **Number of participants randomised**: n = 71 sessions of 34 patients

• **Number of participants analysed**: n = 71 sessions of 34 patients

**Outcomes**

**Proportion of participants developing a new pressure ulcer**

• **Not reported**

• **Notes (e.g. other results reported)**: numbers of trials in which sores developed or worsened: 11 of 71 Ripple bed; 9 of 25 Preventix; 27 of 66


<table>
<thead>
<tr>
<th>Time to pressure ulcer development</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Not reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Support-surface-associated patient comfort</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Not reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>All reported adverse events using allocated support surfaces</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Not reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Health-related quality of life (HRQOL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Not reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cost-effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Not reported</td>
</tr>
</tbody>
</table>

### Notes

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;the patient was randomly allocated to an experimental overlay by the researcher writing the names of all those available at the time on slips of paper which were folded and offered to the nurse to choose one blind&quot; Comment: low risk of bias because drawing of lots is applied to generate random sequence.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>High risk</td>
<td>Quote: &quot;the patient was randomly allocated to an experimental overlay by the researcher writing the names of all those available at the time on slips of paper which were folded and offered to the nurse to choose one blind. The designated overlay was then placed on the bed&quot; Comment: high risk of bias because it appears difficult to conceal the allocation process as the authors described. The nurse would have knowledge of which overlays were available at the time of consent.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other bias</th>
<th>High risk</th>
</tr>
</thead>
</table>
|            | Comment: high risk of bias because some individuals may be repeatedly observed and included in analysis (i.e. correlation issue in analysis). For example, Bliss stated "there were no written criteria determining the decision to stop a trial [i.e. using an overlay as the experimental intervention]. This depended mainly on these experienced
nurses' unwillingness to allow it to continue because of enlargement of an existing sore, a new blister, discoloration, oedema ... Patients who developed pressure damage between assessments might also be taken off their overlay ... if they later improved ... they were re-randomized for another trial period [i.e. comparisons of new overlays]" Additionally, overlays were observed for unequal periods of time. Treatments were discontinued or introduced without pre-specified stopping rules. Some comparisons are not parallel.

Cavicchioli 2007

### Study characteristics

#### Methods

| Study objective | to determine whether alternating low pressure or continuous low pressure is most effective in reducing the incidence of pressure ulcers in high risk patients |
| Study design    | randomised controlled trial |
| Study grouping  | parallel group |
| Duration of follow-up | 2 weeks |
| Number of arms   | 2 |
| Single centre or multi-site | multi-site |
| Study start date and end date | March 2004 to November 2006 |
| Setting          | acute, post-acute and long-term care settings of 3 hospitals |

#### Baseline characteristics

**Inclusion criteria:** those admitted to the unit or deemed "at risk" of pressure ulceration as defined by the Braden Pressure Ulcer Risk Assessment Scale (a total Braden score of \( \leq 17 \) and mobility and activity sub-scores of \( \leq 3 \) respectively); their admission was expected to last at least 2 weeks and they had up to one grade I pressure ulcer.

**Exclusion criteria:** not at risk (Braden \( \geq 17 \) and activity or mobility sub-scales \( \geq 3 \), respectively)

**Sex (M:F):** 20:49 in alternating low pressure; 20:51 in continuous low pressure

**Age (years):** mean 77 in alternating low pressure; 78 in continuous low pressure

**Baseline skin status:** mean 11.4 (range 7 to 16) in alternating low pressure; 11.9 (6 to 17) in continuous low pressure

**Group difference:** no difference

**Total number of participants:** 170

**Unit of analysis:** individuals

**Unit of randomisation (per patient):** individuals

#### Interventions

**Intervention characteristics**

Alternating low pressure modality of Duo2 (Hill-Rom)

- **Description of interventions:** Duo2 (Hill-Rom), "... electrically powered, air-filled mattresses in which adjacent cells inflate and deflate reciprocally underneath the patient"
- **NPUAP S3I classification:** powered, alternating pressure (active) air surface
- **Co-interventions:** not described
- **Number of participants randomised:** n = 86
- **Number of participants analysed:** n = 69

Continuous low pressure modality of Duo2 (Hill-Rom)

- **Description of interventions:** continuous low pressure modality of Duo2
(Hill-Rom)

- **NPUAP S3I classification**: powered, reactive air surface
- **Co-interventions**: not described
- **Number of participants randomised**: n = 84
- **Number of participants analysed**: n = 71

---

**Outcomes**

**Proportion of participants developing a new pressure ulcer**

- **Outcome type**: binary
- **Time points**: 2 weeks
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: assessed by the external observer
- **Definition (including ulcer stage)**: not described
- **Dropouts**: 17 dropouts in alternating low pressure (4 died, 8 discharged prior to assessment, 5 did not complete study due to non-concordance (uncomfortable) and not agreeing to use the modality; 13 dropouts in continuous low pressure (5 died, 4 discharged prior to assessment, 4 did not complete study due to non-concordance and not agreeing to use the modality).

- **Notes (e.g. other results reported)**: 2 of 69 individuals (one Stage 1 and one Stage 2) in alternating low pressure; 1 of 71 individuals (Stage 2) in continuous low pressure.

**Time to pressure ulcer development**

- **Reporting**: not reported

**Support-surface-associated patient comfort**

- **Reporting**: not reported

- **Notes**: 5 dropouts due to discomfort and/or not agreeing to use the assigned modality in alternating low pressure; 4 dropouts due to discomfort and/or not agreeing to use the assigned modality in continuous low pressure.

**All reported adverse events using allocated support surfaces**

- **Reporting**: not reported

**Health-related quality of life (HRQOL)**

- **Reporting**: not reported

**Cost-effectiveness**

- **Reporting**: not reported

---

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;Patients in the treatment group were randomised to receive either continuous or alternating low pressure on the high-tech mattress&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: the method of randomisation was not reported.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided</td>
</tr>
</tbody>
</table>

---

https://archie.cochrane.org/sections/documents/view?version=Z2105051...
### Blinding of participants and personnel (performance bias)
All outcomes

<table>
<thead>
<tr>
<th>Outcome group: primary outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quote: &quot;... independently from the blinded randomised treatment group (who received the Duo2 high-tech mattress).&quot;</td>
</tr>
<tr>
<td>Comment: low risk of bias because blinding method was implemented.</td>
</tr>
</tbody>
</table>

### Blinding of outcome assessment (detection bias)
All outcomes

<table>
<thead>
<tr>
<th>Outcome group: primary outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quote: &quot;As there is no visible difference between these two modes, the external observer was blinded as to which one was in use. The external observers assessed all study patients’ ... presence (or absence) and grade of both existing and new pressure ulcers&quot;</td>
</tr>
<tr>
<td>Comment: low risk of bias because outcome assessment was blinded.</td>
</tr>
</tbody>
</table>

### Incomplete outcome data (attrition bias)
All outcomes

<table>
<thead>
<tr>
<th>Outcome group: primary outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comment: high risk of bias because of high proportions of dropouts in both groups and probably using incorrect analysis methods to address missing data.</td>
</tr>
</tbody>
</table>

### Selective reporting (reporting bias)

<table>
<thead>
<tr>
<th>Outcome group: primary outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comment: the study appears to be free of other sources of bias.</td>
</tr>
</tbody>
</table>

### Conine 1990

#### Study characteristics

**Methods**

- **Study objective:** to determine the efficacy of the alternating air mattress overlay and the silicone mattress overlay in preventing pressure ulcers
- **Study design:** sequential randomised controlled trial
- **Study grouping:** parallel group
- **Duration of follow-up:** 3 months
- **Number of arms:** 2
- **Single centre or multi-site:** single centre
- **Study start date and end date:** study took place between 1985 and 1988
- **Setting:** extended care facility for neurological conditions

**Baseline characteristics**

- **Inclusion criteria:** patients in extended care facility for neurological conditions, 18 to 55 years old, with no evidence of skin breakdown for at least 2 weeks prior to the study, and who were at high risk of developing ulcers according to the Norton’s Scale (i.e. less than the score of 14)
- **Exclusion criteria:** the status of high risk changed during the study
- **Sex (M:F):** 31:41 in alternating air mattress; 29:47 in Silicore
- **Age (years):** mean 38.8 (SD 13.0) in alternating air mattress; 35.6 (13.0) in Silicore
- **Baseline skin status:** mean Norton score 12.9 (SD 2.1) in alternating air mattress; 12.4 (2.3) in Silicore
- **Group difference:** no difference
- **Total number of participants:** 187 randomised; 148 analysed
- **Unit of analysis:** individuals
- **Unit of randomisation (per patient):** individuals
**Intervention characteristics**

**Alternating air mattress**
- **Description of interventions**: "... made of a heavy duty plastic material with honey-combed 10 cm (4 inch) air cells which alternately inflate and deflate by an electrically driven pump" placed over a standard hospital spring mattress or a 10 cm foam and supported by standard hospital bed frames
- **NPUAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: usual care (including turning every 2 or 3 hours)
- **Number of participants randomised**: n = 93
- **Number of participants analysed**: n = 72

**Silicore mattress overlay**
- **Description of interventions**: "... composed of siliconized hollow fibres covered in waterproofed cotton" placed over a standard hospital spring mattress or a 10 cm foam and supported by standard hospital bed frames
- **NPUAP S3I classification**: non-powered, reactive fibre-filled surface
- **Co-interventions**: usual care (including turning every 2 or 3 hours)
- **Number of participants randomised**: n = 94
- **Number of participants analysed**: n = 76

**Outcomes**

**Proportion of participants developing a new pressure ulcer**
- **Outcome type**: binary
- **Time points**: 3 months
- **Reporting**: fully reported
- **Measurement method (e.g. scale, self-reporting)**: measured using the Exton-Smith scale (0 = none; 1 = persistent erythema in an irregular ill-defined area; 2 = localised blister with distinct edges indicating early pigmentation with heat and induration; 3 = superficial sore extending into the subcutaneous fat with irregular rolled skin edges, dark pigmentation and a drainage; 4 = deep sore extending into deep fascia in which bone can be identified at the base of ulceration, with profuse drainage and necrosis; 5 = gangrenous sore with profuse multiple drainages, extensive necrosis, and resultant osteomyelitis and septic arthritis)
- **Definition (including ulcer stage)**: the first appearance of any ulcers (scores of Grade 1 or above defined using Exton-Smith scale)
- **Dropouts**: 21 missing data (including 2 death, 19 discomfort, 0 transferred) in alternating air mattress overlay; 18 (including 0 death, 17 discomfort, 1 transferred) in Silicore overlay
- **Notes (e.g. other results reported)**: 39 individuals (with ulcers of any stages) in alternating air mattress; 45 individuals (with ulcers of any stages) in Silicore. Numbers of ulcers by grade reported also, but not extracted.

**Time to pressure ulcer development**
- **Reporting**: not reported

**Support-surface-associated patient comfort**
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: not described
- **Definition**: discomfort as a reason for dropout
- **Drop outs**: not described
- **Notes**: 19 of 93 in alternating air mattress; 17 of 94 in Silicore
All reported adverse events using allocated support surfaces
- Reporting: not reported

Health-related quality of life (HRQOL)
- Reporting: not reported

Cost-effectiveness
- Notes: total overall cost per year of use presented in cost analysis paper by overlay groups: USD 771 in air overlay group and USD 500 in silicone overlay group

Outcomes that are not considered in this review but reported in trials:
- Healing duration of ulcers
- Severity of new ulcers
- Acceptability measured for 40 patients in total (20 from each group)

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “A modified sequential clinical trial ... was used to assign subjects randomly to one of the two mattresses in groups of 20”</td>
</tr>
<tr>
<td>allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: the method of randomisation was not specified.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td><strong>Outcome group: primary outcome</strong></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>Quote: “Thirty-nine subjects did not complete the trial for reasons shown in Table 3”</td>
</tr>
<tr>
<td>Selective reporting (reporting bias) Low risk</td>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
<td></td>
</tr>
<tr>
<td>Other bias Low risk</td>
<td>Comment: the study appears to be free of other sources of bias.</td>
<td></td>
</tr>
</tbody>
</table>

Daechsel 1985

Study characteristics

Methods | Study objective: to assess 2 commonly used special mattresses in a randomised trial involving adult non-geriatric chronic neurologic patients
Study design: randomised controlled trial
Study grouping: parallel group
Duration of follow-up: 3 months
Number of arms: 2
Single centre or multi-site: single centre
Study start date and end date: not described
Setting: long-term care hospital for chronic neurologic conditions

Baseline characteristics
Inclusion criteria: consenting patients in a long-term care hospital for chronic neurologic conditions ... a) between 19 and 60 years of age, b) free of any evidence of skin breakdown two weeks prior to the study, and c) considered to be at high risk of developing decubitus ulcers (DU) based on assessments conducted by the ward team [Norton scale score of 14 or less; and clinical judgement]
Exclusion criteria:

Sex (M:F): 10:6 in alternating air mattress; 6:10 in Silicore mattress
Age (years): mean 42.6 (SD 13.7) in alternating air mattress; 38.5 (13.82) in Silicore mattress
Baseline skin status: mean Norton score 13.35 (SD 1.86) in alternating air mattress; 12.97 (2.28) in Silicore mattress
Group difference: no difference
Total number of participants: 32
Unit of analysis: individuals
Unit of randomisation (per patient): individuals

Intervention characteristics
Alternating air mattress
- Description of interventions: "... consisted of an electrically driven pump connected to a heavy-duty plastic mattress ... composed of honey combed 4-inch air cells, which alternately inflate and deflate when in operation ... placed over a standard hospital spring mattress or 4-inch foam mattress and supported by a standard hospital bed frame"
- NPUAP S3I classification: powered, alternating pressure (active) air surface
- Co-interventions: usual care including repositioning and additional preventive aids (including heel and ankle protectors, sheepskins and bed cradles)
- Number of participants randomised: n = 16
- Number of participants analysed: n = 16

Silicore mattress
- Description of interventions: "a reversible mattress composed of siliconized hollow fibres in an interwoven mesh that accommodates the body surface and decreases pressure ... placed over a standard hospital spring mattress or 4-inch foam mattress and supported by a standard hospital bed frame"
- NPUAP S3I classification: non-powered, reactive fibre-filled surface
- Co-interventions: usual care including repositioning and additional preventive aids (including heel and ankle protectors, sheepskins and bed cradles)
- Number of participants randomised: n = 16
**Outcomes**

- **Number of participants analysed**: n = 16

**Proportion of participants developing a new pressure ulcer**
- **Outcome type**: binary
- **Time points**: 3 months
- **Reporting**: fully reported
- **Measurement method (e.g. scale, self-reporting)**: measured by 1 investigator using the Exton-Smith scale
- **Definition (including ulcer stage)**: skin condition of degrees of ulcers graded on the Exton-Smith scale (0 = none, 1 = persistent erythema, 2 = localised blister, 3 = superficial sore, 4 = deep sore, 5 = extensive gangrenous sore)
- **Dropouts**: no dropouts
- **Notes (e.g. other results reported)**: 4 of 16 individuals in alternating air mattress; 4 of 16 in Silicore mattress. Severity of ulcers graded and numbers by grade not reported and not extracted.

**Time to pressure ulcer development**
- **Reporting**: not reported

**Support-surface-associated patient comfort**
- **Reporting**: not reported
- **Notes**: "the patients did not indicate a particular like or dislike of the type of mattress to which they were assigned"

**All reported adverse events using allocated support surfaces**
- **Reporting**: not reported

**Health-related quality of life (HRQOL)**
- **Reporting**: not reported

**Cost-effectiveness**
- **Reporting**: not reported

**Outcomes that are not considered in this review but reported in trials**:
- Equipment condition

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;All were randomly assigned to one of the two types of mattresses&quot; Comment: the method of randomisation was not described.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td><strong>Outcome group: primary outcome</strong> Comment: no information provided.</td>
</tr>
</tbody>
</table>
### Outcome group: primary outcome

Quote: "one of the investigators (DD) conducted weekly skin checks of the subjects"

Comment: high risk of bias for pressure ulcer incidence outcome because it is unlikely that the investigator who assessed skin conditions was blinded.

### Outcome group: primary outcome

Quote: "Thirty-two patients met the criteria for this study ... all admitted to the trial and completed it"

Comment: no missing data.

### Other bias

Comment: the study appears to be free of other sources of bias.

### Demarre 2012

#### Study characteristics

**Methods**

- **Study objective**: to compare the effectiveness of an alternating low pressure air mattress with a standard single-stage inflation and deflation cycle of the air cells with an alternating low pressure air mattress with multi-stage inflation and deflation cycle of the air cells
- **Study design**: randomised controlled trial
- **Study grouping**: parallel group
- **Duration of follow-up**: 14 days
- **Number of arms**: 2
- **Single centre or multi-site**: multi-site
- **Study start date and end date**: December 2007 to January 2010
- **Setting**: 25 wards in 5 hospitals in Belgium.

#### Participants

**Baseline characteristics**

- **Inclusion criteria**: patients at risk for pressure ulcer development according to the Braden scale (less than 17), including those with non-blanchable erythema
- **Exclusion criteria**: patients with a pressure ulcer Grade II to IV on admission, the expected admission time < 3 days; aged < 18 years; with a "do not resuscitate code" specifying ending all therapeutic interventions, weight < 30 kg or > 160 kg, and informed consent not obtained
- **Sex (M:F)**: overall 241 (39.4%); 369 (60.6%); 111:187 in multi-stage group; 130:182 in single-stage group
- **Age (years)**: overall mean 76.3 (SD 14.0); 76.15 (14.82) in multi-stage alternating air mattress; 76.50 (13.20) in single-stage alternating air mattress
- **Baseline skin status**: overall median Braden score 14.0 (interquartile range (IQR) 12.0 to 15.0); 14.0 (12 to 15) in multi-stage; 14.0 (12 to 15) in single-stage
- **Group difference**: no difference
- **Total number of participants**: 610
- **Unit of analysis**: individuals
- **Unit of randomisation (per patient)**: individuals

### Interventions

**Intervention characteristics**

- **Multi-stage alternating air mattress**
  - **Description of interventions**: alternating air mattress with the multi-stage
Three air cells with a continuous low pressure on head zone. Seven cells with a continuous ultra low pressure on heel zone. Ten alternating low pressure cells on back and sacrum zone. Ten- to twelve-minute cycle times for inflation and deflation and the air cells width 10 centimetres

- **NPUAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: not described
- **Number of participants randomised**: n = 298
- **Number of participants analysed**: n = 298 (intention-to-treat (ITT) analysis)

### Single-stage alternating air mattress

- **Description of interventions**: standard alternating air mattress (Hill-Rom Alto mattress), an alternating air mattress with a standard single-stage, steep inflation and deflation of the air cells. All air cells were alternating, the cycle time was 10 minutes and the air cell width was 10 centimetres.
- **NPUAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: not described
- **Number of participants randomised**: n = 312
- **Number of participants analysed**: n = 312 (ITT analysis)

### Outcomes

#### Proportion of participants developing a new pressure ulcer
- **Outcome type**: binary
- **Time points**: 14 days
- **Reporting**: fully reported
- **Measurement method (e.g. scale, self-reporting)**: assessed by the ward nurses
- **Definition (including ulcer stage)**: percentage of patients developing a new pressure ulcer of grade 2 to 4 on any location, graded by EPUAP 1999 classification system (Grade I = non-blanchable erythema; Grade II = an abrasion or a blister; Grade III = superficial ulcer; Grade IV = a deep ulcer)
- **Dropouts**: ITT analysis
- **Notes (e.g. other results reported)**: 17 of 298 individuals (including 13 Grade II, 4 Grade III, 0 Grade IV) in multi-stage group; 18 of 312 individuals (including 11 Grade II, 2 Grade III, 5 Grade IV) in single-stage group. Extra data: 51 with new Grade I in multi-stage; 38 with new Grade I in single-stage. Ulcers by sites reported but not extracted.

#### Time to pressure ulcer development
- **Outcome type**: Time-to-event
- **Time points**: not relevant
- **Reporting**: fully reported
- **Measurement method (e.g. scale, self-reporting)**: see above
- **Definition (including ulcer stage)**: time to develop a pressure ulcer Grade II - IV
- **Dropouts**: ITT analysis
- **Notes**: median time 5.0 days (IQR 3.0 to 8.5) in multi-stage group; 8.0 (3.0 to 8.8) in single-stage group (Mann-Whitney U-test = 113, P = 0.182); Kaplan Meier plot reported (log-rank Chi^2 = 0.013, df = 1, P = 0.911); HR
0.96 (95% CI 0.50 to 1.87) estimated by the review authors using the methods in Tierney 2007.

Support-surface-associated patient comfort

- **Outcome type**: binary
- **Time points**: 14 days
- **Reporting**: fully reported
- **Measurement method (e.g. scale, self-reporting)**: probably self-reported
- **Definition**: patient acceptability assessed directly by the number of participants withdrawing their consent to participate during observation period
- **Drop outs**: ITT analysis
- **Notes**: presented as exclusion reasons. Eleven of 298 individuals withdrawing due to discomfort in multi-stage group and 0 exclusion due to consent; 16 of 312 due to discomfort and 1 due to consent in single-stage.

All reported adverse events using allocated support surfaces

- **Reporting**: not reported

Health-related quality of life (HRQOL)

- **Reporting**: not reported

Cost-effectiveness

- **Reporting**: not reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias)   | Low risk           | Quote: "Included patients were randomly assigned to the study groups using simple randomisation. The random allocation sequence was based on a computer-generated list of random numbers"  
Comment: low risk of bias because of the use of a proper random sequence generation method. |
| Allocation concealment (selection bias)       | Low risk           | Quote: "Patients were enrolled by the ward nurses ... assigned to one of the mattresses by contacting the researcher. The ward nurse received a number of the type of allocated mattress"  
Comment: low risk of bias because it is likely that allocation sequence was concealed. |
| Blinding of participants and personnel (performance bias) All outcomes | High risk          | **Outcome group: All outcomes**  
Quote: "Both mattresses were covered with an identical mattress cover ..."  
Quote: "The study could not be blinded, because of the visible differences of the external control unit of the study mattresses"  
Comment: high risk of bias because it is unlikely that participants were blinded. |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk       | **Outcome group: primary outcome**  
Quote: "Daily skin assessment was performed by the ward nurses ... in each patient, in the morning"  
Quote: "No information was provided to the ward nurses about the differences between the experimental and control study device"  
Quote: "The lack of a blinded outcome assessment is a first
<table>
<thead>
<tr>
<th>Limitation</th>
<th>Comment: unclear risk of bias because efforts were made to reduce bias.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outcome group: comfort outcome</strong></td>
<td>Comment: high risk of bias because it is unlikely that patients who reported this outcome were blinded.</td>
</tr>
</tbody>
</table>

| Incomplete outcome data (attrition bias) | Low risk |
| All outcomes | Outcome group: all outcomes |
| Comment: low risk of bias because ITT analysis was undertaken. |

| Selective reporting (reporting bias) | Low risk |
| Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified. |

| Other bias | Low risk |
| Comment: the study appears to be free of other sources of bias. |

---

**Finnegan 2008**

**Study characteristics**

### Methods

**Study objective:** to compare the effectiveness of a specialised alternating air pressure mattress replacement system and an air-fluidised integrated bed in the management of post-operative flap patients

- **Study design:** pilot randomised controlled trial
- **Study grouping:** parallel group
- **Duration of follow-up:** mean length of stage 8.0 days (range 0 to 21)
- **Number of arms:** 2
- **Single centre or multi-site:** single centre
- **Study start date and end date:** not described
- **Setting:** tertiary referral centre

### Participants

**Baseline characteristics**

- **Inclusion criteria:** 18 years or older who were admitted for reconstructive surgery to repair a tissue deficit (full-thickness pressure ulcer involving muscle, fascia and, in some cases, bone) in the sacral-coccygeal, trochanteric or ischial region.
- **Exclusion criteria:** unlikely or unwilling to comply with the treatment protocol, which included a minimum of 7 days bed rest within the surgical unit, or unable to consent.

- **Sex (M:F):** overall 21:12; 7:8 in alternating therapy; 14:4 in air-fluidised bed
- **Age (years):** mean 56 (range 20 to 80); 62 in alternating therapy; 50 in air-fluidised bed
- **Baseline skin status:** severe full-thickness pressure ulcers
- **Group difference:** not described
- **Total number of participants:** 40 randomised, 33 analysed
- **Unit of analysis:** individuals
- **Unit of randomisation (per patient):** individuals

### Interventions

**Intervention characteristics**

- **Alternating therapy**
  - **Description of interventions:** a specialised alternating therapy support surface (Nimbus 3 Professional, Huntleigh Healthcare LLC). Specialised by means of Vent Valve Technology, not a standard alternating pressure therapy. Single cells to be isolated and permanently deflated beneath the operative site. This deflation completely off-loads the most vulnerable tissue.
while the mattress continues to deliver optimised cyclic pressure redistribution to other vulnerable areas.

- **NPUAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: all other care including repositioning, nutrition and continence management in line with the wound centre’s protocol
- **Number of participants randomised**: n = 19
- **Number of participants analysed**: n = 15

### Air-fluidised bed

- **Description of interventions**: air-fluidised bed system (Clinitron, Hill-Rom Inc.) (Finnegan 2008); “Clinitron® Air Fluidized Therapy beds ... minimizes interface pressure, while maximizing the surface's immersion and envelopment properties to support healing ... providing statistically lower interface pressure ... Medical grade, silicone-coated bead fluidization promotes a flotation environment” from Hillrom website ([https://www.hillrom.com/ca/Products/Products-by-Category/Hospital-Beds-and-Long-Term-Care-Beds/Clinitron-RiteHite-Air-Fluidized-Beds/](https://www.hillrom.com/ca/Products/Products-by-Category/Hospital-Beds-and-Long-Term-Care-Beds/Clinitron-RiteHite-Air-Fluidized-Beds/)).
- **NPUAP S3I classification**: non-powered, reactive air-fluidised surface
- **Co-interventions**: all other care including repositioning, nutrition and continence management in line with the wound centre’s protocol
- **Number of participants randomised**: n = 21
- **Number of participants analysed**: n = 18

### Outcomes

<table>
<thead>
<tr>
<th>Proportion of participants developing a new pressure ulcer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outcome type</strong>: binary</td>
</tr>
<tr>
<td><strong>Time points</strong>: unspecified; hospital stay of 8 days</td>
</tr>
<tr>
<td><strong>Reporting</strong>: partially reported</td>
</tr>
<tr>
<td><strong>Measurement method (e.g. scale, self-reporting)</strong>: assessed by surgical team</td>
</tr>
<tr>
<td><strong>Definition (including ulcer stage)</strong>: tissue integrity at other vulnerable anatomical locations</td>
</tr>
<tr>
<td><strong>Dropouts</strong>: 4 in alternating therapy; 3 in air-fluidised bed (all due to not receiving the allocated intervention)</td>
</tr>
<tr>
<td><strong>Notes (e.g. other results reported)</strong>: 0 of 15 in alternating therapy; 0 of 18 in air-fluidised bed</td>
</tr>
</tbody>
</table>

**Time to pressure ulcer development**

- **Reporting**: not reported

**Support-surface-associated patient comfort**

- **Outcome type**: binary
- **Time points**: unspecified; hospital stay of 8 days
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: self-reported
- **Definition**: subject acceptability - numbers of patients having comfortable response on support surfaces
- **Drop outs**: 4 in alternating therapy; 3 in air-fluidised bed (all due to not receiving the allocated intervention)
- **Notes (e.g. other results reported)**: comfortable: 11 of 15 in alternating therapy; 4 of 18 in air-fluidised bed; uncomfortable: 2 of 15 vs 7 of 18; the rest of the patients had no view.
All reported adverse events using allocated support surfaces
- **Reporting**: not reported

Health-related quality of life (HRQOL)
- **Reporting**: not reported

Cost-effectiveness
- **Reporting**: not reported
- **Notes**: cost of support surface provision based on rental costs per day of inpatient care (USD 35/day for alternating therapy; USD 65/day for air-fluidised bed)

Outcomes that are not considered in this review but reported in trials:
- Integrity of the surgical site.

**Notes**

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;allocation was determined by using web-based random-number software&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: low risk of bias due to the use of a proper randomisation method.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;Groups were concealed in sealed envelopes&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk of bias because a proper concealment method is not specified.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td><strong>Outcome group: all outcomes</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>High risk</td>
<td><strong>Outcome group: primary outcome</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quote: &quot;Tissue integrity on discharge was not blinded and determined by the surgical team responsible for this pilot phase.&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: high risk of bias because no blinding was undertaken.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Outcome group: comfort outcome</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk of bias because it is not specified if patients who reported comfort data were blinded.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>Outcome group: all outcomes.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quote: &quot;four subjects in Group A and three subjects in Group B did not receive the allocated intervention (Fig. 2) and were not included in the follow-up&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk of bias because a fair proportion of subjects lost to follow-up.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias) Low risk</td>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
<td></td>
</tr>
<tr>
<td>Other bias Low risk</td>
<td></td>
<td>Comment: the study appears to be free of other sources of bias.</td>
</tr>
</tbody>
</table>

**Gray 2008**

**Study characteristics**
### Methods

**Study objective**: to determine the effect of using the Softform Premier Active™ Mattress versus a standard air mattress on pressure ulcer incidence in 2 acute care of the elderly wards  
**Study design**: randomised controlled trial  
**Study grouping**: parallel group  
**Duration of follow-up**: not given (claimed this is a 6 month study)  
**Number of arms**: 2  
**Single centre or multi-site**: 2 acute wards  
**Study start date and end date**: not described  
**Setting**: acute care of the elderly wards

### Participants

**Baseline characteristics**  
**Inclusion criteria**: patients considered to be at high risk of pressure ulcer development  
**Exclusion criteria**: not given  
**Sex (M:F)**: not given  
**Age (years)**: mean 82.4 in Softform Premier Active mattress; 84.0 in standard air mattress  
**Baseline skin status**: mean Waterlow risk score 22.2 (range 17 to 29) in Softform Premier Active mattress; 21.6 (range 17 to 29) in standard air mattress  
**Group difference**: no difference  
**Total number of participants**: n = 100  
**Unit of analysis**: individuals  
**Unit of randomisation (per patient)**: individuals
### Interventions

#### Softform Premier Active Mattress

**Description of interventions:** Softform Premier Active Mattress consisting of a Softform Premier foam mattress with a dynamic underlay. The underlay alternates on a 10-minute cycle, and can be activated through connection to a portable pump ... to create an alternating surface for use in patients at very high risk of pressure ulcer development. When the alternating surface is not required, the pump can be disconnected, and the mattress becomes static ... The ability to use the mattress as either a dynamic or static surface ... allowing their care to be stepped up or down as appropriate.

**NPUAP S3I classification:** powered, alternating pressure (active) air surface; hybrid (active and reactive modes) mattress

**Co-interventions:** Softform Active mattresses and pressure-reducing cushions (Softform Premier Active Cushions; Invacare, Cardiff) used by all participants if required

**Number of participants randomised:** not described

**Number of participants analysed:** n = 50

#### Standard air mattress

**Description of interventions:** standard alternating pressure air mattress

**NPUAP S3I classification:** powered, alternating pressure (active) air surface

**Co-interventions:** Softform Active mattresses and pressure-reducing cushions (Softform Premier Active Cushions; Invacare, Cardiff) used by all participants if required

**Number of participants randomised:** not described

**Number of participants analysed:** n = 50

### Outcomes

#### Proportion of participants developing a new pressure ulcer

**Outcome type:** binary

**Time points:** 6 months

**Reporting:** partially reported

**Measurement method (e.g. scale, self-reporting):** EPUAP 2001

**Definition (including ulcer stage):** grade 2 ulcer incidence

**Dropouts:** not described

**Notes (e.g. other results reported):** 4 of 50 patients using Softform Premier Active Mattress developed superficial, grade 2 ulcers; 4 of 50 in standard air mattress

#### Time to pressure ulcer development

- Not reported

#### Support-surface-associated patient comfort

- Not reported

#### All reported adverse events using allocated support surfaces

- Not reported

#### Health-related quality of life (HRQOL)

- Not reported

#### Cost-effectiveness

- Not reported
Outcomes that are not considered in this review but reported in trials:
- Patient acceptability rated by staff nurses

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;Patients considered to be at high risk of pressure ulcer development were randomly allocated to a Softform Premier Active or standard air mattress&quot; Comment: unclear risk of bias because the sequence generation process is not described.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Outcome group: ulcer incidence Quote: &quot;Any pressure ulcers that developed during the study period were graded by a member of the tissue viability department.&quot; Comment: unclear risk of bias because blinding of outcome assessment is not described.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>Outcome group: ulcer incidence Comment: unclear risk of bias because the numbers randomised to arms are not detailed.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>Comment: the study appears to be free of other sources of bias.</td>
</tr>
</tbody>
</table>

**Grindley 1996**

**Study characteristics**

**Methods**
- **Study objective**: to compare the performance of the Nimbus II and the Pegasus Airwave mattresses in a hospice setting
- **Study design**: randomised controlled trial
- **Study grouping**: cross-over design
- **Duration of follow-up**: 3 days (the first stage of the cross-over trial)
- **Number of arms**: 2
- **Single centre or multi-site**: single centre
- **Study start date and end date**: not described
- **Setting**: hospice

**Participants**
- **Baseline characteristics**
  - **Inclusion criteria**: patients with existing pressure sores grade 2* or above or patients without existing pressure sores but at high or very high risk of developing pressure sores (Waterlow risk assessment score of 15 or above); minimum anticipated hospice stay of 7 days; patients spending more than 6
hours in a 24-hour period on the mattress; patients must give consent

**Exclusion criteria:** mental frailty; existing inpatients already on either of the study mattresses; gross obesity (greater than 30 stones, 190 kg); extreme emaciation (less than 6 stones, 38 kg); unstable spinal metastases

**Sex (M:F):** overall 8:12

**Age (years):** overall mean 69.05 (SD 14.32)

**Baseline skin status:** overall median Waterlow 22.5 (range 15 to 30) mean 22.65 (SD 4.43); 8 with existing ulcers

**Group difference:** not given

**Total number of participants:** n = 20

**Unit of analysis:** individuals

**Unit of randomisation (per patient):** individuals

### Interventions

#### Intervention characteristics

**Nimbus II mattress**

- **Description of interventions:** Nimbus II (Huntleigh Healthcare, Luton, Beds) is an alternating air pressure mattress replacement, comprising 2 banks of cells which alternately inflate and deflate over a 10-minute cycle
- **NPUAP S3I classification:** powered, alternating pressure (active) air surface
- **Co-interventions:** not described
- **Number of participants randomised:** n = 10
- **Number of participants analysed:** the first-stage data not available

**Pegasus Airwave**

- **Description of interventions:** Pegasus Airwave (Pegasus Airwave, Waterlooville, Hants) is an alternating air pressure mattress replacement, with a 3-cell alternating cycle lasting 7.5 minutes. It consists of a double layer of cells which work together as one.
- **NPUAP S3I classification:** powered, alternating pressure (active) air surface
- **Co-interventions:** not described
- **Number of participants randomised:** n = 10
- **Number of participants analysed:** the first-stage data not available

### Outcomes

**Proportion of participants developing a new pressure ulcer**

- Not reported

**Time to pressure ulcer development**

- Not reported

**Support-surface-associated patient comfort**

- **Outcome type:**
- **Time points:**
- **Reporting:** partially reported
- **Measurement method (e.g. scale, self-reporting):** self-rated using a questionnaire including the question: how would you describe the mattress with respect to comfort? (1 = extremely comfortable; 2 = very comfortable; 3 = comfortable; 4 = fairly comfortable; 5 = uncomfortable; 6 = very uncomfortable; 7 = extremely uncomfortable)
- **Definition:** comfort of using mattress
- **Dropouts:** mattress preference questionnaire completed by 16 patients
Notes: 10 responded Nimbus II is more comfortable and 2 responded Pegasus Airwave is more comfortable. 4 responded No preference [these are the second-phase data].

All reported adverse events using allocated support surfaces

- Not reported

Health-related quality of life (HRQOL)

- Not reported

Cost-effectiveness

- Not reported

Outcomes that are not considered in this review but reported in trials:

- Sleeping quality

Notes

Challenging to contact the study authors to request data at the first stage of this cross-over trial.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;Randomization was performed using a random numbers table&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: low risk of bias because the sequence generation process is proper.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;To avoid bias, the order in which the mattresses were allocated was randomised and selected by the investigator from sealed opaque envelopes in sequential order.&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: low risk of bias because it is likely to conceal allocation properly.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Outcome group: comfort</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td>Quote: &quot;mattress preference questionnaire completed by 16 patients&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk of bias because no information given on which group the missing are from.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>Comment: the study appears to be free of other sources of bias.</td>
</tr>
</tbody>
</table>

Hampton 1997

Study characteristics

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study objective: not described</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Study design: randomised controlled trial</td>
</tr>
<tr>
<td></td>
<td>Study grouping: parallel group</td>
</tr>
</tbody>
</table>
**Duration of follow-up:** 4 months  
**Number of arms:** 2  
**Single centre or multi-site:** single centre  
**Study start date and end date:** not described  
**Setting:** hospitals (Eastbourne NHS Trust)

### Baseline characteristics

**Inclusion criteria:** not described  
**Exclusion criteria:** not described  
**Sex (M:F):** not described  
**Age (years):** mean 75 in Cairwave Therapy; not described for Pegasus  
**Baseline skin status:** 27 of 36 in Cairwave Therapy at high risk; not described for Pegasus  
**Group difference:** not described  
**Total number of participants:** 36 in Cairwave Therapy; not described for Pegasus  
**Unit of analysis:** individuals  
**Unit of randomisation (per patient):** individuals

### Intervention characteristics

**Cairwave Therapy System**
- **Description of interventions:** Cairwave Therapy System (Pegasus Airwave Ltd) ... has a similar approach to pressure reduction, with a three cell, 7.5-minute cycle ... zero pressure is achieved for more than 20% of the cycle ... has a static mode which remains static for 30 minutes  
- **NPUAP S3I classification:** powered, alternating pressure (active) air surface; hybrid (active and reactive modes) mattress  
- **Co-interventions:** not described  
- **Number of participants randomised:** n = 36  
- **Number of participants analysed:** not described

**Pegasus Airwave mattress**
- **Description of interventions:** made from polyurethane-coated nylon. The cells are arranged in sets of three and are inflated in waves: one cell in every three will be deflated and this inflates as the next cell in the series begins to deflate ... 7.5-minute cycle which gives zero pressure for up to 15% of the time, and offers acceptable levels of pressure for the balance of the cycle time  
- **NPUAP S3I classification:** powered, alternating pressure (active) air surface  
- **Co-interventions:** not described  
- **Number of participants randomised:** not described  
- **Number of participants analysed:** not described

### Outcomes

**Proportion of participants developing a new pressure ulcer**
- **Outcome type:** binary  
- **Time points:** not described  
- **Reporting:** partially reported  
- **Measurement method (e.g. scale, self-reporting):** not described  
- **Definition (including ulcer stage):** not described  
- **Dropouts:** not described
Notes

- **Notes (e.g. other results reported):** 0 of 36 in Cairwave Therapy; 0 of (total number not described) in Pegasus

**Time to pressure ulcer development**
- **Reporting:** not reported

**Support-surface-associated patient comfort**
- **Reporting:** not reported

**All reported adverse events using allocated support surfaces**
- **Reporting:** not reported

**Health-related quality of life (HRQOL)**
- **Reporting:** not reported

**Cost-effectiveness**
- **Reporting:** not reported

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;Over a 4-month period, 36 patients were allocated to the Cairwave Therapy System during the randomised controlled trial&quot;&lt;br&gt;Comment: the method of randomisation was not described.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;Over a 4-month period, 36 patients were allocated to the Cairwave Therapy System during the randomised controlled trial&quot;&lt;br&gt;Comment: the method of concealing allocation was not described.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td><strong>Outcome group: primary outcome</strong>&lt;br&gt;Comment: no information provided.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td><strong>Outcome group: primary outcome</strong>&lt;br&gt;Comment: no information provided.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td><strong>Outcome group: primary outcome</strong>&lt;br&gt;Comment: no information provided.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias) Unclear risk</td>
<td>Comment: no information provided.</td>
<td></td>
</tr>
<tr>
<td>Other bias Unclear risk</td>
<td>Comment: no information provided.</td>
<td></td>
</tr>
</tbody>
</table>

### Jiang 2014

**Study characteristics**

**Methods**
- **Study objective:** to investigate the efficacy of static low-air-loss mattress (static LALM) and power pressure air mattress (PPAM) in prevention of pressure ulcers
- **Study design:** randomised controlled trial
- **Study grouping:** parallel group
- **Duration of follow-up:** 5 days after surgery
<table>
<thead>
<tr>
<th><strong>Number of arms</strong>:</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Single centre or multi-site</strong>:</td>
<td>multi-site</td>
</tr>
<tr>
<td><strong>Study start date and end date</strong>:</td>
<td>not described</td>
</tr>
<tr>
<td><strong>Setting</strong>:</td>
<td>hospitals</td>
</tr>
</tbody>
</table>

### Baseline characteristics

**Inclusion criteria**: age ≥ 18 years, male or female with Braden score ≤ 16 points, general anaesthesia for surgery with operating time ≥ 120 min, admitted to the intensive care unit (ICU) or surgical wards after surgery, clear consciousness, able to express their feelings correctly, had contraindications for using air mattress (doctor’s orders: lying on hard-bed or flat-bed), completed informed consent and related information.

**Exclusion criteria**: refused to participate in research; in critical condition and repositioning limited by doctor’s orders; using ice blanket; shed from intervention less than 72 hours; unable to determine the efficacy; incomplete data on the efficacy; or safety judgment.

**Sex (M:F)**: overall 621:453

**Age (years)**: overall mean 57.94 (SD 15.54) years (range 18 to 88)

**Baseline skin status**: overall mean Braden scores 13.15 (SD 2.25) (range 6 to 17)

**Group difference**: no difference

**Total number of participants**: n = 1074

**Unit of analysis**: individuals

**Unit of randomisation (per patient)**: individuals

### Intervention characteristics

#### Static air mattress

- **Description of interventions**: static air mattress ( ®WAFFLE static air mattress, EHOB, United States)
- **NPIAP S3I classification**: non-powered, reactive air surface
- **Co-interventions**: repositioning every 2 hours
- **Number of participants randomised**: n = 562
- **Number of participants analysed**: n = 562

#### Dynamic air mattress

- **Description of interventions**: dynamic air mattress (Sanma mattress manufacturing factory, Shanghai, China)
- **NPIAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: repositioning every 2 hours
- **Number of participants randomised**: n = 512
- **Number of participants analysed**: n = 512

### Outcomes

**Proportion of participants developing a new pressure ulcer**

- **Outcome type**: binary
- **Time points**: partially reported
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: graded by the NPIAP 2007 criteria
- **Definition (including ulcer stage)**: no missing
- **Dropouts**: no missing
Notes (e.g. other results reported): static air mattress group 1.07% (6/562); dynamic air mattress 0.98% (5/512) χ² = 0.148, P = 0.882

Time to pressure ulcer development
- Not reported

Support-surface-associated patient comfort
- Outcome type: binary
- Time points: post-operative 5 days
- Reporting: partially reported
- Measurement method (e.g. scale, self-reporting): asking patients’ feelings after using the mattress 1 = very uncomfortable, 2 = uncomfortable, 3 = just comfortable, 4 = comfortable, 5 = very comfortable
- Definition: the level of patients’ comfort
- Dropouts: 80 of 562 missing in static air mattress; 100 of 562 missing in dynamic air mattress
- Notes: 68 of 482 patients having a comfort level rating more than the median of 4 in static air mattress and 414 of 482 less than the median level; 68 of 462 more than the median of 4 in dynamic air mattress and 394 less than the median (Ch² = 0.071, P = 0.789)

All reported adverse events using allocated support surfaces
- Not reported

Health-related quality of life (HRQOL)
- Not reported

Cost-effectiveness
- Not reported

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;We used a random number table to randomize and parallel control design&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: low risk of bias because the sequence generation process is proper.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>Outcome group: ulcer incidence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: low risk of bias because intention-to-treat (ITT) analysis performed.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Outcome group: comfort</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk of bias because the rates of missing</td>
</tr>
</tbody>
</table>

Cochrane Wounds Group, Shi, Shi, Dumville, Cullum, Rhodes, Jamali... https://archie.cochrane.org/sections/documents/view?version=z2105051...
Laurent 1998

Study characteristics

Methods

- **Study objective**: to assess the effectiveness of 3 prevention strategies and compare them to the standard mattress
- **Study design**: randomised controlled trial
- **Study grouping**: factorial design
- **Duration of follow-up**: mean length of stay 15.04 (SD 7.10)
- **Number of arms**: 4
- **Setting**: hospital

Participants

- **Baseline characteristics**
  - **Inclusion criteria**: adults over 15 years of age, admitted for major cardiovascular surgery, hospital stay likely to be at least 5 days, with a period on the intensive care unit (ICU)
  - **Exclusion criteria**: not reported
  - **Sex (M:F)**: 214:98 across 4 groups
  - **Age (years)**: mean 64.0 (SD 11.88) across 4 groups
  - **Baseline skin status**: not described
  - **Group difference**: no difference
  - **Total number of participants**: n = 312
  - **Unit of analysis**: individuals
  - **Unit of randomisation (per patient)**: individuals

Interventions

- **Standard group**
  - **Description of interventions**: standard mattress in ICU; standard mattress postoperatively
  - **NPIAP S3I classification**: standard hospital surface (ICU); standard hospital surface (postoperation)
  - **Co-interventions**: not described
  - **Number of participants randomised**: n = 80
  - **Number of participants analysed**: n = 80

- **Alternating mattress in ICU**
  - **Description of interventions**: Nimbus (AP) in ICU; standard mattress postoperatively
  - **NPIAP S3I classification**: powered, alternating pressure (active) air surface (ICU); standard hospital surface (postoperation)
  - **Co-interventions**: not described
  - **Number of participants randomised**: n = 80
  - **Number of participants analysed**: n = 80
Constant low-pressure mattress in postoperative hospitalisation

- **Description of interventions**: standard mattress in ICU; Tempur (CLP) postoperatively *(Laurent 1998)*. Additional source of information: "a visco-elastic polyethylene urethane foam mattress (Tempur®, Tempur-World Inc., USA)" *(Vanderwee 2005)*.
- **NPIAP S3I classification**: standard hospital surface (ICU); non-powered reactive foam surface; high specification viscoelastic foam (postoperation)
- **Co-interventions**: not described
- **Number of participants randomised**: n = 75
- **Number of participants analysed**: n = 75

Both mattresses

- **Description of interventions**: Nimbus in ICU and Tempur (CLP) postoperatively
- **NPIAP S3I classification**: powered, alternating pressure (active) air surface (ICU); non-powered, reactive foam surface; high specification viscoelastic foam (postoperation)
- **Co-interventions**: not described
- **Number of participants randomised**: n = 77
- **Number of participants analysed**: n = 77
**Outcomes**

**Proportion of participants developing a new pressure ulcer**
- **Outcome type**: binary
- **Time points**: not described
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: assessed by specially trained nurses and classified as stage 0 (normal skin), stage 1 (non-blanchable erythema), and stage 2 (partial or full thickness skin loss)
- **Definition (including ulcer stage)**: cumulative incidence of pressure sores of stage 2 (the lower the rate, the better the mattress effectiveness)
- **Drop outs**: not described
- **Notes (e.g. other results reported)**: 45 of 312 (14.4%) having pressure sores; 14 of 80 in standard; 10 of 80 in alternating mattress in ICU; 11 of 75 in constant low pressure mattress; 10 of 77 in both mattresses

**Time to pressure ulcer development**
- **Reporting**: not reported

**Support-surface-associated patient comfort**
- **Reporting**: not reported

**All reported adverse events using allocated support surfaces**
- **Reporting**: not reported

**Health-related quality of life (HRQOL)**
- **Reporting**: not reported

**Cost-effectiveness**
- **Reporting**: not reported

### Notes

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “Patients were randomised by blocks”</td>
</tr>
<tr>
<td></td>
<td>Comment: unclear risk of bias because the randomisation method was not stated.</td>
<td></td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Outcome group: primary outcome</td>
</tr>
<tr>
<td></td>
<td>Quote: “Given the kind of material tested, blinding was not possible”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comment: high risk of bias as the above statement suggests.</td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>High risk</td>
<td>Outcome group: primary outcome</td>
</tr>
<tr>
<td></td>
<td>Quote: “Given the kind of material tested, blinding was not possible”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comment: high risk of bias as the above statement suggests.</td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>Outcome group: primary outcome</td>
</tr>
<tr>
<td></td>
<td>Comment: no attrition identified.</td>
<td></td>
</tr>
</tbody>
</table>
### Selective reporting (reporting bias)

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk</td>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
</tr>
</tbody>
</table>

### Other bias

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>High risk</td>
<td>Comment: the study appears not to consider the interaction between the effects of the different interventions that results from the factorial design used.</td>
</tr>
</tbody>
</table>

### Malbrain 2010

#### Study characteristics

**Study objective:** to compare pressure ulcer outcomes in medical intensive care unit (ICU) patients nursed on either a reactive mattress overlay (ROHO®, ROHO Inc, Belleville, IL, USA) or an active alternating pressure mattress (NIMBUS®3, ArjoHuntleigh, Luton Bedfordshire, UK)

**Study design:** randomised controlled trial

**Study grouping:** parallel group

**Duration of follow-up:** not specified; mean study duration reported 12.2 days (SD 5.5) in ROHO and 15 (14) in NIMBUS 3

**Number of arms:** 2

**Single centre or multi-site:** single centre

**Study start date and end date:** not described

**Setting:** medical ICU of a hospital

#### Methods

**Baseline characteristics**

**Inclusion criteria:** patients admitted to the ICU with a high pressure ulcer risk (Norton score ≤ 8) and requiring mechanical ventilation for an estimated duration of at least 5 days either (a) with intact skin or (b) with pressure ulcers on admission

**Exclusion criteria:** refused to consent to the study; either of 2 mattresses unavailable for patients admitted

**Sex (M:F):** 8:8 across groups; 5:3 in ROHO; 3:5 in NIMBUS 3

**Age (years):** mean 64.7 (SD 15.6) across groups; 71.6 (11.9) in ROHO overlay; 56.9 (16.3) in NIMBUS 3 mattress

**Baseline skin status:** mean Norton score 7.2 (SD 0.7) across groups; 7 (0) in ROHO and 7.4 (1.1) in NIMBUS 3

**Group difference:** different age distributions between groups

**Total number of participants:** n = 16

**Unit of analysis:** individuals

**Unit of randomisation (per patient):** individuals

#### Participants

**Interventions**

**Description of interventions:** the ROHO DRY FLOATATION mattress overlay (ROHO Inc, Belleville, IL, USA) ... a manually inflatable reactive low-pressure mattress, overlaying a normal hospital mattress that moulds to the body surface in order to distribute the pressure over an area as large as possible.

**NPIAP S3I classification:** non-powered, reactive air surface

**Co-interventions:** Belgian consensus protocol for ulcer prevention and treatment (including 2-hourly repositioning)

**Number of participants randomised:** n = 8

**Number of participants analysed:** n = 8 assumed
NIMBUS 3 mattress

- **Description of interventions**: a fully automatic active alternating pressure mattress replacement consisting of 20 individual cells (3 head, 8 torso, 4 leg and 5 heel) that alternatively inflate and deflate over a 10-minute cycle repeatedly off-loading the tissues.

- **NPIAP S3I classification**: powered, alternating pressure (active) air surface

- **Co-interventions**: Belgian consensus protocol for ulcer prevention and treatment (including 2-hourly repositioning)

- **Number of participants randomised**: n = 8

- **Number of participants analysed**: n = 8 assumed

### Outcomes

**Proportion of participants developing a new pressure ulcer**

- **Outcome type**: binary
- **Time points**: not specified
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: nurse/clinician-rated ulcers using EPUAP system
- **Definition (including ulcer stage)**: pressure ulcer incidence of stage 1 and incidence of stage 2 to 4 according to EPUAP system
- **Dropouts**: no missing data
- **Notes (e.g. other results reported)**: 3 of 8 individuals (2 stage 3 or 4 and 1 stage 1) in ROHO and 2 of 8 individuals (both stage 1) in NIMBUS 3

**Time to pressure ulcer development**

- **Reporting**: not reported

**Support-surface-associated patient comfort**

- **Reporting**: not reported

**All reported adverse events using allocated support surfaces**

- **Reporting**: not reported

**Health-related quality of life (HRQOL)**

- **Reporting**: not reported

**Cost-effectiveness**

- **Reporting**: not reported

**Outcomes that are not considered in this review but reported in trials**:

- Pressure ulcer healing outcome (reported but not extracted because patients with ulcers are not units of randomisation)

### Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;Randomisation of patients to products was performed blinded by the insertion of equivalent numbers of labels written with 'active' or 'reactive' placed in identical sealed envelopes that were shuffled and placed in a box and drawn in sequence&quot; Comment: low risk of bias because a simple randomisation was applied.</td>
</tr>
</tbody>
</table>
**Nixon 2006**

### Study characteristics

**Methods**
- **Study objective**: to compare whether differences exist between alternating pressure overlays and alternating pressure mattresses in the development of new pressure ulcers, healing of existing pressure ulcers, and patient acceptability.
- **Study design**: randomised controlled trial with cost-effectiveness analysis
- **Study grouping**: parallel group
- **Duration of follow-up**: 30 days; 60 days
- **Number of arms**: 2
- **Single centre or multi-site**: multi-site
- **Study start date and end date**: not described
- **Setting**: NHS hospitals

**Participants**
- **Baseline characteristics**
  - **Inclusion criteria**: participants aged at least 55 years who had been admitted to vascular, orthopaedic, medical, or care of elderly people wards, either as acute or elective admissions, in the previous 24 hours; expected length of stay of at least 7 days and either limitation of activity and mobility (Braden scale activity and mobility scores of 1 or 2; box 25) or an existing pressure ulcer of grade 2 (using the skin grading tool from Nixon et al, 3 box 1); elective surgical patients without limitation of activity and mobility or an existing pressure ulcer
  - **Exclusion criteria**: those who had a pressure ulcer on admission of grade 3 or worse, had a planned admission to an intensive care unit after surgery, were...
admitted to hospital more than 4 days before surgery, slept at night in a chair, or weighed more than 140 kg or less than 45 kg

Sex (M:F): 346:636 in mattress; 365:624 in overlay

Age (years): mean 75.0 (SD 9.2) in mattress; 75.4 (SD 9.7) in overlay

Baseline skin status: total Braden scores not reported; 1558 (79%) of patients bedfast and 1342 (68.1%) patients very limited mobility and 362 completely immobile

Group difference: no difference

Total number of participants: 1972

Unit of analysis: individuals

Unit of randomisation (per patient): individuals

Interventions

Intervention characteristics

Alternating pressure mattress

- Description of interventions: consist of air-filled sacs that sequentially inflate and deflate to relieve pressure for short periods; provided as a full size replacement mattress; with 7.5– to 30-minute cycle

- NPIAP S3I classification: powered, alternating pressure (active) air surface

- Co-interventions: not described

- Number of participants randomised: n = 982

- Number of participants analysed: n = 982

Alternating pressure overlay

- Description of interventions: consist of air-filled sacs that sequentially inflate and deflate to relieve pressure for short periods; provided as a shallower overlay that is placed on top of a mattress; with 7.5– to 30-minute cycle

- NPIAP S3I classification: powered, alternating pressure (active) air surface

- Co-interventions: not described

- Number of participants randomised: n = 990

- Number of participants analysed: n = 989

Outcomes

Proportion of participants developing a new pressure ulcer

- Outcome type: binary

- Time points: 60 days

- Reporting: fully reported

- Measurement method (e.g. scale, self-reporting): staff nurses rated and validated by researchers; using the ulcer classification system evaluated in Nixon 2006 (see the seventh reference of Nixon 2006 for the detail of the system).

- Definition (including ulcer stage): the proportion of participants developing 1 or more new pressure ulcers of grade 2 or worse; proportions of participants developing a new ulcer within 30 days

- Dropouts: 1 excluded

- Notes (e.g. other results reported): 60 days: 101 of 982 in mattress (5 grade 3; probably the rest all grade 2); 106 of 989 in overlay (3 grade 3; probably the rest all grade 2); 30 days: 91 (9.3%) in mattress and 99 (10.0%) in overlay (Chi², P = 0.58).

Time to pressure ulcer development

- Outcome type: time-to-event

- Time points: 60 days

- Reporting: fully reported
Support-surface-associated patient comfort

- **Outcome type**: binary
- **Time points**: 60 days
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: self-reported
- **Definition**: patient acceptability assessed indirectly from the number of people requesting a change because they were dissatisfied with the assigned surface
- **Dropouts**: 1 excluded
- **Notes**: 186 of 982 (18.9%) in mattress; 230 of 989 (23.3%) people in overlay

All reported adverse events using allocated support surfaces

- **Outcome type**: binary
- **Time points**: 60 days
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: clinical research nurse-rated (gained information from ward staff and healthcare records)
- **Definition**: adverse events due to support surfaces allocated
- **Dropouts**: not relevant
- **Notes**: 377 adverse events reported for 308 patients that were not reported by study groups; 10 patients with mattress-related events in mattress and 4 in overlay; ‘not mattress related’ adverse events also reported, but not extracted (see the primary reference of Nixon 2006).

Health-related quality of life (HRQOL)

- **Reporting**: partially reported
- **Definition**: how patients, after discharged, perceive and describe their health and quality of life, their experiences of developing a pressure ulcer and their experiences of pressure area care.
- **Notes**: HRQOL measured and reported as qualitative analysis results. Participants of the qualitative interviews were 23 people with experience of having a pressure ulcer, but not limited to those eligible for this trial. From patients’ perspectives, the development of a pressure ulcer has physical, emotional, mental and social impacts. The development of a pressure ulcer can be pivotal in the patient’s trajectory from illness to recovery, with the development of an ulcer preventing them from making a full recovery and causing varied impacts on their quality of life.

Cost-effectiveness

- **Outcome type**: continuous
- **Reporting**: fully reported in the primary reference of Nixon 2006
- **Measurement method (e.g. scale, self-reporting)**: health benefit measures using Kaplan Meier estimates of restricted mean time to development of pressure ulcers. Overall costs at pricing year of 2002-3 included hospital
treatment costs per day based on estimates from the Chartered Institute of Public Finance and Accountancy; unit purchasing and rental costs of each surface based on UK retail prices provided by the manufacturers. Hospital costs analysed by using generalised linear model. Economic analysis from the perspective of the UK NHS and Personal Social Service; no cost or benefit discounting due to time horizon shorter than 1 year; non-parametric bootstrapping techniques applied; sampling uncertainty explored in an incremental cost effectiveness plane; sensitivity analysis conducted for 3 different scenarios.

- **Definition**: incremental cost-effectiveness ratio (ICER), the ratio of the difference in costs relative to the difference in health benefit associated with the technology under evaluation.

- **Notes**: because dominance was identified, an incremental analysis is not justified and the estimates of differential costs and health benefits were not combined in an ICER. Base case analysis results: mean overall hospital costs £6793.33 (SD 8196.52) in overlay group and £6509.73 (7347.56) in mattress group and mean difference in total hospital cost of £283.60 (95% confidence interval £377.59 to £976.79, P = 0.418). Difference in the Kaplan Meier restricted estimates of the mean time to development of pressure ulcers - 10.64 days (95% bias corrected confidence interval 24.40 to 3.09 days; overlay versus mattress). The mattresses are a dominant strategy when compared with the overlays; they are associated with a delay in the development of pressure ulcers and lower hospital costs. Cost-effectiveness acceptability curve indicated that on average alternating pressure mattresses compared with alternating pressure overlays were associated with an 80% probability of being cost saving.

**Outcomes that are not considered in this review but reported in trials:**

- Time to healing and grade of ulcer at trial completion.
- Healing of existing pressure ulcers.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;Randomisation was through an independent, secure, 24 hour randomisation automated telephone system, ensuring allocation concealment. We used minimisation so that groups were comparable. We minimised on centre, existing pressure ulcer ... specialty ... and type of admission&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: low risk of bias due to the use of a proper randomisation method.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;Randomisation was through an independent, secure, 24 hour randomisation automated telephone system, ensuring allocation concealment. We used minimisation so that groups were comparable. We minimised on centre, existing pressure ulcer ... specialty ... and type of admission&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: low risk of bias due to proper concealment.</td>
</tr>
</tbody>
</table>
### Blinding of participants and personnel (performance bias)

| All outcomes | High risk |

*Quote:* "This was an open trial. Owing to the nature of the mattresses under investigation, it was not possible to mask the randomised intervention to the patients participating in the trial, ward nursing staff or the CRNs conducting the skin assessments"

*Quote:* "The PRESSURE Trial CRNs worked closely with ward staff and informed ward staff of the randomised mattress allocation"

Comment: high risk of bias because it was impossible to blind participants and personnel but some efforts were made to improve the compliance of using the allocated interventions.

### Blinding of outcome assessment (detection bias)

| All outcomes | Unclear risk |

*Quote:* "This was an open trial. Owing to the nature of the mattresses under investigation, it was not possible to mask the randomised intervention to the patients participating in the trial, ward nursing staff or the CRNs conducting the skin assessments ... To minimise the potential for bias it was planned that qualified ward-based nursing staff (WNs) would record daily skin assessments and CRNs would undertake assessments twice weekly to validate ward staff records, ward staff remaining blind to the CRN record" (HTA report).

Comment: unclear risk of bias because of the efforts to reduce detection bias.

### Incomplete outcome data (attrition bias)

| All outcomes | Low risk |

*Quote:* "The analysis was by intention to treat, with participants being analysed according to the group to which they were randomised ..."

*Quote:* "... 1972 were randomised ... One patient was randomised twice and therefore excluded, providing an intention to treat population of 1971 people ...

Comment: low risk of bias because intention-to-treat analysis was done.

### Selective reporting (reporting bias)

| Low risk |

Comment: the study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way.

### Other bias

| Low risk |

Comment: the study appears to be free of other sources of bias.

---

### Nixon 2019

#### Study characteristics

**Study objective:** to compare the clinical effectiveness and cost-effectiveness of 2 mattress types: alternating pressure mattresses (APMs) or high specification foam (HSF)

**Study design:** randomised controlled trial (double triangular group sequential design)

**Study grouping:** parallel group

**Duration of follow-up:** maximum treatment phase of 60 days; 30 days post-treatment

**Number of arms:** 2

**Single centre or multi-site:** multi-site

**Study start date and end date:** August 2013 to November 2016
**Setting:** 42 UK secondary/community inpatient facilities

### Baseline characteristics

**Inclusion criteria:** inpatient with evidence of acute illness; ≥ 18 years; expected stay ≥ 5 days; expected to comply with follow-up; on electric profiling bed-frame; high pressure ulcer (PU) risk due to at least 1 of following: Braden activity score 1/2 and mobility score 1/2; category 1 ulcers; localised skin pain on a healthy/altered /category 1 pressure area

**Exclusion criteria:** had previously participated; current/previous ulcer category ≥ 3; planned intensive care unit (ICU) admission; unable to receive intervention; outside mattress weight limits (< 45 kg or > 180 kg); ethically inappropriate e.g. thought to be in the last few days of their life

**Sex (M:F):** 907:1119 overall; 462:553 in APM; 445:566 in HSF

**Age (years):** median 81 (range 21 to 105) overall; mean 77.8 (SD 13.42) in APM; 78.2 (12.87) in HSF

**Baseline skin status:** overall 78 with a Braden score > 18 (not at risk) in APM and 69 in HSF; 937 with a score ≤ 18 (at risk) in APM; 942 in HSF. At risk and allowed to have category 1 ulcers

**Group difference:** no difference

**Total number of participants:** n = 2029

**Unit of analysis:** individuals

**Unit of randomisation (per patient):** individuals

### Interventions

#### Alternating pressure air mattress (APM)

- **Description of interventions:** fully automatic; some may have dual therapy, for example, the mattress comprises a combination of alternating pressure or low-air-loss. The trial will include only those participants nursed on the alternating pressure mode of action, with a 7.5 to 30 minute cycle time.

- **NPIAP S3I classification:** powered, alternating pressure (active) air surface

- **Co-interventions:** not reported

- **Number of participants randomised:** n = 1017

- **Number of participants analysed:** n = 1016

#### High-specification foam mattress (HSF)

- **Description of interventions:** be high-density foam, viscoelastic (memory) foam or a combination of both, and can be castellated (for ventilation and profiling); have a cover with the following characteristics: removable, minimum two-way stretch, vapour permeable and covered zips as defined in BS 3379.36; be replacement mattresses with a minimum depth of 150 to 200 mm

- **NPIAP S3I classification:** non-powered, reactive foam surface

- **Co-interventions:** not reported

- **Number of participants randomised:** n = 1013

- **Number of participants analysed:** n = 1013

### Outcomes

**Proportion of participants developing a new pressure ulcer**

- **Outcome type:** binary

- **Time points:** 90 days

- **Reporting:** partially reported

- **Measurement method (e.g. scale, self-reporting):** classified using the 2009 NPIAP/EPUAP system.

- **Definition (including ulcer stage):** incidence of PU category ≥ 2 from randomisation to 30 days from the end of the treatment phase (maximum of...
90 days)

- **Dropouts**: intention-to-treat (ITT) analysis but 1 participant excluded from alternating pressure mattress due to their previous inclusion/randomisation

- **Notes (e.g. other results reported)**: 
  - **Primary time point (90 days)**: 70 of 1016 (6.9%) in alternating pressure air mattress; 90 of 1013 (8.9%) in high-specification foam mattress.
  - **Data from randomisation to end of treatment (60 days)**: 53 of 1016 (5.2) in alternating pressure air mattress; 79 of 1013 (7.8%) in high-specification foam mattress.
  - **Secondary endpoint (incidence of a new PU category ≥ 1 by 90 days)**: 160 of 1016 in alternating pressure air mattress; 190 of 1013 in high-specification foam mattress.
  - **Secondary endpoint (incidence of a new PU category ≥ 3 by 90 days)**: 14 of 1016 vs 18 of 1013

**Time to pressure ulcer development**

- **Outcome type**: time-to-event
- **Time points**: maximum 90 days
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: classified using the 2009 NPIAP/EPUAP system
- **Definition (including ulcer stage)**: time to developing a new PU category ≥ 2 from randomisation to 30 days from the end of the treatment phase (maximum of 90 days)
- **Dropouts**: ITT analysis but 1 participant excluded from alternating pressure mattress due to their previous inclusion/randomisation

- **Notes (e.g. other results reported)**: primary time point (90 days): median time to first new ulcer 18 days (range 2 to 86) in alternating pressure air mattress; 12 (2 to 94) in high-specification foam mattress; adjusted analysis Fine and Gray model HR 0.76 (95% CI 0.56 to 1.04, exact P = 0.0890). 
  - **Data within 60 days**: Fine and Gray model HR 0.66 (95% CI 0.46 to 0.93; exact P = 0.0176). 
  - **Secondary endpoint (incidence of a new PU category ≥ 1 by 90 days)**: Fine and Gray model HR 0.83 (95% CI 0.67 to 1.02; exact P = 0.0733). 
  - **Secondary endpoint (incidence of a new PU category ≥ 3 by 90 days)**: HR 0.81 (95% CI 0.40 to 1.62); exact P = 0.5530. Univariate survival analysis curves presented in Fig 2.

**Support-surface-associated patient comfort**

- **Reporting**: not reported

**All reported adverse events**

- **Outcome type**: binary
- **Time points**: 90 days
- **Reporting**: partially reported.
- **Measurement method (e.g. scale, self-reporting)**:
- **Definition (including ulcer stage)**:
- **Dropouts**: ITT analysis but 1 participant excluded from alternating pressure mattress due to their previous inclusion/randomisation

- **Notes (e.g. other results reported)**: no safety concerns indicated for either mattress. No related and unexpected serious adverse events in either group. Expected adverse events/serious adverse events: 163 of 1017 in APM and 167 of 1013 in HSFM. The proportion of deaths (APM 82/1017, 8.1% vs. HSFM 84/1013, 8.3%), re-admission rates (APM 82/1017, 8.1% vs. HSFM 62/1013, 6.1%) and fall rates (APM 152/1017, 14.9% vs. HSFM 159/1013, 15.7%) similar between arms.

**Health-related quality of life (HRQOL)**
• Outcome type: binary
• Time points: 90 days
• Reporting: partially reported
• Measurement method (e.g. scale, self-reporting): HRQOL assessed using the EQ-5D-5L and quality-adjusted life-years (QALY) calculated based on EQ-5D-5L using an equation: QALY = \[\frac{[(\text{EQ5DBaseline} + \text{EQ5Dweek1}) \times t]}{2} + \frac{[(\text{EQ5Dweek1} + \text{EQ5Dweek3}) \times t]}{2} + \frac{[(\text{EQ5Dweek3} + \text{EQ5DEndpoint}) \times t]}{2}\]. Sensitivity analysis performed with HRQOL measure of PU-QoL-UI. The utility values of the EQ-5D-5L and PU-QoL-UI have a scale of negative 1 to 1, with 1 representing perfect health, 0 representing death, and −1 representing worse than death.
• Definition (including ulcer stage): mean estimated QALYs
• Dropouts: 267 participants (APM arm, n = 118; HSFM arm, n = 149) completed the EQ-5D-5L at all 4 time points, and 233 had completed the PU-QoL-UI at all 4 time points (APM arm, n = 107; HSFM arm, n = 126)
• Notes (e.g. other results reported): 90-day EQ-5D-5L: mean 0.52 (SD 0.21) in APM, 0.52 (0.22) in HSF; P = 0.49. Mean QALYs higher in alternating pressure air mattress 0.128 (95% 0.126 to 0.130) than high-specification foam mattress 0.127 (0.124 to 0.129); P = 0.47. 90-day PU-QoL-UI: mean 0.69 (SD 0.13) in APM, 0.69 (0.13) in HSF; P = 0.28

Cost-effectiveness
• Outcome type: binary
• Time points: 90 days
• Reporting: partially reported
• Measurement method (e.g. scale, self-reporting): an ITT analysis used quality-adjusted life-years (QALYs) as the main outcome and adopted the perspective of the UK National Health Service (NHS) and Personal Social Services (PSS). The NICE GBP (pounds sterling) 20,000 per QALY gained threshold was used to determined cost-effectiveness. Utility values were derived from the EQ-5D-5L, and costs were estimated using the UK tariff. Costs and outcomes were adjusted for baseline imbalances. Sampling uncertainty was determined via a probabilistic sensitivity analysis (PSA) using a non-parametric bootstrap.
• Definition (including ulcer stage): the incremental cost per QALY gained; within-trial analyses using QALYs derived from the EQ-5D-5L
• Drop outs: ITT analysis
• Notes (e.g. other results reported): adjusted for baseline costs and QALYs, deterministic analysis suggests the mean total costs of APM and HSFM are GBP 4,533 and GBP 4,646, respectively, with mean QALYs of 0.128 and 0.127, respectively. ICER = GBP −136,171; NMB = GBP −2,077; probabilistic analysis shows mean total costs of APM and HSFM are GBP 4,533 and GBP 4,646, respectively, and mean QALYs are 0.128 and 0.127, respectively. ICER = GBP −101,699 and NMB = GBP −2,114. Estimates indicate that APM has a 99% probability of being cost-effective at a threshold of GBP 20,000 (APMs dominate HSFM, as APM has lower costs and higher QALY values). Lifetime decision-analytic model developed for lifetime cost-effectiveness analysis but data not extracted for this review. Finding is: APM is cost-effective over both the short and the long term.

Outcomes that are not considered in this review but reported in trials:
• Time to healing of all pre-existing category 2 ulcers
• Mattress compliance
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation</td>
<td>Low risk</td>
<td>Quote: &quot;Participants were randomised centrally (24 h automated telephone system, ensuring allocation concealment) on a 1:1 basis using minimisation (with random element) and minimisation factors: centre, PU status, type of facility, and type of consent&quot; Comment: low risk of bias because of the use of a proper randomisation method.</td>
</tr>
<tr>
<td>Allocation concealment</td>
<td>Low risk</td>
<td>Quote: &quot;Participants were randomised centrally (24 h automated telephone system, ensuring allocation concealment) on a 1:1 basis using minimisation (with random element) and minimisation factors: centre, PU status, type of facility, and type of consent&quot; Comment: low risk of bias because allocation is properly concealed.</td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>High risk</td>
<td>Quote: &quot;Blinding of the research and clinical staff or patients was not possible due to the appearance of the mattresses&quot; Comment: high risk of bias because non-blinding is clearly stated.</td>
</tr>
<tr>
<td>Blinding of outcome assessment</td>
<td>Low risk</td>
<td>Quote: &quot;Assessment of risk of bias of the primary endpoint was done with central blind review of photographs and a 10% sample of patients who had skin assessments by a practitioner blinded to previous assessments was performed&quot; Comment: low risk of bias because attempts were made to mask outcome assessment.</td>
</tr>
<tr>
<td>Incomplete outcome data</td>
<td>Low risk</td>
<td>Quote: &quot;All participants recruited were included using Intention-To-Treat (ITT) and analysed by randomised allocation&quot; Comment: low risk of bias because ITT analysis was performed.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Comment: the study protocol is available and it is clear that the published reports include all outcomes, including those that were pre-specified.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>Comment: the study appears to be free of other sources of bias.</td>
</tr>
</tbody>
</table>

### Phillips 1999

**Study characteristics**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study objective: to compare the mattress overlay system with a second dynamic overlay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Study design: randomised n-of-1 controlled trial, with a series design</td>
</tr>
<tr>
<td></td>
<td>Study grouping: parallel group</td>
</tr>
<tr>
<td></td>
<td>Duration of follow-up: 12 weeks</td>
</tr>
<tr>
<td></td>
<td>Number of arms: 2</td>
</tr>
<tr>
<td></td>
<td>Single centre or multi-site: single centre</td>
</tr>
<tr>
<td></td>
<td>Study start date and end date: not described</td>
</tr>
<tr>
<td></td>
<td>Setting: community care</td>
</tr>
<tr>
<td>Participants</td>
<td>Baseline characteristics</td>
</tr>
<tr>
<td></td>
<td>Inclusion criteria: those aged over 16 years old and did not have established pressure ulcers; in need of a pressure-redistributing mattress; with a prognosis of remaining medically stable over 12 weeks; able to provide informed consent</td>
</tr>
<tr>
<td></td>
<td>Exclusion criteria: not given</td>
</tr>
<tr>
<td></td>
<td>Sex (M:F): overall 11:26</td>
</tr>
</tbody>
</table>
### Interventions

#### Viaclin dynamic mattress overlay
- **Description of interventions**: Viaclin dynamic mattress overlay (formerly known as the Overture dynamic mattress overlay) consisting of 18 alternating pressure air cells ... manufactured in polyurethane (PU)-coated nylon ... overlay cells inflate and deflate over a 12-minute cycle by means of an electro-pneumatic system
- **NPIAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: not described
- **Number of participants randomised**: 37 participants
- **Number of participants analysed**: not given

#### Alternative dynamic overlay
- **Description of interventions**: alternative dynamic overlay
- **NPIAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: not described
- **Number of participants randomised**: 37 participants
- **Number of participants analysed**: not given

### Outcomes

#### Proportion of participants developing a new pressure ulcer
- **Outcome type**: binary
- **Time points**: unclear
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: not given
- **Definition (including ulcer stage)**: ulcer incidence
- **Dropouts**: unclear
- **Notes (e.g. other results reported)**: 2 subjects developed an ulcer on the alternative overlay, 0 ulcers reported with the Viaclin mattress

#### Time to pressure ulcer development
- **Not reported**

#### Support-surface-associated patient comfort
- **Reporting**: partially reported
- **Notes**: 1 of 6 patients who failed on the alternative overlay was uncomfortable upon the overlay

#### All reported adverse events using allocated support surfaces
- **Not reported**

#### Health-related quality of life (HRQOL)

---

**Age (years)**: overall median 87 (range 21 to 92)

**Baseline skin status**: median Waterlow score 16 (range 13 to 26); without existing ulcers

**Group difference**: no difference due to the use of n-of-1 trial design

**Total number of participants**: n = 37 (the use of n-of-1 trial design means 37 trials are run)

**Unit of analysis**: observations of each individual

**Unit of randomisation (per patient)**: order of treatment sequence
Study objective: to compare the effects on pressure damage prevalence by using 2 different support systems in patients with fractured neck of femur who were at high risk

Study design: randomised controlled trial

Study grouping: parallel group

Duration of follow-up: post-operation 7 days; post-operation 14 days

Number of arms: 2

Single centre or multi-site: single centre

Study start date and end date: not described

Setting: hospital ward

Inclusion criteria: patients with fractured neck of femur (confirmed by X-ray), who were over 60 years old and identified as being ‘at very high risk’ of developing tissue damage (Medley score > 25)
<table>
<thead>
<tr>
<th>Exclusion criteria:</th>
<th>not specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex (M:F):</strong></td>
<td>11:29 in Repose; 5:35 in NIMBUS II</td>
</tr>
<tr>
<td><strong>Age (years):</strong></td>
<td>mean 83.5 (range 67.3 to 96.2) in Repose and 80.9 (64.4 to 98.4) in NIMBUS II</td>
</tr>
<tr>
<td><strong>Baseline skin status:</strong></td>
<td>at very high risk defined by Medley score &gt; 25</td>
</tr>
<tr>
<td><strong>Group difference:</strong></td>
<td>no difference</td>
</tr>
<tr>
<td><strong>Total number of participants:</strong></td>
<td>80</td>
</tr>
<tr>
<td><strong>Unit of analysis:</strong></td>
<td>individuals</td>
</tr>
<tr>
<td><strong>Unit of randomisation (per patient):</strong></td>
<td>individuals</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention characteristics</strong></td>
</tr>
<tr>
<td>Repose</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>NIMBUS II plus Alpha TranCell</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proportion of participants developing a new pressure ulcer</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
### Time to pressure ulcer development
- **Reporting**: not reported

### Support-surface-associated patient comfort
- **Outcome type**: continuous
- **Time points**: 14 days
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: measured using a 100 mm visual analogue scale
- **Definition**: not specified what patient comfort is
- **Dropouts**: 16 in Repose and 14 in NIMBUS II plus Alpha TranCell
- **Notes**: mean 67 (SD 18) for 24 individuals in Repose; 60 (25) for 26 individuals in NIMBUS II

All reported adverse events using allocated support surfaces
- **Reporting**: not reported

### Health-related quality of life (HRQOL)
- **Reporting**: not reported

### Cost-effectiveness
- **Reporting**: not reported

### Notes

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;a concealed computer generated list was used to randomise eligible consecutive consenting patients to one of the support systems&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: low risk of bias because of the use of a proper randomisation method.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;a concealed computer generated list was used to randomise eligible consecutive consenting patients to one of the support systems&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: low risk of bias because of a proper concealment method.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td><strong>Outcome group: primary outcome</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: high risk of bias because blinding was not possible for this comparison.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>High risk</td>
<td><strong>Outcome group: primary outcome</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quote: &quot;Patients were not assessed blindly as it was considered that displacement for examination would cause excessive discomfort. A team of trained researchers completed all assessments&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: high risk of bias because no blinding was done.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td><strong>Outcome group: primary outcome</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quote: &quot;No patient was excluded from all the analyses&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quote: &quot;Data were not available for the 14-day follow-up assessment for a further 12 patients who were transferred to wards or hospitals that were not involved in the study or were discharged home&quot;</td>
</tr>
</tbody>
</table>
Comment: high risk of bias because 16 in Repose and 14 in NIMBUS II plus Alpha TranCell actually missed and were not included in analysis.

| Selective reporting (reporting bias) | Low risk | Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified. |
| Other bias | Low risk | Comment: the study appears to be free of other sources of bias. |

Pring 1998

**Study characteristics**

**Methods**
- **Study objective**: to compare 3 mattresses in relation to patient pain, comfort and sleep disturbance
- **Study design**: randomised controlled trial, with a series design
- **Study grouping**: n-of-1 trial
- **Duration of follow-up**: 1 week
- **Number of arms**: 3
- **Single centre or multi-site**: single centre
- **Study start date and end date**: not described
- **Setting**: Regional Rehabilitation Centre. Southern Birmingham Community NHS Trust.

**Participants**
- **Baseline characteristics**
  - **Inclusion criteria**: all patients admitted to the unit (for patients with neurological disorders aged 16 to 65) with a Waterlow score of 15 and above, with no existing pressure sore or a sore of Grade 2 or lower
  - **Exclusion criteria**: not given
  - **Sex (M:F)**: not given
  - **Age (years)**: mean 40 years (range 17-60) overall
  - **Baseline skin status**: mean Waterlow score 19 (range 16-26); no existing ulcer, or a sore of Grade 2 or lower
  - **Group difference**: not given
  - **Total number of participants**: n = 40
  - **Unit of analysis**: treatment sessions
  - **Unit of randomisation (per patient)**: individuals

**Interventions**

**Nimbus II**
- **Description of interventions**: Nimbus II comprises 2 banks of cells which alternately inflate and deflate over a 10-minute cycle. A sensor pad (Automat) enables the system to vary the inflation pressure automatically in response to changes in weight distribution.
- **NPIAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: not described
- **Number of participants randomised**: 40 participants
- **Number of participants analysed**: n = 39 treatment sessions

**Pegasus Airwave**
- **Description of interventions**: Pegasus Airwave consists of a double layer of cells which work together as 1 layer, with a 3-cell cycle of 7.5 minutes.
- **NPIAP S3I classification**: powered, alternating pressure (active) air
### Quattro DC2000

- **Description of interventions:** Quattro DC2000 has 28 separate deep cells which operate in a 1-in-4 sequential cycle. The mattress pressure can be selected and controlled with respect to the patient's weight.
- **NPIAP S3I classification:** powered, alternating pressure (active) air surface
- **Co-interventions:** not described
- **Number of participants randomised:** 40 participants
- **Number of participants analysed:** n = 39 treatment sessions

### Outcomes

<table>
<thead>
<tr>
<th>Proportion of participants developing a new pressure ulcer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time to pressure ulcer development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not reported</td>
</tr>
</tbody>
</table>

**Support-surface-associated patient comfort**

- **Outcome type:** unclear
- **Time points:** 1 week
- **Reporting:** partially reported
- **Measurement method (e.g. scale, self-reporting):** visual analogue scale (VAS) used to indicate how comfortable a patient found the mattress; self-rated by patients
- **Definition:** patient comfort ratings
- **Dropouts:** 1 patient withdrawn due to clinical condition
- **Notes:** 4 patients (10.3%) refused to be nursed on Nimbuss II and 20 (51.3%) on Pegasus Airwave because they found these mattresses too uncomfortable. One-way analysis of variance indicates that there are significant differences between the 3 mattresses in relation to comfort ($F = 18.28, P < 0.01$). Patients found Quattro DC2000 more comfortable than Nimbus II and Pegasus Airwave; this was significant ($P < 0.01$ in both cases).

**All reported adverse events using allocated support surfaces**

- Not reported

**Health-related quality of life (HRQOL)**

- Not reported

**Cost-effectiveness**

- Not reported

**Outcomes that are not considered in this review but reported in trials:**

- Pain
- Sleep disturbance
<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Unclear risk       | Quote: "Patients were randomly allocated to one of three alternating-pressure mattress replacements."  
Quote: "The order in which patients used the mattresses was randomly allocated prior to admission to the study"  
Comment: unclear risk of bias because the sequence generation process was not described. |
|Allocation concealment (selection bias)    | Unclear risk       | Comment: no information provided.                                                                                                                                 |
| Blinding of participants and personnel (performance bias) All outcomes | High risk          | Outcome group: all outcomes  
Quote: "Patients were not given information about the mattresses during the study but it was not possible to disguise the make of mattress"  
Comment: high risk of bias because non-blinding of patients is stated. |
| Blinding of outcome assessment (detection bias) All outcomes | High risk          | Outcome group: all outcomes  
Quote: "Patients were not given information about the mattresses during the study but it was not possible to disguise the make of mattress"  
Comment: high risk of bias because non-blinding of patients is stated and this affects the assessment of patient self-rated outcomes; pain and comfort. |
| Incomplete outcome data (attrition bias) All outcomes | Low risk           | Quote: "one patient was withdrawn from the trial due to her clinical condition"  
Comment: low risk of bias because the rate of dropout is low. |
| Selective reporting (reporting bias)      | Low risk           | Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified. |
| Other bias                                | High risk          | Comment: high risk of bias because the clustering issue probably occurs but is not addressed.                                                             |

### Rafter 2011

#### Study characteristics

**Study objective**: to determine the effect of the Dyna-Form Mercury Advance Mattress versus Softform Premier Active Mattress on pressure ulcer incidence for those in high risk rehabilitation wards over a 1-month period  
**Study design**: randomised controlled trial  
**Study grouping**: parallel group  
**Duration of follow-up**: 1 month  
**Number of arms**: 2  
**Single centre or multi-site**: single centre  
**Study start date and end date**: not described  
**Setting**: hospital

#### Participants

**Baseline characteristics**  
**Inclusion criteria**: no existing skin damage or up to category 2 EPUAP pressure ulcers  
**Exclusion criteria**: unwilling to participate, re-admitted with pressure ulcers and weighed above 25 stone
Sex (M:F): 0: 5 in Dyna-Form; and 4:1 in Softform

Age (years): median 73 in Dyna-Form; and 76.8 in Softform

Baseline skin status: median Waterlow 21.1 (range 11 to 30) in Dyna-Form; and 18.4 (15 to 26)

Group difference: not specified

Total number of participants: 10

Unit of analysis: individuals

Unit of randomisation (per patient): individuals

Interventions

Dyna-Form Mercury Advance

- **Description of interventions**: being a static mattress combined with a dynamic alternating system ... the foam is actually inside the alternating cells. The pump has a cycle of 10 minutes ... There is a CPR and static mode. It has an automatic pump that is also adjustable in two modes for patient comfort and 'dynamic use' (dynamic use refers to an alternating cell mattress driven by an electrical pump with air sacks which sequentially inflate and deflate to relieve pressure for short periods under the patient) ... the mattresses can be used as a static system when an alternating surface is not required.

- **NPIAP S3I classification**: powered, alternating pressure (active) air surface; hybrid mattress (active and reactive modes)

- **Co-interventions**: not described

- **Number of participants randomised**: n = 5

- **Number of participants analysed**: n = 5

Softform Premier Active

- **Description of interventions**: consists of a foam mattress with a dynamic underlay. The underlay alternates on a 2-cell 10-minute cycle time through the pump ... The pump is also able to assess the patient's weight and adjusts the supply of an appropriate level of air to provide an alternating surface ... the mattresses can be used as a static system when an alternating surface is not required.

- **NPIAP S3I classification**: powered, alternating pressure (active) air surface; hybrid mattress (active and reactive modes)

- **Co-interventions**: not described

- **Number of participants randomised**: n = 5

- **Number of participants analysed**: n = 5

Outcomes

**Proportion of participants developing a new pressure ulcer**

- **Outcome type**: binary

- **Time points**: 1 month

- **Reporting**: fully reported

- **Measurement method (e.g. scale, self-reporting)**: defined by EPUAP system

- **Definition (including ulcer stage)**: no. of patients with new ulcers of any stage

- **Dropouts**: no

- **Notes (e.g. other results reported)**: 0 of 5 in Dyna-Form; 2 of 5 in Softform

  (1 Stage 1 and 1 Stage 1 & 2)

**Time to pressure ulcer development**
Support-surface-associated patient comfort

- **Outcome type**: binary
- **Time points**: 1 month
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: self-reported
- **Definition**: participants’ opinions on the comfort aspects of the mattress
- **Dropouts**: 2 in each group
- **Notes**: 6 patients were able to respond to the patient questionnaire. All slept well in both groups.

*All reported adverse events using allocated support surfaces*

- **Reporting**: not reported

Health-related quality of life (HRQOL)

- **Reporting**: not reported

Cost-effectiveness

- **Reporting**: not reported

Notes

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Unclear risk       | Quote: “Patients considered to be at high risk of pressure ulcer development were randomly allocated …”  
Comment: unclear risk of bias. |
| Allocation concealment (selection bias)   | Unclear risk       | Comment: no information provided. |
| Blinding of participants and personnel (performance bias) All outcomes | High risk          | **Outcome group: primary outcome**  
Comment: high risk of bias because it was unlikely to be possible to blind ward staff who were trained in using both systems for this study. |
| Blinding of outcome assessment (detection bias) All outcomes | High risk          | **Outcome group: primary outcome**  
Quote: “Their skin was assessed daily for any changes or development of pressure ulcers by ward staff and by the co-ordinator of the audit three times a week.”  
Comment: high risk of bias because it was unlikely to be possible to blind ward staff. |
| Incomplete outcome data (attrition bias) All outcomes | Low risk           | **Outcome group: primary outcome**  
Comment: low risk of bias because of no missing.  
**Outcome group: comfort**  
Comment: high risk of bias because 2 of 5 missed in each group. |
| Selective reporting (reporting bias)      | Low risk           | Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified. |
| Other bias                                | Low risk           | Comment: the study appears to be free of other sources of bias. |
### Rosenthal 2003

#### Study characteristics

<table>
<thead>
<tr>
<th>Methods</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study objective:</strong></td>
<td>to compare the rate of healing when patients were treated with low-air-loss bed, pressure-relieving bed overlays, and generic total contact seat surface</td>
</tr>
<tr>
<td><strong>Study design:</strong></td>
<td>randomised controlled trial</td>
</tr>
<tr>
<td><strong>Study grouping:</strong></td>
<td>parallel group</td>
</tr>
<tr>
<td><strong>Duration of follow-up:</strong></td>
<td>6 months</td>
</tr>
<tr>
<td><strong>Number of arms:</strong></td>
<td>2 (of 3 arms) considered eligible for inclusion</td>
</tr>
<tr>
<td><strong>Single centre or multi-site:</strong></td>
<td>multiple site</td>
</tr>
<tr>
<td><strong>Study start date and end date:</strong></td>
<td>not described</td>
</tr>
<tr>
<td><strong>Setting:</strong></td>
<td>long-term care facilities, and community nursing homes</td>
</tr>
</tbody>
</table>

**Baseline characteristics**

| Inclusion criteria: | those being alert, able to sit in the 6 months before the study, still sit up with assistance, with a stage III or IV ulcer on the coccyx, trochanter or ischial tuberosities  |
| Exclusion criteria: | those with sacral pressure ulcers; previously in a trial to treat their current pressure ulcer; already on low-air-loss, or transfer to low-air-loss planned; skin grafting planned within 1 week; with an active sinus tract or fistula; poor nutrition; requiring antibiotics to treat methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant *Enterococci*, or active skin infection; osteomyelitis diagnosed; body weight below 60 kg; unable to flex both hip and knee at least 90 degrees  |
| **Sex (M:F):** | not given  |
| **Age (years):** | mean 69.0 (SD 4.1) in low-air-loss (LAL) bed and 68.6 (3.0) in overlay  |
| **Baseline skin status:** | all with grade III or IV ulcer  |
| **Group difference:** | no difference  |
| **Total number of participants:** | n = 76  |
| **Unit of analysis:** | individuals  |
| **Unit of randomisation (per patient):** | individuals  |

**Interventions**

| Low-air-loss bed |
| Description of interventions: | low-air-loss suspension bed (TheraPulse bed) attaching a rack of inflatable fabric pillows to a modified bed frame to provide pulsating air support that was intended to increase capillary blood flow and to lower interface pressure. These beds are covered with the manufacturer's Gore-Tex fabric surface to reduce friction.  |
| NPIAP S3I classification: | powered, alternating pressure (active), low air loss air surface  |
| Co-interventions: | turning every 2 hours  |
| Number of participants randomised: | n = 38  |
| Number of participants analysed: | unspecified  |

| Bed overlay |
| Description of interventions: | a pressure-reducing advanced medium density open-cell polyurethane foam overlay that was contour cut from 8.89 cm (3.5 inches) of solid foam. Each Geo-Matt cell was meant to respond individually to the weight put on it, thereby customising support to minimise pressure and shear. Additional source of information is from Cochrane Wounds Group, Shi, Shi, Dumville, Cullum, Rhodes, Jammali... [https://archie.cochrane.org/sections/documents/view?version=z2105051...](https://archie.cochrane.org/sections/documents/view?version=z2105051...)  |

**Number of participants randomised:** | n = 38  |
| Number of participants analysed: | unspecified  |
NPIAP S3I classification: non-powered, reactive foam surface

Co-interventions: turning every 2 hours

Number of participants randomised: n = 38

Number of participants analysed: unspecified

### Outcomes

<table>
<thead>
<tr>
<th>Proportion of participants developing a new pressure ulcer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outcome type</strong>: binary</td>
</tr>
<tr>
<td><strong>Time points</strong>: 6 months</td>
</tr>
<tr>
<td><strong>Reporting</strong>: partially reported</td>
</tr>
<tr>
<td><strong>Measurement method (e.g. scale, self-reporting)</strong>: not given</td>
</tr>
<tr>
<td><strong>Definition (including ulcer stage)</strong>: not given</td>
</tr>
<tr>
<td><strong>Dropouts</strong>: 1 death excluded; 3 participants withdrawn at 4 weeks due to worsened condition, all in overlay group</td>
</tr>
<tr>
<td><strong>Notes (e.g. other results reported)</strong>: no new pressure ulcers were found in either arm</td>
</tr>
</tbody>
</table>

**Time to pressure ulcer development**

- Not reported

**Support-surface-associated patient comfort**

- Not reported

**All reported adverse events using allocated support surfaces**

- **Notes**: 1 death in this study but the authors did not specify which group the death was in; 3 participants withdrawn at 4 weeks due to worsened condition, all in overlay group

**Health-related quality of life (HRQOL)**

- Not reported

**Cost-effectiveness**

- Not reported

**Outcomes that are not considered in this review but reported in trials**:

- Ulcer healing
- Time to ulcer healing

### Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;Randomization was performed by placing a number corresponding to each experimental condition into a sealed envelope with an equal number of envelopes per condition. A research assistant with no clinical experience drew envelopes by lot as eligible subjects were identified&quot; Comment: low risk of bias because the sequence generation process seems proper.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
</tbody>
</table>
Blinding of participants and personnel (performance bias) All outcomes: Unclear risk Comment: no information provided.

Blinding of outcome assessment (detection bias) All outcomes: Unclear risk Comment: no information provided.

Incomplete outcome data (attrition bias) All outcomes: Unclear risk Comment: unclear risk of bias because the dropout rates are low but are unbalanced (1 death is excluded from analysis and it is unclear which group the death is in; 3 participants withdrawn at 4 weeks due to worsened condition, all in overlay group).

Selective reporting (reporting bias): Low risk Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.

Other bias: Low risk Comment: the study appears to be free of other sources of bias.

Russell 2000

Study characteristics

Methods

Study objective: to determine the efficacy and safety of a multi-cell pulsating dynamic mattress system in comparison with conventional management for the prevention of pressure ulcers in the operative and postoperative period in patients having cardiovascular surgery.

Study design: randomised controlled trial

Study grouping: parallel group

Duration of follow-up: 7 days

Number of arms: 2

Single centre or multi-site: single centre

Study start date and end date: not described

Setting: hospital

Participants

Baseline characteristics

Inclusion criteria: be 18 years of age or older and be scheduled for cardiovascular surgery with general anaesthesia for at least 4 hours with an actual operative time of 3 hours or more

Exclusion criteria: had a pressure ulcer at the baseline visit

Sex (M:F): 75:23 in multi-cell pulsating dynamic mattress; 75:25 in conventional management

Age (years): mean 65.2 (SD 10.9) in multi-cell pulsating dynamic mattress; 65.2 (10.6) in conventional management

Baseline skin status: mean Knoll score 3.6 (SD 1) in multi-cell pulsating dynamic mattress; 3.8 (1) in conventional management; no pressure ulcer

Group difference: no difference

Total number of participants: n = 198

Unit of analysis: individuals

Unit of randomisation (per patient): individuals

Interventions

Intervention characteristics

Multi-cell pulsating dynamic mattress

- Description of interventions: multi-cell pulsating dynamic mattress system
(MicroPulse Inc., Portage, Mich.) ... comprised of a thin pad with more than 2,500 small air cells enclosed in a fluid-proof cover. The air cells are arranged in rows so that the patient is supported by 50% of the cells (the inflated cells) at any given time ... With a cycle time of less than 5 minutes ... on the system in the operating room and in their hospital room until discharge from the hospital or for a maximum of 7 days post-surgery.

- **NPIAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: not described
- **Number of participants randomised**: n = 98
- **Number of participants analysed**: unspecified

Conventional management

- **Description of interventions**: the use of a gel pad (Action Pad®, Action Products, Inc.) in the operating room and then a standard hospital mattress on the hospital bed (the Hill-Rom Centra with 6-inch foam overlay in the critical care recovery unit; and the Hill-Rom Century with 4-inch foam overlay in the cardiac ward)
- **NPIAP S3I classification**: non-powered, reactive gel surface; non-powered, reactive foam surface; applied sequentially
- **Co-interventions**: not described
- **Number of participants randomised**: n = 100
- **Number of participants analysed**: n = 100

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Proportion of participants developing a new pressure ulcer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outcome type</strong>: binary</td>
<td><strong>Time points</strong>: day 7</td>
</tr>
<tr>
<td><strong>Measurement method (e.g. scale, self-reporting)</strong>: defined and staged using the National Pressure Ulcer Advisory Panel scoring system</td>
<td><strong>Definition (including ulcer stage)</strong>: the occurrence of pressure ulcers at any time within 7 days of surgery</td>
</tr>
<tr>
<td><strong>Notes (e.g. other results reported)</strong>: 2 in multi-cell pulsating dynamic mattress (both grade 1); 7 of 100 in conventional management (5 grade 1, 1 grade 2, 1 grade 3) (2.2% vs. 7%, P = 0.170)</td>
<td></td>
</tr>
</tbody>
</table>

**Time to pressure ulcer development**

- **Reporting**: not reported

**Support-surface-associated patient comfort**

- **Reporting**: not reported

**All reported adverse events using allocated support surfaces**

- **Reporting**: partially reported
- **Notes**: approximately 1/2 of all participants in each group reported adverse events, with no differences between groups reported. All adverse events were related to the participant's condition; none were related to the multi-cell pulsating dynamic mattress system or conventional management support system.

**Health-related quality of life (HRQOL)**

- **Reporting**: not reported

**Cost-effectiveness**
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Unclear risk | Quote: "Before surgery, patients were randomly assigned to either the multi-cell pulsating dynamic mattress system or conventional management. Randomization was done blindly by using a sealed opaque envelope that contained the randomization information (i.e. multi-cell pulsating dynamic mattress system vs. conventional management)"
Comment: unclear risk of bias because randomisation method is not described. |
| Allocation concealment (selection bias) | Unclear risk | Quote: "Randomization was done blindly by using a sealed opaque envelope that contained the randomization information (i.e. multi-cell pulsating dynamic mattress system vs. conventional management)"
Comment: unclear risk of bias because randomisation method is not described. |
| Blinding of participants and personnel (performance bias) All outcomes | High risk | Outcome group: primary outcome
Comment: high risk of bias because it is unlikely that participants were blinded, though no information provided. |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Outcome group: primary outcome
Quote: "Patients were examined immediately post-surgery for pressure ulcers, including number, stage (I to IV), size (area), location, and appearance. Patients were assessed daily for ... presence of pressure ulcers. A skin risk assessment was performed on days 1, 4, and 7 and on other days if a change in status was noted. Adverse events and concomitant medications were recorded daily"
Comment: unclear risk of bias because information on outcome assessment is insufficient for a proper judgement. |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Outcome group: primary outcome
Quote: "Baseline characteristics and safety were evaluated for all randomised patients (i.e. intent-to-treat sample) ... The intent-to-treat sample included all patients who signed consent forms and who were placed either on a multi-cell pulsating dynamic mattress system or on a conventional mattress and had at least 1 day of observation post-surgery ... An evaluable sample of patients was defined as patients who signed consent forms, had a surgery length of at least 3 hours, and had a minimum of 3 days of observation post-surgery ... One analysis included the intent-to-treat sample (multi-cell pulsating dynamic mattress system, n = 89; conventional management, n = 96)"
Comment: low risk of bias because of the use of intention-to-treat (ITT) analysis. |
| Selective reporting (reporting bias) | Low risk | Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified. |
| Other bias | Low risk | Comment: the study appears to be free of other sources of bias. |

### Sanada 2003

**Study characteristics**
Methods

Study objective: to examine the effectiveness of a new overlay for at-risk patients who require head elevation

Study design: randomised controlled trial

Study grouping: parallel group

Duration of follow-up: not described

Number of arms: 3

Single centre or multi-site: single centre

Study start date and end date: August 1999 to September 2000

Setting: a general acute care unit (hospital)

Participants

Baseline characteristics

Inclusion criteria: had a Braden score ≤ 16, bed bound, pressure ulcer-free, required head elevation

Exclusion criteria: not described


Age (years): mean 69.5 (SD 14.7) in 29 participants in double-layer; 73.9 (10.4) in 26 participants in single-layer; 70.6 (10.7) in 27 participants in standard hospital mattress

Baseline skin status: Braden 12.5 (SD 1.7) in double-layer; 12.1 (1.4) in single-layer; 12.7 (1.7) in standard; free of pressure ulcers

Group difference: no difference

Total number of participants: n = 108

Unit of analysis: individuals

Unit of randomisation (per patient): individuals

Interventions

Intervention characteristics

Double-layer air-cell overlay

- Description of interventions: "... a new double-layer air-cell overlay ... incorporated an extra layer ... reconstructed the air-cell design from the originally round-shaped cell to a newly designed cylinder-shaped cell ... (Tricell®, Cape Ltd, Japan), dimensions (cm): 191 (l) x 84 (w) x 10 (h) ... consist of multiple air cells that are 'dynamic' in nature - the cell pressure was alternated at 5-minute intervals ... two layers consisting of 24 narrow cylinder-shaped air-cells"

- NPIAP S3I classification: powered, alternating pressure (active) surface

- Co-interventions: no difference between groups; repositioning every 2 hours, special skin care, and nutritional intervention where necessary

- Number of participants randomised: n = 36

- Number of participants analysed: n = 29

Single-layer air-cell overlay

- Description of interventions: a single-layer air-cell overlay (Air Doctor®, Cape Ltd, Japan), dimensions (cm): 191 (l) x 84 (w) x 7.5 (h) ... consist of multiple air cells that are 'dynamic' in nature - the cell pressure was alternated at 5-minute intervals ... only one layer and consists of 20 round air cells

- NPIAP S3I classification: powered, alternating pressure (active) surface

- Co-interventions: no difference between groups; repositioning every 2 hours, special skin care, and nutritional intervention where necessary

- Number of participants randomised: n = 37

- Number of participants analysed: n = 26
Standard hospital mattress

- **Description of interventions**: made of polyester and used widely in Japanese hospitals (Paracare®, Paramount Beds Ltd, USA), dimensions (cm): 191 (l) x 91 (w) x 8.5 (h)
- **NPIAP S3I classification**: standard hospital surface
- **Co-interventions**: no difference between groups; repositioning every 2 hours, special skin care, and nutritional intervention where necessary
- **Number of participants randomised**: n = 35
- **Number of participants analysed**: n = 27

### Outcomes

**Proportion of participants developing a new pressure ulcer**

- **Outcome type**: binary
- **Time points**: not described
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: measured by nurses using National Pressure Ulcer Advisory Panel (NPIAP) classification system
- **Definition (including ulcer stage)**: the number of individuals with pressure ulcers of any stage
- **Dropouts**: 1 discontinued due to mattress malfunction, 4 died, and 2 head elevation ≤ 30 in double-layer; 2 discontinued due to discomfort or interfered with treatment, 2 died, and 7 head elevation ≤ 30 in single-layer; 1 died and 7 head elevation ≤ 30 in standard mattress
- **Notes (e.g. other results reported)**: 1 of 29 (stage II) in double-layer group; 5 of 26 (1 stage I; 4 stage II) in single-layer group; 10 of 27 (4 stage I; 6 stage II) in standard hospital mattress

**Time to pressure ulcer development**

- **Reporting**: not reported.

**Support-surface-associated patient comfort**

- **Reporting**: not reported.

**All reported adverse events using allocated support surfaces**

- **Reporting**: not reported.

**Health-related quality of life (HRQOL)**

- **Reporting**: not reported.

**Cost-effectiveness**

- **Reporting**: not reported.

### Notes

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;The subjects were randomly allocated to the groups by sequentially-labelled sealed envelopes.&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk of bias because the method of random number generation was not described.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;The subjects were randomly allocated to the groups by sequentially-labelled sealed envelopes.&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk because it is unclear if the envelopes were opaque.</td>
</tr>
<tr>
<td></td>
<td>Risk Level</td>
<td>Comment</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>Outcome group: all outcome (primary outcome) Comment: high risk of bias because 7 of 36 individuals randomised in double-layer group; 11 of 37 in single-layer group; and 8 of 35 in standard mattress excluded from analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>Comment: the study appears to be free of other sources of bias.</td>
</tr>
</tbody>
</table>

### Sauvage 2017

#### Study characteristics

**Methods**

**Study objective:** to compare Axtair One, an alternating pressure air mattress (APAM), with a viscoelastic foam mattress (VFM) in elderly patients at moderate to high risk of developing pressure ulcers (PUs).

**Study design:** randomised controlled trial

**Study grouping:** parallel group

**Duration of follow-up:** 30 days

**Number of arms:** two

**Single centre or multi-site:** multi-site

**Study start date and end date:** February 2012 to March 2015

**Setting:** medium- and long-term stay facilities

**Baseline characteristics**

**Inclusion criteria:** males and females aged 70 and over, bedridden for at least 15 hours per day, with reduced mobility due to medical problems (such as malnutrition, low blood pressure, urinary incontinence, neurological diseases and sensory disorders), a low to zero positioning capability, a Karnofsky score ≤ 40% and a planned period of hospitalisation of at least 2 weeks, had no PUs at the time of enrolment but had a medium to high risk for developing PUs, as defined by a Braden score ≤14

**Exclusion criteria:** a weight > 120 kg, body mass index (BMI) < 12 kg/m², a nutritional status score < 12 according to the Mini Nutritional Assessment (MNA), uncompensated nutritional insufficiency and ongoing participation, or within 15 days before, in another clinical research study

**Sex (M:F):** 13:26 in APAM; 9:28 in VFM

**Age (years):** mean 86.03 (SD 5.49) in APAM, 84.59 (6.68) in VFM

**Baseline skin status:** mean Braden score 11.77 (SD 1.27) in APAM, 12.08 (1.26) in VFM; all intact skin

**Group difference:** no difference

**Total number of participants:** n = 76

**Unit of analysis:** individuals

**Unit of randomisation (per patient):** individuals
### Interventions

#### Alternating pressure air mattress (APAM)
- **Description of interventions**: APAM (Axtair One, Asklé Santé, Nîmes, France) consisted of therapeutic air cells with a height of 12 cm, supplied by a compressor, which adjusts the pressure based on the patient's weight and whose mode of operation allows alternating inflation of 1 out of 2 cells, with a 6-minute cycle time.
- **NPIAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: not reported
- **Number of participants randomised**: n = 39
- **Number of participants analysed**: n = 39

#### Viscoseastic foam mattress (VFM)
- **Description of interventions**: VFM (ALOVA mattress, Asklé Santé, Nîmes, France) was composed of a base made of high resilience foam (density > 34 kg/m$^3$) and an upper layer of viscoelastic foam (density > 75 kg/m$^3$)
- **NPIAP S3I classification**: non-powered, reactive foam surface; high specification foam (2 layered; base layer of high resilience foam, density > 34 kg/m$^3$; upper layer of viscoelastic foam, density > 75 kg/m$^3$)
- **Co-interventions**: not reported
- **Number of participants randomised**: n = 37
- **Number of participants analysed**: n = 37

### Outcomes

#### Proportion of participants developing a new pressure ulcer
- **Outcome type**: binary
- **Time points**: 30 days
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: not reported
- **Definition (including ulcer stage)**: incidence of pressure ulcers of any stage
- **Dropouts**: intention-to-treat (ITT) analysis performed
- **Notes (e.g. other results reported)**: 2 of 39 participants in APAM (1 category I ulcer and 1 category II ulcer); 13 of 37 participants in VFM (7 category I ulcers, 5 category II ulcers and 1 category III ulcer)

#### Time to pressure ulcer development
- **Outcome type**: binary
- **Time points**: 30 days
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: not reported
- **Definition (including ulcer stage)**: time to appearance of ulcers
- **Dropouts**: censoring
- **Notes (e.g. other results reported)**: the cumulative risk of PUs was estimated at 6.46% (95% confidence interval (CI) 1.64 to 23.66) in the APAM group and at 38.91% (95% CI 24.66 to 57.59) in the VFM group, P = 0.001 (logrank test). Kaplan-Meier curves presented in Fig 2 and HR 0.18 (95% CI 0.07 to 0.50) estimated by the review authors using the methods in Tierney 2007.

### Support-surface-associated patient comfort

Cochrane Wounds Group, Shi, Shi, Dumville, Cullum, Rhodes, Jammali... https://archie.cochrane.org/sections/documents/view?version=z2105051...
- **Outcome type:**
- **Time points:** day 8, day 15, day 22, and day 30
- **Reporting:** fully reported
- **Measurement method (e.g. scale, self-reporting):** perception of patient comfort collected on days 8, 15, 22 and 30 via a satisfaction questionnaire (skin-mattress contact, feeling of warmth, discomfort due to motor noise and disturbed sleep)
- **Definition (including ulcer stage):** comfort rates
- **Dropouts:** 3 of 39 APAM vs 6 of 37 VFM at day 8; 6 of 39 APAM vs 10 of 37 VFM at day 15; 11 of 39 vs 16 of 37 at day 22; 15 of 39 APAM vs 20 of 37 VFM at day 30
- **Notes:** data presented by subscales of the measurement tool and not extracted for this review. Difference in satisfaction between the 2 groups not significant, P = 0.21

All reported adverse events using allocated support surfaces
- **Notes:** the serious adverse events (SAEs) reported in the APAM group were 2 deaths, a massive septic shock with acute pulmonary oedema and a decompensation of an insulin-dependent diabetes. No SAEs were reported in the VFM group. There were 20 adverse events reported in each group, including 2 discomforts in the APAM group and 1 hyperalgesia in the VFM group. The other events did not involve the mattresses.

**Health-related quality of life (HRQOL)**
- **Reporting:** not reported

**Cost-effectiveness**
- **Reporting:** not reported

**Outcomes that are not considered in this review but reported in trials:**
- duration of bed rest
- duration of sitting in a chair
- frequency of preventative interventions
- any therapeutic change

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation       | Low risk           | Quote: "Randomisation was centralised (RANDLIST software v1.2) and globally balanced intracentre with random block sizes established from two possibilities (2 and 4)"
|                                  |                    | Comment: low risk of bias because of the use of a proper randomisation method.         |
| Allocation concealment           | Unclear risk       | Quote: "Randomisation was centralised (RANDLIST software v1.2) and globally balanced intracentre with random block sizes established from two possibilities (2 and 4)"
|                                  |                    | Comment: unclear risk of bias because even though central randomisation was performed, the small block size means that the allocation in the subsequent block is predictable if a prior randomisation sequence has already been known.|
| Blinding of participants and personnel | High risk         | Quote: "This randomised, controlled, superiority, parallel-group, open-label, multicentre ... "  |
|                                  |                    | Quote: "PU's preventive care had to be performed in compliance with validated care protocols compliant with Good Professional Care protocols."

Cochrane Wounds Group, Shi, Shi, Dumville, Cullum, Rhodes, Jammal...
<table>
<thead>
<tr>
<th>bias) All outcomes</th>
<th>Practice Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comment: high risk of bias because open label is clearly stated. Additionally, it is unknown if performance between groups might be unbiased even though there seems to be standardised care plan.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blinding of outcome assessment (detection bias) All outcomes</th>
<th>High risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quote: &quot;This randomised, controlled, superiority, parallel-group, open-label, multicentre ... &quot;</td>
<td></td>
</tr>
<tr>
<td>Comment: high risk of bias because open label is clearly stated.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Incomplete outcome data (attrition bias) All outcomes</th>
<th>Low risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quote: &quot;The population selected for the main analysis were all randomised patients in intention-to-treat (ITT).&quot;</td>
<td></td>
</tr>
<tr>
<td>Comment: low risk of bias because ITT analysis was performed.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>Low risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other bias</th>
<th>Low risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comment: the study appears to be free of other sources of bias.</td>
<td></td>
</tr>
</tbody>
</table>

### Sideranko 1992

#### Study characteristics

**Study objective:** to compare the pressure-reducing properties of 3 types of mattress overlays (water, alternating air, and static air mattress surfaces) as used with bed bound patients in a clinical setting

**Study design:** randomised controlled trial

**Study grouping:** parallel group

**Duration of follow-up:** mean 10.0 (SD 10.9) days of surgical intensive care unit (SICU) stay in alternating air; 9.4 (8.8) in static air; 8.9 (7.1) in water

**Number of arms:** 3

**Single centre or multi-site:** single centre

**Study start date and end date:** not described

**Setting:** 2 surgical ICUs of a hospital

### Participants

**Baseline characteristics**

**Inclusion criteria:** a minimum SICU stay of 48 hr; presence of ventilatory support, or some form of haemodynamic support on admission

**Exclusion criteria:** those with any evidence of existing skin breakdown upon admission to the SICUs

**Sex (M:F):** 33:24 across groups

**Age (years):** mean 67.9 (SD 11.1) in alternating air; 63.6 (18.6) in static air; 66.1 (15.6) in water

**Baseline skin status:** free of existing skin breakdown

**Group difference:** no difference

**Total number of participants:** n = 57

**Unit of analysis:** individuals

**Unit of randomisation (per patient):** individuals

### Interventions

**Intervention characteristics**

- **Description of interventions:** "a 1.5-in. thick, alternating air mattress, the Lapidus Airfloat System manufactured by the American Hospital Supply Corp., Valencia, CA"
<table>
<thead>
<tr>
<th><strong>NPIAP S3I classification</strong></th>
<th>Powered, alternating pressure (active) surface</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Co-interventions</strong></td>
<td>Not described</td>
</tr>
<tr>
<td><strong>Number of participants randomised</strong></td>
<td>n = 20</td>
</tr>
<tr>
<td><strong>Number of participants analysed</strong></td>
<td>n = 20</td>
</tr>
</tbody>
</table>

**Static air**

- **Description of interventions**: "A 4-in. thick static air mattress, the Gaymar Sof Care bed cushion, manufactured by Gaymar Industries Inc., Orchard Park, NY"
- **NPIAP S3I classification**: Non-powered, reactive air surface
- **Co-interventions**: Not described
- **Number of participants randomised**: n = 20
- **Number of participants analysed**: n = 20

**Water**

- **Description of interventions**: "A 4-in. thick water mattress, the Lotus PXM 3666, manufactured by Connecticut Artcraft Corp., Naugatuck, CT"
- **NPIAP S3I classification**: Non-powered, reactive water surface
- **Co-interventions**: Not described
- **Number of participants randomised**: n = 17
- **Number of participants analysed**: n = 17
Outcomes

**Proportion of participants developing a new pressure ulcer**
- **Outcome type**: binary
- **Time points**: not reported
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: not reported
- **Definition (including ulcer stage)**: the number of patients developing pressure ulcers
- **Dropouts**: not described; no missing assumed
- **Notes (e.g. other results reported)**: 5 of 20 in alternating air; 1 of 20 in static air; 2 of 17 in water

**Time to pressure ulcer development**
- **Reporting**: not reported

**Support-surface-associated patient comfort**
- **Reporting**: not reported

**All reported adverse events using allocated support surfaces**
- **Reporting**: not reported

**Health-related quality of life (HRQOL)**
- **Reporting**: not reported

**Cost-effectiveness**
- **Reporting**: not reported

**Outcomes that are not considered in this review but reported in trials**:
- Interface pressure

Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Unclear risk       | Quote: "... subjects were randomly assigned to be placed on one of the three surfaces studied"  
Comment: unclear risk of bias because the method of randomisation was not specified. |
| Allocation concealment (selection bias)     | Unclear risk       | Comment: no information provided.                                                                                                                      |
| Blinding of participants and personnel (performance bias) All outcomes | Unclear risk       | Comment: no information provided.                                                                                                                      |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk       | Comment: no information provided.                                                                                                                      |
| Incomplete outcome data (attrition bias) All outcomes | Low risk           | Outcome group: all outcomes (primary outcome)  
Comment: no missing assumed.                                                             |
| Selective reporting (reporting bias)         | Low risk           | Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified. |
| Other bias                                   | Low risk           | Comment: the study appears to be free of other sources of bias.                                                                                       |
## Stapleton 1986

### Study characteristics

<table>
<thead>
<tr>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study objective:</strong> not provided</td>
</tr>
<tr>
<td><strong>Study design:</strong> randomised controlled trial</td>
</tr>
<tr>
<td><strong>Study grouping:</strong> parallel group</td>
</tr>
<tr>
<td><strong>Duration of follow-up:</strong> not described</td>
</tr>
<tr>
<td><strong>Number of arms:</strong> 3</td>
</tr>
<tr>
<td><strong>Single centre or multi-site:</strong> single centre</td>
</tr>
<tr>
<td><strong>Study start date and end date:</strong> not described</td>
</tr>
<tr>
<td><strong>Setting:</strong> acute care setting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline characteristics</strong></td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong> female elderly patients with fractured neck of femur, without existing pressure ulcers, Norton score 14 or less</td>
</tr>
<tr>
<td><strong>Exclusion criteria:</strong> patients did not meet the criteria, or admitted with existing pressure sores</td>
</tr>
<tr>
<td><strong>Sex (M:F):</strong> all female patients (0:32 in large cell Ripple; 0:34 in polyether foam pad; 0:34 in Spenco pad)</td>
</tr>
<tr>
<td><strong>Age (years):</strong> mean 81 across groups</td>
</tr>
<tr>
<td><strong>Baseline skin status:</strong> mean Norton score 12.0 in large cell Ripple; 12.8 in polyether foam pad; 12.9 in Spenco pad; no existing pressure ulcers</td>
</tr>
<tr>
<td><strong>Group difference:</strong> no difference</td>
</tr>
<tr>
<td><strong>Total number of participants:</strong> n = 100</td>
</tr>
<tr>
<td><strong>Unit of analysis:</strong> individuals</td>
</tr>
<tr>
<td><strong>Unit of randomisation (per patient):</strong> individuals</td>
</tr>
</tbody>
</table>

### Interventions

<table>
<thead>
<tr>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention characteristics</strong></td>
</tr>
<tr>
<td>Large Cell Ripple (Talley)</td>
</tr>
<tr>
<td>• <strong>Description of interventions:</strong> Large Cell Ripple (Talley)</td>
</tr>
<tr>
<td>• <strong>NPIAP S3I classification:</strong> powered, alternating pressure (active) air surface</td>
</tr>
<tr>
<td>• <strong>Co-interventions:</strong> not described</td>
</tr>
<tr>
<td>• <strong>Number of participants randomised:</strong> not described</td>
</tr>
<tr>
<td>• <strong>Number of participants analysed:</strong> n = 32</td>
</tr>
<tr>
<td>Polyether foam pad</td>
</tr>
<tr>
<td>• <strong>Description of interventions:</strong> Polyether foam pad 2 feet x 2 feet x 3-inch thickness</td>
</tr>
<tr>
<td>• <strong>NPIAP S3I classification:</strong> non-powered, reactive foam surface</td>
</tr>
<tr>
<td>• <strong>Co-interventions:</strong> not described</td>
</tr>
<tr>
<td>• <strong>Number of participants randomised:</strong> not described</td>
</tr>
<tr>
<td>• <strong>Number of participants analysed:</strong> n = 34</td>
</tr>
<tr>
<td>Spenco pad</td>
</tr>
<tr>
<td>• <strong>Description of interventions:</strong> Spenco pad</td>
</tr>
<tr>
<td>• <strong>NPIAP S3I classification:</strong> non-powered, reactive fibre surface</td>
</tr>
<tr>
<td>• <strong>Co-interventions:</strong> not described</td>
</tr>
<tr>
<td>• <strong>Number of participants randomised:</strong> not described</td>
</tr>
</tbody>
</table>
Number of participants analysed: n = 34

Outcomes

Proportion of participants developing a new pressure ulcer

- Outcome type: binary
- Time points: not reported
- Reporting: partially reported
- Measurement method (e.g. scale, self-reporting): graded by Borders (Grade A superficial/blister; Grade B a break in skin but no crater; Grade C a break in skin with crater; Grade D blackened tissue)
- Definition (including ulcer stage): patients with the development of pressure ulcers graded by Borders
- Dropouts: not described.
- Notes (e.g. other results reported): 12 of 34 in Spenco (2 Grade A/8 Grade B/2 Grade C/0 Grade D); 14 of 34 in Foam (1/5/3/5); 11 of 32 in Ripple (2/9/0/0)

Time to pressure ulcer development

- Reporting: not reported

Support-surface-associated patient comfort

- Reporting: not reported

All reported adverse events using allocated support surfaces

- Reporting: not reported

Health-related quality of life (HRQOL)

- Reporting: not reported

Cost-effectiveness

- Reporting: not reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgment</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;patients for the first two groups were selected by lottery, and thereafter patients were allocated to each group systematically, in rotation&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear risk of bias because it is unclear if a proper randomisation method was applied.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>------------</td>
<td>--------------</td>
<td>----------------------------------</td>
</tr>
</tbody>
</table>

### Taylor 1999

#### Study characteristics

**Study objective**: "... developing such a data hierarchy to support the adoption of a new PR support surface, the Pegasus Trinova, within an acute care setting"

**Study design**: randomised controlled trial

**Study grouping**: parallel group

**Duration of follow-up**: Trinova group mean 10.5 days (SD 1.2); control group 11.6 days (SD 1.4)

**Number of arms**: 2

**Single centre or multi-site**: single centre

**Study start date and end date**: not described

**Setting**: an acute care setting

#### Baseline characteristics

**Inclusion criteria**: inpatients within a large NHS trust hospital; provided informed consent; free from pressure damage (including non-blanching erythema); aged 16 or older; required nursing upon a pressure redistributing support surface

**Exclusion criteria**: not described

**Sex (M:F)**: 12:10 in Trinova; 13:9 in alternating pressure air mattress

**Age (years)**: mean 66.50 (SD 2.20) in Trinova; mean 70.27 (SD 2.73) in alternating pressure air mattress

**Baseline skin status**: median Waterlow 19 (range 10 to 30) in Trinova; 17 (10 to 35) in alternating pressure air mattress; free of existing ulcers

**Group difference**: no difference

**Total number of participants**: n = 44

**Unit of analysis**: individuals

**Unit of randomisation (per patient)**: individuals

#### Intervention characteristics

**Pegasus Trinova**

- **Description of interventions**: "an integrated dynamic mattress and chair cushion ... a mattress ... constructed in two layers, each with 19 cells ... A number of the air cells are designed to remain inflated during use ... Where cells are designed to provide dynamic support, these inflate and deflate in a three-cell cycle over a 7.5 minute period ... alternating pressure air cushion, with four cells inflating and deflating over a 7.5 minute cycle"

- **NPIAP S3I classification**: powered, alternating pressure (active) air surface; hybrid system (active and reactive modes)

- **Co-interventions**: not described

**Number of participants randomised**: n = 22

**Number of participants analysed**: n = 22

**Alternative dynamic mattress system**

- **Description of interventions**: "The inflatable cells of the control mattress operated with alternate cells inflating, then deflating, over a 10-minute cycle"

- **NPIAP S3I classification**: powered, alternating pressure (active) air surface

- **Co-interventions**: not described.
Number of participants randomised: n = 22
Number of participants analysed: n = 22

**Outcomes**

**Proportion of participants developing a new pressure ulcer**

- **Outcome type**: binary
- **Time points**: not described
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: not described
- **Definition (including ulcer stage)**: the number of individuals developing new ulcers
- **Dropouts**: not described
- **Notes (e.g. other results reported)**: 0 of 22 in Trinova; 2 of 22 in alternating pressure air surface (1 non-blanching erythema and 1 superficial skin breakdown)

**Time to pressure ulcer development**

- **Reporting**: not reported

**Support-surface-associated patient comfort**

- **Outcome type**: binary
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: not described
- **Definition**: patients rated their perceptions of both their comfort while resting upon the mattress and their overall opinion of the support surface ... elicited using Likert-type scales
- **Dropouts**: not relevant
- **Notes**: only 1 arm has data. Eighteen of the 22 patients allocated to the Trinova completed the comfort questionnaire with the majority (n = 11; 61.1%) describing the mattress as being comfortable ...

**All reported adverse events using allocated support surfaces**

- **Reporting**: not reported

**Health-related quality of life (HRQOL)**

- **Reporting**: not reported

**Cost-effectiveness**

- **Reporting**: not reported

**Outcomes that are not considered in this review but reported in trials**:

- Interface pressure

---

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation                    | Unclear risk       | Quote: "randomised controlled trial (efficacy data)"
Comment: unclear risk because no information about randomisation method provided. |
| Allocation concealment                        | Unclear risk       | Quote: "Upon recruitment, the data collector opened the next opaque envelope in sequence to reveal to which mattress group the subject should be allocated"
Comment: unclear risk of bias because it is unclear if envelopes are concealed. |
<table>
<thead>
<tr>
<th>Blinding of participants and personnel (performance bias) All outcomes</th>
<th>Unclear risk</th>
<th>Comment: no information provided.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: no information provided.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>Outcome group: all outcomes (primary outcome) Comment: low risk of bias because no missing assumed.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>Comment: the study appears to be free of other sources of bias.</td>
</tr>
</tbody>
</table>

### Theaker 2005

#### Study characteristics

**Methods**

- **Study objective:** evaluate the effectiveness of 2 devices, the Hill-Rom Duo mattress and the KCI TheraPulse
- **Study design:** randomised controlled trial
- **Study grouping:** parallel group
- **Duration of follow-up:** 20 (5-127) days length of stay (2 weeks follow-up after study)
- **Number of arms:** 2
- **Single centre or multi-site:** single centre
- **Study start date and end date:** not described
- **Setting:** an intensive care unit of a hospital

**Participants**

- **Baseline characteristics**
  - **Inclusion criteria:** patients admitted to the intensive care unit and classified as being at high-risk.
  - **Exclusion criteria:** patients aged < 18 years and those with a pressure sore upon admission; those transferred from other ward areas or hospitals and had been nursed on a pressure-relieving device other than a Transfoam (Karomed – Division of Verna Ltd, Somerset, UK) or Therarest (KCI Medical Ltd) mattress within the last 7 days
  - **Sex (M:F):** 20:10 in KCI TheraPulse; 19:13 in Hill-Rom Duo
  - **Age (years):** 65 (26-85) across groups
  - **Baseline skin status:** at risk; free of existing ulcers
  - **Group difference:** no difference
  - **Total number of participants:** n = 62
  - **Unit of analysis:** individuals

**Interventions**

- **Intervention characteristics**
  - **KCI TheraPulse bed**
    - **Description of interventions:** KCI TheraPulse bed ... uses optional pulsation technology and low-air-loss to reduce tissue interface pressure
... consist of cells that are connected to a pump that inflate and deflate either at a 5-10 min time cycle or continuously

- **NPIAP S3I classification**: powered, alternating pressure (active) air surface; hybrid (active and reactive modes) low-air-loss surface
- **Co-interventions**: not described
- **Number of participants randomised**: n = 30
- **Number of participants analysed**: n = 30

### Hill-Rom Duo mattress

- **Description of interventions**: Hill-Rom Duo mattress ... uses either continuous or alternating low pressure modes ... consist of cells that are connected to a pump that inflate and deflate either at a 5-10 min time cycle or continuously
- **NPIAP S3I classification**: powered, alternating pressure (active) air surface; hybrid mattress (active and reactive modes)
- **Co-interventions**: not described
- **Number of participants randomised**: n = 32
- **Number of participants analysed**: n = 32

### Outcomes

**Proportion of participants developing a new pressure ulcer**

- **Outcome type**: binary
- **Time points**: not described
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: classified using the Lowthain scale
- **Definition (including ulcer stage)**: not described
- **Dropouts**: not described
- **Notes (e.g. other results reported)**: 3 of 30 in KCI TheraPulse; 6 of 32 in Hill-Rom Duo

**Time to pressure ulcer development**

- **Reporting**: not reported

**Support-surface-associated patient comfort**

- **Reporting**: not reported

**All reported adverse events using allocated support surfaces**

- **Reporting**: not reported

**Health-related quality of life (HRQOL)**

- **Reporting**: not reported

**Cost-effectiveness**

- **Reporting**: not reported

### Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation</td>
<td>Low risk</td>
<td>Quote: &quot;... randomly assigned to either a Hill-Rom Duo mattress or a KCI TheraPulse bed&quot;</td>
</tr>
<tr>
<td>(selection bias)</td>
<td></td>
<td>Quote: &quot;Selection of an unmarked envelope from a pile of envelopes by staff unconnected with the study formed the&quot;</td>
</tr>
</tbody>
</table>
### Whitney 1984

#### Study characteristics

| Methods | |  
| --- | --- | --- |
| **Study objective:** to provide data that will assist nurses in determining which mattress is the best choice for pressure sore prevention, and under which circumstances | **Study design:** randomised controlled trial |  
| **Study grouping:** parallel group | **Duration of follow-up:** the average length of study 8.9 days in alternating pressure mattress; 7.6 in foam mattress |  
| **Number of arms:** 2 | **Single centre or multi-site:** unspecified |  
| **Study start date and end date:** not described | **Setting:** 3 medical-surgical units. |  

| Participants | |  
| --- | --- | --- |
| **Baseline characteristics** | |  
| **Inclusion criteria:** patients on 3 medical-surgical units who were in bed for 20 out of 24 hours daily | |  
| **Exclusion criteria:** not described | |  
| **Sex (M:F):** not described | |  
| **Age (years):** mean 63.2 (range 19 to 91) | |  
| **Baseline skin status:** people with ulcers included (2 has serious decubiti on admission, 1 in each of the groups) | |  

---

<table>
<thead>
<tr>
<th>Allocation concealment (selection bias)</th>
<th>Unclear risk</th>
<th>Comment: &quot;Selection of an unmarked envelope from a pile of envelopes by staff unconnected with the study formed the randomisation process&quot; Comment: low risk of bias because it is likely that allocation was properly concealed.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Outcome group: all outcomes (primary outcome) Quote: &quot;... unblinded randomised prospective trial&quot; Comment: high risk of bias because it is clearly stated that this is an unblinded trial.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>Outcome group: all outcomes (primary outcome) Quote: &quot;If the nurse in charge of the patient’s care had a high level of suspicion that a pressure sore was present, the wound was digitally photographed. For study purposes, the digital photographs were anonymised and analysed subsequently by two independent Tissue Viability Nurses for confirmation of the existence of a pressure sore and assessment of severity&quot; Comment: low risk of bias because efforts were made to minimise the risk of detection bias.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>Outcome group: all outcomes (primary outcome) Comment: no attrition.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Comment: the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>Comment: the study appears to be free of other sources of bias.</td>
</tr>
<tr>
<td>Interventions</td>
<td>Group difference:</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Total number of participants</strong>: n = 51</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Unit of analysis</strong>: individuals</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Unit of randomisation (per patient)</strong>: individuals</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Interventions

**Alternating pressure mattress**
- **Description of interventions**: an alternating pressure mattress consisting of 134 three-inch diameter air cells with a 2.5-inch lift, and micro air vents for air circulation. Adjacent air cells inflated and deflated alternately every 3 minutes.
- **NPIAP S3I classification**: powered, alternating pressure (active) air surface
- **Co-interventions**: routine nursing care received, including turning every 2 hours
- **Number of participants randomised**: n = 25
- **Number of participants analysed**: n = 25

**Foam mattress**
- **Description of interventions**: a 4-inch polyurethane convoluted foam pad
- **NPIAP S3I classification**: non-powered, reactive foam surface; polyurethane convoluted foam
- **Co-interventions**: routine nursing care received, including turning every 2 hours
- **Number of participants randomised**: n = 26
- **Number of participants analysed**: n = 26

### Outcomes

**Proportion of participants developing a new pressure ulcer**
- **Outcome type**: binary
- **Time points**: not described
- **Reporting**: partially reported
- **Measurement method (e.g. scale, self-reporting)**: not described
- **Definition (including ulcer stage)**: changes in skin condition; the definition of pressure ulcers not given
- **Dropouts**: not described
- **Notes (e.g. other results reported)**: 20% of 25 with worse skin condition, 20% with better condition, and 60% with the same condition in alternating pressure mattress; 23.1% with worse skin condition, 19.2% with better condition, and 57.7% with the same condition in foam mattress

**Time to pressure ulcer development**
- **Reporting**: not reported

**Support-surface-associated patient comfort**
- **Reporting**: not reported

**All reported adverse events using allocated support surfaces**
- **Reporting**: not reported

**Health-related quality of life (HRQOL)**
- **Reporting**: not reported
Cost-effectiveness
• Reporting: not reported

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias)   | Unclear risk       | Quote: "26 were selected at random and placed in the foam mattress group, 25 in the AP mattress group"  
Comment: unclear risk of bias because it is unclear how the random sequence was generated. |
| Allocation concealment (selection bias)       | Unclear risk       | Comment: no information provided.                                                                                                                      |
| Blinding of participants and personnel        | High risk          | Outcome group: primary outcome  
Quote: "... the investigators, who assessed the patient and placed him/her in one of the two mattress groups"  
Comment: high risk of bias because it is likely the investigators performed this study. |
| Blinding of outcome assessment (detection bias)| High risk          | Outcome group: primary outcome  
Quote: "In most cases patients were assessed by two investigators as a team, and occasionally by only one of the investigators"  
Quote: "The investigators who rated patient risk and evaluated skin condition knew the mattress assignment of each patient, making investigator bias possible"  
Comment: high risk of bias because non-blinding of outcome assessment is clearly stated. |
| Incomplete outcome data (attrition bias)      | Unclear risk       | Comment: no information provided.                                                                                                                      |
| Selective reporting (reporting bias)          | Unclear risk       | Comment: no information provided.                                                                                                                      |
| Other bias                                    | Unclear risk       | Comment: no information provided.                                                                                                                      |

Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTRN12618000319279</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Allman 1987a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Andrews 1988</td>
<td>Ineligible study design - not a RCT</td>
</tr>
<tr>
<td>Anonymous 2006</td>
<td>Ineligible study design - review article</td>
</tr>
<tr>
<td>Bell 1993</td>
<td>Ineligible study design - not a RCT</td>
</tr>
<tr>
<td>Bennett 1998a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Berthe 2007a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Bliss 1966</td>
<td>Ineligible study design - not a RCT</td>
</tr>
<tr>
<td>Bliss 1993</td>
<td>Ineligible study design - review article</td>
</tr>
<tr>
<td>Bliss 1995a</td>
<td>Ineligible study design - review article</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>Bliss 2003</td>
<td>Reproduction of previous work</td>
</tr>
<tr>
<td>Bliss 2004</td>
<td>Commentary on a trial</td>
</tr>
<tr>
<td>Branom 1999</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Branom 2001</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Brown 2001</td>
<td>Summary of the Cochrane Review McInnes 2015</td>
</tr>
<tr>
<td>Bueno de Camargo 2018a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Cadue 2008</td>
<td>RCT on heel suspending devices</td>
</tr>
<tr>
<td>Caley 1994</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Cassino 2013</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Cassino 2013b</td>
<td>Incorrect randomisation method (alternation to allocate patients into groups)</td>
</tr>
<tr>
<td>Chaloner 2000b</td>
<td>Incorrect randomisation method (quasi-randomisation)</td>
</tr>
<tr>
<td>ChiCTR1800017466</td>
<td>Ineligible interventions</td>
</tr>
<tr>
<td>Chou 2013</td>
<td>Review articles</td>
</tr>
<tr>
<td>Cobb 1997b</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Collier 1996a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Cooper 1998a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Cummins 2019</td>
<td>Ineligible study design - quality improvement project without RCT design</td>
</tr>
<tr>
<td>Day 1993</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Defloor 2005</td>
<td>Ineligible interventions - different combinations of turning and support surfaces under evaluations</td>
</tr>
<tr>
<td>De Oliveira 2017</td>
<td>Review article</td>
</tr>
<tr>
<td>Devine 1995</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Economides 1995</td>
<td>Ineligible outcome (the breakdown of flaps after operations rather than the incidence of new ulcers or other outcomes)</td>
</tr>
<tr>
<td>Evans 2000</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Ewing 1964a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Exton-Smith 1982</td>
<td>Incorrect randomisation method (alternation to allocate patients into groups)</td>
</tr>
<tr>
<td>Ferrell 1993</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Ferrell 1995</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Feuchtinger 2006a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Feuchtinger 2006b</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Fleischer 1997</td>
<td>Ineligible study design</td>
</tr>
<tr>
<td>García Fernández 2004</td>
<td>Commentary on a RCT</td>
</tr>
<tr>
<td>Gazzaro 2008</td>
<td>Ineligible outcome (wound healing of flap surgery)</td>
</tr>
<tr>
<td>Gebhardt 1994a</td>
<td>Incorrect randomisation method (randomisation based on participants’ hospital numbers)</td>
</tr>
<tr>
<td>Gebhardt 1994b</td>
<td>Incorrect randomisation method (randomisation based on participants’ hospital numbers)</td>
</tr>
<tr>
<td>Gebhardt 1996</td>
<td>Incorrect randomisation method</td>
</tr>
<tr>
<td>Geelkerken 1994</td>
<td>Commentary</td>
</tr>
<tr>
<td>Goldstone 1982</td>
<td>Incorrect randomisation method</td>
</tr>
<tr>
<td>Gray 1994a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Gray 1998</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Greer 1988</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Groen 1999</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Gunningberg 2000a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Gunningberg 2001</td>
<td>Ineligible study design (cross-sectional design)</td>
</tr>
<tr>
<td>Haalboom 1994</td>
<td>Commentary</td>
</tr>
<tr>
<td>Hale 1990</td>
<td>Ineligible study design (cost analysis without RCT data)</td>
</tr>
<tr>
<td>Hampton 1998</td>
<td>Ineligible study design (not a RCT)</td>
</tr>
<tr>
<td>Hampton 1999</td>
<td>Ineligible study design (not a RCT)</td>
</tr>
<tr>
<td>Hawkins 1997</td>
<td>Ineligible study design (not a RCT)</td>
</tr>
<tr>
<td>Hofman 1994</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Holzgreve 1993</td>
<td>Ineligible study design (not a RCT)</td>
</tr>
<tr>
<td>Hommel 2008</td>
<td>Ineligible study design (not a RCT)</td>
</tr>
<tr>
<td>Hoshowsky 1994</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Hoskins 2007a</td>
<td>Summary of findings of Nixon 2006</td>
</tr>
<tr>
<td>Hoskins 2007b</td>
<td>Summary of findings of Nixon 2006</td>
</tr>
<tr>
<td>Huang 2013</td>
<td>Review article</td>
</tr>
<tr>
<td>Huang 2018</td>
<td>Ineligible interventions (head pad rather than beds or mattresses)</td>
</tr>
<tr>
<td>Hungerford 1998</td>
<td>Commentary on a RCT</td>
</tr>
<tr>
<td>Iglesias 2006</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Inman 1993</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>IRCT2015110619919N3</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>IRCT2016091129781N1</td>
<td>Ineligible interventions (cushions rather than beds or mattresses)</td>
</tr>
<tr>
<td>Ismail 2001</td>
<td>Ineligible interventions (a number of specific surfaces applied)</td>
</tr>
<tr>
<td>Jolley 2004a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>JPRN-UMIN000029680</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Kemp 1993</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Keogh 2001</td>
<td>Ineligible interventions (profiling bed rather than beds or mattresses)</td>
</tr>
<tr>
<td>Klein 1989</td>
<td>Review article</td>
</tr>
<tr>
<td>Lazzara 1991a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Lee 1974</td>
<td>Ineligible study design (not a RCT)</td>
</tr>
<tr>
<td>Maklebust 1988</td>
<td>Ineligible interventions (cushions rather than beds or mattresses)</td>
</tr>
<tr>
<td>Marutani 2019</td>
<td>Incorrect randomisation method</td>
</tr>
<tr>
<td>Mastrangelo 2010a</td>
<td>Treatment study</td>
</tr>
<tr>
<td>McGinnis 2011</td>
<td>Review article</td>
</tr>
<tr>
<td>McGowan 2000</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>McInnes 2015</td>
<td>Review article</td>
</tr>
<tr>
<td>McInnes 2018</td>
<td>Review article</td>
</tr>
<tr>
<td>Mendoza 2019</td>
<td>Ineligible participants and outcome (flap closure)</td>
</tr>
<tr>
<td>Mistiaen 2010</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Mistiaen 2010a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Nakahara 2012</td>
<td>Ineligible study design (not a RCT)</td>
</tr>
<tr>
<td>NCT01402765</td>
<td>Ineligible outcome (interface pressure)</td>
</tr>
<tr>
<td>NCT02565797</td>
<td>Ineligible study design (case control design)</td>
</tr>
<tr>
<td>NCT02634892</td>
<td>RCT comparing reactive air surfaces versus standard hospital surfaces, withdrawn due to funding issue</td>
</tr>
<tr>
<td>NCT02735135</td>
<td>RCT withdrawn due to methodological difficulties</td>
</tr>
<tr>
<td>NCT03048357</td>
<td>Ineligible interventions (rotation therapy versus turning)</td>
</tr>
<tr>
<td>NCT03211910</td>
<td>Ineligible interventions (not beds or mattresses)</td>
</tr>
<tr>
<td>NCT03351049</td>
<td>Ineligible interventions (reactive air surfaces versus reactive surfaces)</td>
</tr>
<tr>
<td>Nixon 1998</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Ooka 1995</td>
<td>Ineligible study design (not a RCT)</td>
</tr>
<tr>
<td>Osterbrink 2005</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Ozyurek 2015</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Park 2017a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Rae 2018</td>
<td>Review article</td>
</tr>
<tr>
<td>Reddy 2006</td>
<td>Review article</td>
</tr>
<tr>
<td>Reddy 2008</td>
<td>Review article</td>
</tr>
<tr>
<td>Ricci 2013a</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Ricci 2013b</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Rithalia 1995</td>
<td>Ineligible participants (healthy people)</td>
</tr>
<tr>
<td>Russell 1999</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Russell 2000b</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Russell 2000c</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Russell 2003a</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Russell 2003b</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Santy 1994</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Santy 1995</td>
<td>Review article</td>
</tr>
<tr>
<td>Scheffel 2011</td>
<td>Summary of a review</td>
</tr>
<tr>
<td>Schultz 1999a</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Scott 2000</td>
<td>Ineligible interventions</td>
</tr>
<tr>
<td>Scott-Williams 2006</td>
<td>Ineligible study design (not a RCT)</td>
</tr>
<tr>
<td>Serraes 2018</td>
<td>Review article</td>
</tr>
<tr>
<td>Shakibamehr 2019</td>
<td>Ineligible interventions (cushions rather than beds or mattresses)</td>
</tr>
<tr>
<td>Sharp 2007</td>
<td>Ineligible study design</td>
</tr>
<tr>
<td>Shi 2018a</td>
<td>Review article</td>
</tr>
<tr>
<td>Smith 2013</td>
<td>Review article</td>
</tr>
<tr>
<td>Stannard 1993</td>
<td>Commentary on a RCT</td>
</tr>
<tr>
<td>Sterzi 2003</td>
<td>Ineligible study design (not a RCT)</td>
</tr>
<tr>
<td>Strauss 1991</td>
<td>Treatment study</td>
</tr>
<tr>
<td>Takala 1994</td>
<td>Ineligible study design (not a RCT)</td>
</tr>
<tr>
<td>Takala 1996</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Tewes 1993</td>
<td>Review article</td>
</tr>
<tr>
<td>Vanderwee 2005</td>
<td>Ineligible intervention (alternating pressure active air surfaces without turning versus foam surfaces plus turning)</td>
</tr>
</tbody>
</table>
### Study Reasons for Exclusion

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Van Leen 2011</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Van Leen 2013</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Van Leen 2018</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Van Rijswijk 1994</td>
<td>Commentary</td>
</tr>
<tr>
<td>Vermette 2012</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Vyhlidal 1997</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Wallace 2009</td>
<td>Review article</td>
</tr>
<tr>
<td>Whittingham 1999</td>
<td>Ineligible interventions (i.e. comparisons of interventions that are ineligible for inclusion in this review)</td>
</tr>
<tr>
<td>Yao 2018</td>
<td>Review article</td>
</tr>
</tbody>
</table>

### Characteristics of Studies Awaiting Classification

#### Chaloner 2000

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Not available</td>
</tr>
<tr>
<td>Participants</td>
<td>Not available</td>
</tr>
<tr>
<td>Interventions</td>
<td>Two types of alternating pressure air surfaces</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Not available</td>
</tr>
<tr>
<td>Notes</td>
<td>Unable to obtain the full-text</td>
</tr>
</tbody>
</table>

#### Gardner 2008

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial (two arm)</td>
</tr>
<tr>
<td>Inclusion criteria</td>
<td>patients at risk of pressure injury (Waterlow score &gt; 9)</td>
</tr>
<tr>
<td>Exclusion criteria</td>
<td>under 16 years, unable to tolerate extended time lying supine and with sacral pressure injury of Stage 2 or above</td>
</tr>
<tr>
<td>Number of participants</td>
<td>66</td>
</tr>
<tr>
<td>Age</td>
<td>on average 68 (12.7) years</td>
</tr>
<tr>
<td>Gender (M:F)</td>
<td>34:25</td>
</tr>
<tr>
<td>Baseline skin status</td>
<td>at risk of ulcer (Waterlow score &gt; 9), without existing severe ulcers</td>
</tr>
<tr>
<td>Interventions</td>
<td>Airflotation and Ruby mattress</td>
</tr>
<tr>
<td></td>
<td>- Description of interventions: alternating pressure air mattress</td>
</tr>
<tr>
<td></td>
<td>- NPIAP S3I classification: powered, alternating pressure, active, air surface</td>
</tr>
<tr>
<td></td>
<td>ComfortPlus mattress</td>
</tr>
<tr>
<td></td>
<td>- Description of interventions: unspecified, probably foam surfaces</td>
</tr>
<tr>
<td></td>
<td>- NPIAP S3I classification: non-powered, reactive, foam surfaces</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Outcomes of the interest of this review</td>
</tr>
<tr>
<td></td>
<td>- Unspecified</td>
</tr>
<tr>
<td></td>
<td>Outcomes unrelated to this review</td>
</tr>
</tbody>
</table>
- Interface pressure

### Notes

**Henn 2004**
- Methods: Not available
- Participants: Not available
- Interventions: Alternating pressure air surfaces and a type of surface that cannot be defined
- Outcomes: Not available
- Notes: Unable to obtain the full-text

**Knight 1999**
- Methods: Not available
- Participants: Not available
- Interventions: Pressure-relieving surfaces that cannot be defined
- Outcomes: Not available
- Notes: Unable to obtain the full-text

**Mastrangelo 2010b**
- Methods: Not available
- Participants: Not available
- Interventions: ‘Anti-decubitus lesion mattress cover’ that cannot be defined
- Outcomes: Not available
- Notes: Unable to obtain the full-text

**Melland 1998**
- Methods: Not available
- Participants: Not available
- Interventions: ‘Freedom bed’ that cannot be defined
- Outcomes: Not available
- Notes: Unable to obtain the full-text

### Appendices

**Appendix 1. Full details of classifications of support surfaces**

<table>
<thead>
<tr>
<th>Overarching class of support surface (as used in this review)</th>
<th>Corresponding subclasses of support surfaces used in Shi 2018a</th>
<th>Descriptions of support surfaces</th>
<th>Selected examples (with example brands where possible)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cochrane Wounds Group, Shi, Shi, Dumville, Cullum, Rhodes, Jammali... https://archie.cochrane.org/sections/documents/view?version=z2105051...
### Reactive air surfaces

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powered/non-powered reactive air surfaces</td>
<td>A group of support surfaces constructed of air-cells, which redistribute body weight over a maximum surface area (i.e. has reactive pressure redistribution mode), with or without the requirement for electrical power.</td>
<td>Static air mattress overlay, dry flotation mattress (e.g. Roho, Sofflex), static air mattress (e.g. EHOB), and static mode of Duo 2 mattress.</td>
</tr>
<tr>
<td>Powered/non-powered reactive low-air-loss air surfaces</td>
<td>A group of support surfaces made of air-cells, which have reactive pressure redistribution modes and a low-air-loss function, with or without the requirement for electrical power.</td>
<td>Low-air-loss hydrotherapy.</td>
</tr>
<tr>
<td>Powered reactive air-fluidised surfaces</td>
<td>A group of support surfaces made of air-cells, which have reactive pressure redistribution modes and an air-fluidised function, with the requirement for electrical power.</td>
<td>Air-fluidised bed (e.g. Clinitron).</td>
</tr>
</tbody>
</table>

### Foam surfaces

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-powered reactive foam surfaces</td>
<td>A group of support surfaces made of foam materials, which have a reactive pressure redistribution function, without the requirement for electrical power.</td>
<td>Convoluted foam overlay (or pad), elastic foam overlay (e.g. Aiartex, microfluid static overlay), polyether foam pad, foam mattress replacement (e.g. MAXIFLOAT), solid foam overlay, viscoelastic foam mattress/overlay (e.g. Tempur, CONFOR-Med, Aktion, Thermo).</td>
</tr>
</tbody>
</table>

### Alternative reactive support surfaces (non-foam or air-filled)

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactive fibre surfaces</td>
<td>A group of support surfaces made of fibre materials, which have a reactive pressure redistribution function, without the requirement for electrical power.</td>
<td>Silicone (e.g. Spenco) overlay/pad.</td>
</tr>
<tr>
<td>Reactive gel surfaces</td>
<td>A group of support surfaces made of gel materials, which have a reactive pressure redistribution function, without the requirement for electrical power.</td>
<td>Gel mattress, gel pad used in operating theatre.</td>
</tr>
<tr>
<td>Reactive sheepskin surfaces</td>
<td>A group of support surfaces made of sheepskin, which have a reactive pressure redistribution function, without the requirement for electrical power.</td>
<td>Australian Medical Sheepskins overlay.</td>
</tr>
<tr>
<td>Reactive water surfaces</td>
<td>A group of support surfaces based on water, which has the capability of a reactive pressure redistribution function, without the requirement for electrical power.</td>
<td>Water mattress.</td>
</tr>
<tr>
<td>Active air surfaces</td>
<td>A group of support surfaces made of air-cells, which mechanically alternate the pressure beneath the body to</td>
<td>Alternating pressure-relieving air mattress (e.g. Nimbus II, Cairwave, Airwave, MicroPulse), large-</td>
</tr>
</tbody>
</table>
reduce the duration of the applied pressure (mainly via inflating and deflating to alternately change the contact area between support surfaces and the body; i.e. alternating pressure (or active) mode), with the requirement for electrical power.

<table>
<thead>
<tr>
<th>Powered active low-air-loss air surfaces</th>
<th>A group of support surfaces made of air-cells, which have the capability of alternating pressure redistribution as well as low air loss for drying local skin, with the requirement for electrical power.</th>
<th>Alternating pressure low-air-loss air mattress.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powered hybrid system air surfaces</td>
<td>A group of support surfaces made of air-cells, which offer both reactive and active pressure redistribution modes, with the requirement for electrical power.</td>
<td>Foam mattress with dynamic and static modes (e.g. Softform Premier Active).</td>
</tr>
<tr>
<td>Powered hybrid system low-air-loss air surfaces</td>
<td>A group of support surfaces made of air-cells, which offer both reactive and active pressure redistribution modes as well as a low-air-loss function, with the requirement for electrical power.</td>
<td>Stand-alone bed unit with alternating pressure, static modes and low air-loss (e.g. TheraPulse).</td>
</tr>
<tr>
<td>Standard hospital surfaces</td>
<td>A group of support surfaces made of any materials, used as-usual in a hospital and without reactive or active pressure redistribution capabilities, nor any other functions (e.g. low air loss, or air-fluidised).</td>
<td>Standard hospital (foam) mattress, National Health Service Contract hospital mattress, standard operating theatre surface configuration, standard bed unit and usual care.</td>
</tr>
</tbody>
</table>

**Appendix 2. Search strategies**

**Cochrane Wounds Specialised Register**

1 MESH DESCRIPTOR beds EXPLODE ALL AND INREGISTER
2 mattress* AND INREGISTER
3 (foam or transfoam) AND INREGISTER
4 overlay* AND INREGISTER
5 (pad or pads) AND INREGISTER
6 gel AND INREGISTER
7 (pressure NEXT relie*) AND INREGISTER
8 (pressure NEXT reduc*) AND INREGISTER
9 (pressure NEXT alleviat*) AND INREGISTER
10 ("low pressure” near2 device*) AND INREGISTER


142 of 203

11/05/2021, 09:04
11 ("low pressure" near2 support) AND INREGISTER
12 (constant near2 pressure) AND INREGISTER
13 "static air" AND INREGISTER
14 (alternat* next pressure) AND INREGISTER
15 (air next suspension*) AND INREGISTER
16 (air next bag*) AND INREGISTER
17 (water next suspension*) AND INREGISTER
18 sheepskin AND INREGISTER
19 (turn* or tilt*) next (bed* or frame*) AND INREGISTER
20 kinetic next (therapy or table*) AND INREGISTER
21 (net next bed*) AND INREGISTER
22 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 AND INREGISTER
23 MESH DESCRIPTOR Pressure Ulcer EXPLODE ALL AND INREGISTER
24 (pressure next (ulcer* or sore* or injur*)) AND INREGISTER
25 (decubitus next (ulcer* or sore*)) AND INREGISTER
26 ((bed next sore*) or bedsore*) AND INREGISTER
27 #23 OR #24 OR #25 OR #26 AND INREGISTER
28 #22 AND #27 AND INREGISTER

The Cochrane Central Register of Controlled Clinical Trials (CENTRAL)

#1 MeSH descriptor: [Beds] explode all trees
#2 mattress*:ti,ab,kw
#3 (foam or transfoam):ti,ab,kw
#4 overlay*:ti,ab,kw
#5 "pad" or "pads":ti,ab,kw
#6 "gel":ti,ab,kw
#7 (pressure next relie*):ti,ab,kw
#8 (pressure next reduc*):ti,ab,kw
#9 (pressure next alleviat*):ti,ab,kw
#10 ("low pressure" near/2 device*):ti,ab,kw
#11 ("low pressure" near/2 support):ti,ab,kw
#12 (constant near/2 pressure):ti,ab,kw
#13 "static air":ti,ab,kw
#14 (alternat* next pressure):ti,ab,kw
#15 (air next suspension*):ti,ab,kw
#16 (air next bag*):ti,ab,kw
#17 (water next suspension*):ti,ab,kw
#18 sheepskin:ti,ab,kw
#19 (turn* or tilt*) next (bed* or frame*):ti,ab,kw
#20 kinetic next (therapy or table*):ti,ab,kw
#21 (net next bed*):ti,ab,kw
#22 {or #1-#21}
#23 MeSH descriptor: [Pressure Ulcer] explode all trees
#24 (pressure next (ulcer* or sore* or injur*)):ti,ab,kw
#25 (decubitus next (ulcer* or sore*)):ti,ab,kw
#26 ((bed next sore*) or bedsore*):ti,ab,kw
#27 {or #23-#26}
#28 (#22 and #27) in Trials

**Ovid MEDLINE**

1 exp Beds/
2 mattress*.mp.
3 (foam or transfoam).mp.
4 overlay*.mp.
5 (pad or pads).ti,ab.
6 gel.ti,ab.
7 pressure relie*.mp.
8 pressure reduc*.mp.
9 pressure alleviat*.mp.
10 (low pressure adj2 device*).mp.
11 (low pressure adj2 support).mp.
12 (constant adj2 pressure).mp.
13 static air.mp.
14 (alternat* adj pressure).mp.
15 air suspension*.mp.
16 air bag*.mp.
17 water suspension*.mp.
18 sheepskin.mp.
19 ((turn* or tilt*) adj (bed* or frame*)).mp.
20 (kinetic adj (therapy or table*)).mp.
21 net bed*.mp.
22 or/1-21
23 exp Pressure Ulcer/
24 (pressure adj (ulcer* or sore*)).mp.
25 (decubitus adj (ulcer* or sore*)).mp.
26 (bed adj (ulcer* or sore*)).mp.
27 or/23-26
28 and/22,27
29 randomized controlled trial.pt.
30 controlled clinical trial.pt.
31 randomi?ed.ab.
32 placebo.ab.
33 clinical trials as topic.sh.
34 randomly.ab.
35 trial.ti.
36 or/29-35
37 exp animals/ not humans.sh.
38 36 not 37
39 28 and 38

Ovid Embase
1 exp Bed/
2 mattress*.mp.
3 (foam or transfoam).mp.
4 overlay*.mp.
5 (pad or pads).ti,ab.
6 gel.ti,ab.
7 pressure relie*.mp.
8 pressure reduc*.mp.
9 pressure alleviat*.mp.
10 (low pressure adj2 device*).mp.
11 (low pressure adj2 support).mp.
12 (constant adj2 pressure).mp.
13 static air.mp.
14 (alternat* adj pressure).mp.
15 air suspension*.mp.
16 air bag*.mp.
17 water suspension*.mp.
18 sheepskin.mp.
19 ((turn* or tilt*) adj (bed* or frame*)).mp.
20 (kinetic adj (therapy or table*)).mp.
21 net bed*.mp.
22 or/1-21
23 exp Decubitus/
24 (pressure adj (ulcer* or sore*)).mp.
25 (decubitus adj (ulcer* or sore*)).mp.
26 (bed adj (ulcer* or sore*)).mp.
27 or/23-26
28 and/22,27
29 Randomized controlled trials/
30 Controlled clinical study/
31 Single-Blind Method/
32 Double-Blind Method/
33 Crossover Procedure/
34 (random* or factorial* or crossover* or cross over* or cross-over* or placebo* or assign* or allocat* or volunteer*).ti,ab.
35 (doubl* adj blind*).ti,ab.
36 (singl* adj blind*).ti,ab.
37 or/29-36
38 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
39 human/ or human cell/
40 and/38-39
41 38 not 40
42 37 not 41
43 28 and 42

**EBSCO CINAHL Plus**

S50 S26 AND S49
S49 S48 NOT S47
S48 S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41
S47 S45 NOT S46
S46 MH (human)
S45 S42 OR S43 OR S44
S44 TI (animal model*)
S43 MH (animal studies)
S42 MH animals+
S41 AB (cluster W3 RCT)
S40 MH (crossover design) OR MH (comparative studies)
S39 AB (control W5 group)
S38 PT (randomized controlled trial)
S37 MH (placebos)
S36 MH (sample size) AND AB (assigned OR allocated OR control)
S35 TI (trial)
S34 AB (random*)
S33 TI (randomised OR randomized)
S32 MH cluster sample
S31 MH pretest-posttest design
S30 MH random assignment
S29 MH single-blind studies
S28 MH double-blind studies
S27 MH randomized controlled trials
S26 S20 AND S25
S25 S21 OR S22 OR S23 OR S24
S24 TI decubitus or AB decubitus
S23 TI ( bed sore* or bedsore* ) or AB ( bed sore* or bedsore* )
S22 TI ( pressure ulcer* or pressure sore* ) or AB ( pressure ulcer* or pressure sore* )
S21 (MH "Pressure Ulcer")
S20 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19
S19 TI net bed* or AB net bed*
S18 TI ( kinetic therapy or kinetic table* ) or AB ( kinetic therapy or kinetic table* )
S17 TI ( turn* bed* or tilt* bed* ) or AB ( turn* frame* or tilt* frame* )
S16 TI sheepskin OR AB sheepskin
S15 TI water suspension or AB water suspension
S14 TI air bag* or AB air bag*
S13 TI air suspension or AB air suspension
S12 TI alternat* pressure or AB alternat* pressure
S11 TI static air or AB static air
S10 TI constant N2 pressure or AB constant N2 pressure
S9 TI low pressure N2 support or AB low pressure N2 support
Appendix 3. Risk of bias

1 'Risk of bias' assessment in individually randomised controlled trials

1. Was the allocation sequence randomly generated?

Low risk of bias
The study authors describe a random component in the sequence generation
process such as referring to a random number table, using a computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice, drawing of lots.

**High risk of bias**

The study authors describe a non-random component in the sequence generation process. Usually, the description would involve some systematic, non-random approach, for example, sequence generated by odd or even date of birth, sequence generated by some rule based on date (or day) of admission, sequence generated by some rule based on hospital or clinic record number.

**Unclear**

Insufficient information about the sequence generation process to permit judgement of low or high risk of bias.

2. **Was the treatment allocation adequately concealed?**

**Low risk of bias**

Participants and study authors enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.

**High risk of bias**

Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on using an open random allocation schedule (e.g. a list of random numbers), assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered), alternation or rotation, date of birth, case record number, any other explicitly unconcealed procedure.

**Unclear**

Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.

3. **Blinding: was knowledge of the allocated interventions by participants and personnel adequately prevented during the study?**

**Low risk of bias**

Any one of the following.

- No blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding.
- Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

**High risk of bias**
Any one of the following.
- No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding.
- Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
- Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.

**Unclear**
Any one of the following.
- Insufficient information to permit judgement of low or high risk of bias.
- The study did not address this outcome.

4. **Blinding: was knowledge of the allocated interventions by outcome assessors adequately prevented during the study?**

**Low risk of bias**
Any one of the following.
- No blinding, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding.
- Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

**High risk of bias**
Any one of the following.
- No blinding or incomplete blinding, and the outcome measurement is likely to be influenced by lack of blinding.
- Blinding of outcome assessment attempted, but likely that the blinding could have been broken.

**Unclear**
Any one of the following.
- Insufficient information to permit judgement of low or high risk of bias.
- The study did not address this outcome.

5. **Were incomplete outcome data adequately addressed?**

**Low risk of bias**
Any one of the following.
- No missing outcome data.
- Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias).
- Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
- For dichotomous outcome data, the proportion of missing outcomes compared
with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate.

- For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size.

- Missing data have been imputed using appropriate methods.

**High risk of bias**

Any one of the following.

- Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups.

- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate.

- For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size.

- ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.

- Potentially inappropriate application of simple imputation.

**Unclear**

Any one of the following.

- Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated, no reasons for missing data provided).

- The study did not address this outcome.

**6. Are reports of the study free of suggestion of selective outcome reporting?**

**Low risk of bias**

Any of the following.

- The study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way.

- The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon).

**High risk of bias**

Any one of the following.

- Not all of the study’s prespecified primary outcomes have been reported.

- One or more primary outcomes are reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified.
One or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect).

One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.

The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

**Unclear**

Insufficient information to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.

7. Other sources of potential bias

**Low risk of bias**

The study appears to be free of other sources of bias.

**High risk of bias**

There is at least one important risk of bias. For example, the study:

- had a potential source of bias related to the specific study design used; or
- has been claimed to have been fraudulent; or
- had some other problem.

**Unclear**

There may be a risk of bias, but there is either:

- insufficient information to assess whether an important risk of bias exists; or
- insufficient rationale or evidence that an identified problem will introduce bias

2 'Risk of bias' assessment in cluster-randomised controlled trials (cluster-RCTs)

1. Recruitment bias

Recruitment bias (or identification bias) is the bias that occurs in cluster-RCTs if the personnel recruiting participants know individuals' allocation, even when the allocation of clusters has been concealed appropriately. The knowledge of the allocation of clusters may lead to bias because the individuals' recruitment in cluster trials is often behind the clusters' allocation to different interventions; and the knowledge of allocation can determine whether individuals are recruited selectively.

This bias can be judged through considering the following questions.

- Were all the individual participants identified/recruited before randomisation of clusters?
- Is it likely that selection of participants was affected by knowledge of the intervention?
- Were there baseline imbalances that suggest differential identification or recruitment of individual participants between arms?
2. Baseline imbalance

Baseline imbalance between intervention groups can occur due to chance, problems with randomisation, or identification/recruitment bias. The issue of recruitment bias has been considered above.

In terms of study design, the risk of chance baseline imbalance can be reduced by the use of stratified or pair-matched randomisation. Minimisation — an equivalent technique to randomisation — can be used to achieve better balance in cluster characteristics between intervention groups if there is a small number of clusters.

Concern about the influence of baseline imbalance can be reduced if studies report the baseline comparability of clusters, or statistical adjustment for baseline characteristics.

3. Loss of clusters

Similar to missing outcome data in individually randomised trials, bias can occur if clusters are completely lost from a cluster-RCT, and are omitted from the analysis.

The amount of missing data, the reasons for missingness and the way of analysing data given the missingness should be considered in assessing the possibility of bias.

4. Incorrect analysis

Data analyses, which do not take the clustering into account, in cluster-RCTs will be incorrect. Such analyses lead to a 'unit of analysis error' and over-precise results (too small standard error) and too small P values. Though these analyses will not result in biased estimates of effect, they (if not correctly adjusted) will lead to too much weight allocated to cluster trials in a meta-analysis.

Note that the issue of analysis may not lead to concern any more and will not be considered substantial if approximate methods are used by review authors to address clustering in data analysis.

5. Comparability with individually randomised trials

In the case that a meta-analysis includes, for example, both cluster and individually randomised trials, potential differences in the intervention effects between different trial designs should be considered. This is because the 'contamination' of intervention effects may occur in cluster-RCTs, which would lead to underestimates of effect. The contamination could be known as a 'herd effect': that is, within clusters, individuals' compliance with using an intervention may be enhanced, which in return affects the estimation of effect.

Appendix 4. Interventions used in the included studies

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Specific alternating pressure (active) air surfaces</th>
<th>Specific comparators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternating</td>
<td>Alternating pressure (active) air surfaces versus another type of alternating pressure</td>
<td></td>
</tr>
<tr>
<td>pressure (active)</td>
<td>(active) air surface</td>
<td></td>
</tr>
<tr>
<td>Ballard 1997</td>
<td>Debut MR mattress (SSI Hill-Rom), with a one-in-four alternating cycle lasting 30</td>
<td>Nimbus (HNE Huntleigh, with a 10-minute cycle).</td>
</tr>
<tr>
<td>Authors</td>
<td>Description</td>
<td>Control</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Demarre 2012</td>
<td>Alternating air mattress with the multi-stage inflation and deflation of air cells (Hill-Rom ClinActiv, with 10- to 12-minute cycle times)</td>
<td>Standard alternating air mattress (Hill-Rom Alto mattress, with a 10-minute cycle time)</td>
</tr>
<tr>
<td>Gray 2008</td>
<td>Softform Premier Active Mattress (consisting of a foam mattress with a dynamic underlay having a 10-minute cycle)</td>
<td>Standard alternating pressure air mattress</td>
</tr>
<tr>
<td>Grindley 1996</td>
<td>Nimbus II mattress (Huntleigh Healthcare, with a 10-minute cycle)</td>
<td>Pegasus Airwave (with a 7.5-minute cycle)</td>
</tr>
<tr>
<td>Hampton 1997</td>
<td>Cairwave Therapy System (Pegasus Airwave Ltd, with a 7.5-minute cycle and a 30-minute static mode)</td>
<td>Pegasus Airwave</td>
</tr>
<tr>
<td>Nixon 2006</td>
<td>Alternating pressure replacement mattress (with a 7.5- to 30-minute cycle time)</td>
<td>Alternating pressure overlay (with a 7.5- to 30-minute cycle time)</td>
</tr>
<tr>
<td>Pring 1998</td>
<td>Nimbus II (with a 10-minute cycle)</td>
<td>Two comparators were used</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pegasus Airwave</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Quattro DC2000 (operating in a one-in-four sequential cycle)</td>
</tr>
<tr>
<td>Rafter 2011</td>
<td>Dyna-Form Mercury Advance (with a 10-minute cycle), consisting of the foam inside the alternating cells and being a static mattress combined with a dynamic alternating system</td>
<td>Softform Premier Active, consisting of the foam inside the alternating cells and being a static mattress combined with a dynamic alternating system.</td>
</tr>
<tr>
<td>Taylor 1999</td>
<td>Pegasus Trinova (an integrated dynamic mattress and chair cushion that have a static mattress in combination with a dynamic alternating system, with a 7.5-minute cycle)</td>
<td>Alternative dynamic mattress system (with a 10-minute cycle)</td>
</tr>
<tr>
<td>Theaker 2005</td>
<td>KCI TheraPulse bed (with low-air-loss feature), either applied at a 5- to 10-minute alternating pressure cycle or continuously static</td>
<td>Hill-Rom Duo mattress, either applied at a 5- to 10-minute alternating pressure cycle or continuously static</td>
</tr>
<tr>
<td>Bliss 1995</td>
<td>Large cell Ripple bed (with a 10-minute interval of alternating pressure)</td>
<td>Three types of foam mattresses, each as an arm:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Groove contoured foam overlay</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Modular Propad</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Preventix foam mattress.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The characteristics (e.g. densities) of these foam were unspecified.</td>
</tr>
<tr>
<td>Nixon 2019</td>
<td>Alternating pressure air mattress (with a 7.5- to 30-minute cycle time)</td>
<td>High-specification foam mattress (high-density foam, and/or viscoelastic (memory) foam)</td>
</tr>
<tr>
<td>Author</td>
<td>Type</td>
<td>Details</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Rosenthal 2003</td>
<td>Low-air-loss suspension bed (TheraPulse bed)</td>
<td>A medium density polyurethane foam overlay</td>
</tr>
<tr>
<td>Sauvage 2017</td>
<td>Alternating pressure air mattress (Axtair One, with a 6-minute cycle)</td>
<td>Viscoelastic foam mattress (ALOVA mattress, high resilience foam with a density &gt; 34 kg/m³ and an upper layer of viscoelastic foam of density &gt; 75 kg/m³)</td>
</tr>
<tr>
<td>Stapleton 1986</td>
<td>Large Cell Ripple (Talley)</td>
<td>Polyether foam pad, more details not specified</td>
</tr>
<tr>
<td>Whitney 1984</td>
<td>Alternating pressure mattress (with a 3-minute cycle)</td>
<td>A polyurethane convoluted foam pad, more details not specified</td>
</tr>
<tr>
<td></td>
<td>Alternating pressure (active) air surfaces versus reactive air surfaces</td>
<td></td>
</tr>
<tr>
<td>Beeckman 2019</td>
<td>A range of alternating air pressure support surfaces (with a 3– to 30-minute cycle time)</td>
<td>Static air support surfaces (Repose)</td>
</tr>
<tr>
<td>Cavicchioli 2007</td>
<td>Alternating low pressure modality of Duo2 (Hill-Rom)</td>
<td>Continuous low pressure modality of Duo2</td>
</tr>
<tr>
<td>Finnegan 2008</td>
<td>A specialised alternating therapy support surface (Nimbus 3 Professional, Huntleigh Healthcare LLC)</td>
<td>Air-fluidised bed system (Clinitron, Hill-Rom Inc)</td>
</tr>
<tr>
<td>Jiang 2014</td>
<td>Dynamic air mattress (Sanma mattress manufacturing), more details not specified</td>
<td>Static air mattress (WAFFLE® static air mattress, EHOB)</td>
</tr>
<tr>
<td>Malbrain 2010</td>
<td>NIMBUS 3 mattress (with a 10-minute cycle)</td>
<td>ROHO dry floatation mattress overlay</td>
</tr>
<tr>
<td>Price 1999</td>
<td>Dynamic flotation mattress NIMBUS II plus Alpha TranCell system</td>
<td>Repose</td>
</tr>
<tr>
<td>Sideranko 1992</td>
<td>Alternating air mattress (Lapidus Airfloat System)</td>
<td>Static air mattresses (Gaymar Sof Care bed cushion)</td>
</tr>
<tr>
<td></td>
<td>Alternating pressure (active) air surfaces versus reactive water surfaces</td>
<td></td>
</tr>
<tr>
<td>Andersen 1982</td>
<td>Alternating-pressure air-mattress, more details not specified</td>
<td>Water-filled mattresses, more details not specified</td>
</tr>
<tr>
<td>Bliss 1995</td>
<td>Large cell Ripple bed (with a 10-minute interval of alternating pressure)</td>
<td>Ardo Watersoft</td>
</tr>
<tr>
<td>Sideranko 1992</td>
<td>Alternating air mattress (Lapidus Airfloat System)</td>
<td>Water mattress (Lotus PXM 3666)</td>
</tr>
<tr>
<td></td>
<td>Alternating pressure (active) air surfaces versus reactive fibre surfaces</td>
<td></td>
</tr>
<tr>
<td>Bliss 1995</td>
<td>Large cell Ripple bed (with a 10-minute interval of alternating pressure)</td>
<td>Two types of fibre-filled mattresses, each as an arm:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Spenco (cotton hollow-core fibre-filled)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Surgicgoods Hollowcore Mattress fibre-filled pad</td>
</tr>
<tr>
<td>Conine 1990</td>
<td>Alternating pressure (active) air mattress, more details not specified</td>
<td>Silicore mattress overlay (consisting of siliconised hollow fibers)</td>
</tr>
<tr>
<td>Daechsel 1985</td>
<td>Alternating pressure (active) air mattress, more details not specified</td>
<td>Silicore mattress overlay (consisting of siliconised hollow fibers)</td>
</tr>
<tr>
<td>Stapleton 1986</td>
<td>Large cell Ripple (Talley)</td>
<td>Spenco pad</td>
</tr>
<tr>
<td>Alternating pressure (active) air surfaces in operating tables and subsequently on ward beds versus reactive gel surfaces used on operating tables followed by foam surfaces applied on ward beds</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aronovitch 1999</td>
<td>MicroPulse System used during and after operations</td>
<td>Conventional management consisting of a gel pad (Action Pad) used in the operating room and a foam mattress or overlay used on the hospital bed</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>MicroPulse System used during and after operations</td>
<td>Conventional management consisting of a gel pad (Action Pad) used in the operating room and a foam mattress or overlay used on the hospital bed</td>
</tr>
<tr>
<td>Alternating pressure (active) air surfaces versus standard hospital surfaces</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andersen 1982</td>
<td>Alternating-pressure air-mattress, more details not specified</td>
<td>Standard hospital mattress, more details not specified</td>
</tr>
<tr>
<td>Bliss 1967</td>
<td>Large-celled Ripple bed consisting of 14 large cells and with a cycle of four to five minutes</td>
<td>Standard hospital mattress, more details not specified</td>
</tr>
<tr>
<td>Laurent 1998</td>
<td>Comparison (a): Nimbus used in ICU and standard mattress applied postoperatively (details of standard mattress not specified)</td>
<td>Comparison (a): standard hospital mattresses used in both ICU and post-operation (details of standard mattress not specified)</td>
</tr>
<tr>
<td></td>
<td>Comparison (b): Nimbus in ICU and Tempur (CLP) used postoperatively</td>
<td>Comparison (b): standard mattress in ICU and Tempur (CLP) postoperatively (details of standard mattress not specified)</td>
</tr>
<tr>
<td>Sanada 2003</td>
<td>Two types of alternating pressure (active) air surfaces, both alternating pressure at 5-minute intervals, each as an arm:</td>
<td>Standard hospital mattress made of polyester (Paracare®)</td>
</tr>
<tr>
<td></td>
<td>- Double-layer air-cell overlay (Tricell®)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Single-layer air-cell overlay (Air Doctor®)</td>
<td></td>
</tr>
</tbody>
</table>

### Appendix 5. Results of studies that used undefined surfaces

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparison: Alternating pressure (active) air surfaces compared with undefined 'standard hospital surfaces'</td>
<td></td>
</tr>
</tbody>
</table>
All four studies (830 participants) reported this outcome and consistently showed that alternating pressure (active) air surfaces could reduce the proportion of participants developing a new pressure ulcer compared with the undefined ‘standard hospital surfaces’ (Andersen 1982; Bliss 1967; Laurent 1998; Sanada 2003).

### Appendix 6. Sensitivity analyses

<table>
<thead>
<tr>
<th>Sensitivity analysis</th>
<th>Studies</th>
<th>Participants</th>
<th>Statistical Method</th>
<th>Effect Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparison: Alternating pressure (active) air surfaces compared with foam surfaces</td>
<td><strong>Outcome: Proportion of participants developing a new pressure ulcer</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Disentangling the single intervention</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Alternating pressure (active) air surfaces compared with foam surfaces</strong></td>
<td>3</td>
<td>2171</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.63 [0.34, 1.17]</td>
</tr>
<tr>
<td><strong>Alternating pressure (active) low-air-loss surfaces compared with foam surfaces</strong></td>
<td>1</td>
<td>76</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Not estimable</td>
</tr>
<tr>
<td><strong>Fixed-effect model used</strong></td>
<td>4</td>
<td>2247</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.71 [0.55, 0.93]</td>
</tr>
<tr>
<td><strong>Time to pressure ulcer development considered as our primary outcome</strong></td>
<td>2</td>
<td></td>
<td>Hazard Ratio (IV, Random, 95% CI)</td>
<td>0.41 [0.10, 1.64]</td>
</tr>
<tr>
<td><strong>Post hoc analysis using pressure ulcer incidence data from Nixon 2019 only</strong></td>
<td>1</td>
<td>2029</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.78 [0.57, 1.05]</td>
</tr>
<tr>
<td>Comparison: Alternating pressure (active) air surfaces compared with reactive air surfaces</td>
<td><strong>Outcome: Proportion of participants developing a new pressure ulcer</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Complete case data used</td>
<td>6</td>
<td>1611</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>1.62 [0.90, 2.89]</td>
</tr>
<tr>
<td>• Fixed-effect model used</td>
<td>6</td>
<td>1648</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.72 [1.00, 2.97]</td>
</tr>
<tr>
<td>• Time to pressure ulcer development considered as the primary outcome</td>
<td>1</td>
<td>308</td>
<td>Hazard Ratio (IV, Random, 95% CI)</td>
<td>2.25 [1.05, 4.83]</td>
</tr>
<tr>
<td>Comparison: Alternating pressure (active) air surfaces compared with reactive water surfaces</td>
<td><strong>Outcome: Proportion of participants developing a new pressure ulcer</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Fixed-effect model</td>
<td>2</td>
<td>358</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.21 [0.53, 2.78]</td>
</tr>
<tr>
<td>Comparison: Alternating pressure (active) air surfaces compared with reactive fibre surfaces</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Outcome: Proportion of participants developing a new pressure ulcer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>● Complete case data analysed</td>
<td>3</td>
<td>246</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.93 [0.72, 1.20]</td>
</tr>
<tr>
<td>● Fixed-effect model used</td>
<td>3</td>
<td>285</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.90 [0.68, 1.20]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comparison: Alternating pressure (active) air surfaces in operating tables and subsequently on ward beds compared with reactive gel surfaces used on operating tables followed by foam surfaces applied on ward beds</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome: Proportion of participants developing a new pressure ulcer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>● Fixed-effect model used</td>
<td>2</td>
<td>415</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
</tr>
</tbody>
</table>

---

**References**

**References to studies included in this review**

**Andersen 1982 {published data only}**  
16775153

16775154

**Aronovitch 1999 {published data only}**  
16775155

16775156

16775157

**Ballard 1997 {published data only}**  
16775158

16775159

**Beeckman 2019 {published data only}**  
16775160


NCT03597750. Comparison of static air support devices (Repose©) and alternating-pressure devices in the prevention of pressure ulcers. ClinicalTrials.gov/show/NCT03597750. 16775163

Bliss 1967 {published data only}

16775164


Bliss 1995 {published data only}

16775166

* Bliss MR. Preventing pressure sores in elderly patients: a comparison of seven mattress overlays. Age and Ageing 1995;24:297-302. 16775167


Cavicchioli 2007 {published data only}

16775169


Conine 1990 {published data only}

16775171


Daechsel 1985 {published data only}

16775174

Daechsel D, Conine TA. Special mattresses: effectiveness in preventing

Demarre 2012 {published data only}
16775176


Demarre L, Vanderwee K, Beeckman D, Defloor T. Pressure ulcer prevention: randomized controlled trial comparing the effect of a standard alternating pressure air mattress and a alternating low pressure air mattress with gradual inflation and deflation. EWMA Journal 2010;10(2):44. 16775178


Finnegan 2008 {published data only}
16775181


Gray 2008 {published data only}
16775183


Grindley 1996 {published data only}
16775185


Hampton 1997 {published data only}
16775187

Hampton S. Evaluation of the new Cairwave Therapy System in one hospital

**Jiang 2014 {published data only}**

16775189


**Laurent 1998 {published data only}**

16775191


**Malbrain 2010 {published data only}**

16775193


**Nixon 2006 {published data only}**

16775195

ISRCTN78646179. Randomised controlled trial comparing alternating pressure overlays with alternating pressure mattresses for pressure sore prevention and treatment. isrctn.com/ISRCTN78646179. 16775196


Nixon 2019 {published data only}


Phillips 1999 {published data only}


Price 1999 {published data only}


Pring 1998 {published data only}

Rafter 2011 {published data only} 16775217

Rosenthal 2003 {published data only} 16775219

Russell 2000 {published data only} 16775221
Lichtenstein S. A 7 day comparative randomized parallel single centre study to determine the safety and efficacy of the Micropulse system for the prevention of pressure ulcers. Micropulse 1997. 16775223

Sanada 2003 {published data only} 16775225

Sauvage 2017 {published data only} 16775228

**Sideranko 1992 {published data only}**

16775230


**Stapleton 1986 {published data only}**

16775232


**Taylor 1999 {published data only}**

16775234


**Theaker 2005 {published data only}**

16775236


**Whitney 1984 {published data only}**

16775238


**References to studies excluded from this review**

**ACTRN12618000319279 {published data only}**

16775240


**Allman 1987a {published data only}**

16775242

Andrews 1988 {published data only}

16775244


Anonymous 2006 {published data only}

16775247


Bell 1993 {published data only}

16775249


Bennett 1998a {published data only}

16775251


Berthe 2007a {published data only}

16775253


Bliss 1966 {published data only}

16775255


Bliss 1993 {published data only}

16775257

Bliss 1995a \{published data only\}


Bliss 2003 \{published data only\}


Bliss 2004 \{published data only\}


Branom 1999 \{published data only\}


Branom 2001 \{published data only\}


Brown 2001 \{published data only\}


Bueno de Camargo 2018a \{published data only\}

NCT02844166 . Support surfaces to prevent pressure injuries. clinicaltrials.gov/show/NCT02844166. 16775273

Cadue 2008 \{published data only\}

16775274

Caley 1994 {published data only}

16775276


Cassino 2013 {published data only}

16775278


Cassino 2013b {published data only}

16775280


Chaloner 2000b {published data only}

16775282


ChiCTR1800017466 {published data only}

16775284


Chou 2013 {published data only}

16775286


Cobb 1997b {unpublished data only}
Cobb GA, Yoder LH, Warren JB. Pressure ulcers: patient outcomes on a KinAir bed or EHOB waffle mattress. TriService Nursing Research Program (TSNRP) 1997. 16775289

**Collier 1996a {published data only}**

16775290


**Cooper 1998a {published data only}**

16775292


**Cummins 2019 {published data only}**

16775294


**Day 1993 {published data only}**

16775296


**Defloor 2005 {published data only}**

16775298


**De Oliveira 2017 {published data only}**

16775300


**Devine 1995 {published data only}**

16775302

Devine B. Alternating pressure air mattresses in the management of established

**Economides 1995 {published data only}**

16775304


**Evans 2000 {published data only}**

16775306


**Ewing 1964a {published data only}**

16775308


**Exton-Smith 1982 {published data only}**

16775310


**Ferrell 1993 {published data only}**

16775312


**Ferrell 1995 {published data only}**

16775314


**Feuchtinger 2006a {published data only}**

16775316

Feuchtinger J. Preventing decubitus ulcer in heart surgery interventions: visco-elastic foam layer on the operating room table—a study [Dekubitusprävention während kardiochirurgischer Eingriffe: Viskoelastische Schaumstoffauflage
Feuchtinger 2006b {published data only}


Fleischer 1997 {published data only}


García Fernández 2004 {published data only}


Gazzerro 2008 {published data only}


Gebhardt 1994a {published data only}


* Gebhardt K. A randomized trial of alternating pressure (AP) and constant low pressure (CLP) supports for the prevention of pressure sores. Journal of Tissue Viability 1994;4(3):93. 16775328

Gebhardt 1994b {published data only}

Gebhardt KS, Bliss MR, Winwright PL. A randomised controlled trial to compare the efficacy of alternating and constant low pressure supports for preventing pressure sores in an intensive care unit (ICU). Clinical Science 1994. 16775330
**Gebhardt 1996 {published data only}**

16775331


**Geelkerken 1994 {published data only}**

16775333


**Goldstone 1982 {published data only}**

16775335


**Gray 1994a {published data only}**

16775337


**Gray 1998 {published data only}**

16775342


**Greer 1988 {published data only}**

16775345

Groen 1999 {published data only}
16775347
Groen HW, Groenier KH, Schuling J. Comparative study of a foam mattress and a water mattress. Journal of Wound Care 1999;8(7):333-5. 16775348

Gunningberg 2000a {published data only}
16775349

Gunningberg 2001 {published data only}
16775351

Haalboom 1994 {published data only}
16775353

Hale 1990 {published data only}
16775355

Hampton 1998 {published data only}
16775357

Hampton 1999 {published data only}
16775359

Hawkins 1997 {published data only}
16775361
Hawkins JE. The effectiveness of pressure-reducing table pads as an intervention to reduce the risk of intraoperatively acquired pressure sores. Military Medicine 1997;162(11):759-61. 16775362 [PMID: 9358724]

Hofman 1994 {published data only}
16775363

Holzgreve 1993 {published data only}
16775365

Hommel 2008 {published data only}
16775367

Hoshowsky 1994 {published data only}
16775369

Hoskins 2007a {published data only}
16775371
Hoskins A. Alternating pressure mattresses were more cost effective than alternating pressure overlays for preventing pressure ulcers. Evidence-Based Nursing 2007;10(1):23. 16775372 [PMID: 17218297]

Hoskins 2007b {published data only}
16775373
Hoskins A. Similar proportions of patients developed pressure ulcers on alternating pressure overlays and alternating pressure mattresses. Evidence-Based Nursing 2007;10(1):22. 16775374 [PMID: 17218296]

Huang 2013 {published data only}
16775375
Huang 2018 {published data only}

16775377

Hungerford 1998 {published data only}

16775379
Hungerford K. A specially designed foam mattress replacement reduced pressure ulcers in nursing home residents. Evidence-Based Nursing 1998;1(2):51. 16775380

Iglesias 2006 {published data only}

16775381

Inman 1993 {published data only}

16775385

IRCT2015110619919N3 {published data only}

16775387
IRCT2015110619919N3. The effect of silicone protective pad on pressure ulcer. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2015110619919N3 2016. 16775388

IRCT2016091129781N1 {published data only}

16775389
IRCT2016091129781N1. Comparison gum gel and foam cushions to prevent bedsores. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016091129781N1. 16775390
Ismail 2001 {published data only}

16775391

Ismail ZB. Comparative study between the use of a pressure relieving overlay mattress and other mattresses commonly used by homebound patients in the community. Singapore Nursing Journal 2001;28(2):13-6. 16775392

Jolley 2004a {published data only}

16775393


Jolley DJ. A multilevel analysis of three randomised controlled trials of the Australian Medical Sheepskin in the prevention of sacral pressure ulcers. Medical Journal of Australia 2011;194(2):104. 16775395

JPRN-UMIN000029680 {published data only}

16775396

JPRN-UMIN000029680. Effects of robotic mattress on pressure ulcer healing, comfort level among pressure ulcer patients, and nursing work load: a randomized controlled trial. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000029680. 16775397

Kemp 1993 {published data only}

16775398


Keogh 2001 {published data only}

16775400


Klein 1989 {published data only}

16775402


Lazzara 1991a {published data only}

16775404

Lee 1974 {published data only}
16775406

Maklebust 1988 {published data only}
16775408

Marutani 2019 {published data only}
16775410

Mastrangelo 2010a {published data only}
16775413

McGinnis 2011 {published data only}
16775415

McGowan 2000 {published data only}
16775417
McGowan S, Montgomery K, Jolley D, Wright R. The role of sheepskins in preventing pressure ulcers in elderly orthopaedic patients. Primary Intention 2000:127-34. 16775418
McInnes 2015 {published data only}

16775419


McInnes 2018 {published data only}

16775421


Mendoza 2019 {published data only}

16775423


Mistiaen 2010 {published data only}

16775425


NTR878 . Cost-effectiveness of the Australian Medical Sheepskin for the prevention of pressure ulcers in somatic nursing home clients. trialregister.nl/trial/864. 16775430

Mistiaen 2010a {published data only}

16775431


Nakahara 2012 {published data only}

16775436

NCT01402765 {published data only}

16775438
NCT01402765. Interface pressure measures for mattresses: Nimbus 3 versus Summit. clinicaltrials.gov/show/NCT01402765. 16775439

NCT02565797 {published data only}

16775440
NCT02565797. Comparative prevention-effectiveness trial of DabirAIR overlay system. ClinicalTrials.gov/show/NCT02565797. 16775441

NCT02634892 {published data only}

16775442
NCT02634892. Pressure Redistributing Overlay with Targeted Cooling Technology (PRO-TECT) for pressure ulcer prevention. ClinicalTrials.gov/show/NCT02634892. 16775443
NCT02735135 {published data only}

16775444

NCT02735135. Comparison of 2 mattresses for the prevention of bedsores by measuring skin pressure in the sacral area. clinicaltrials.gov/show/NCT02735135. 16775445

NCT03048357 {published data only}

16775446

NCT03048357. Effectiveness of Freedom Bed compared to manual turning in prevention of pressure injuries in persons with limited mobility due to traumatic brain injury and/or spinal cord injury. clinicaltrials.gov/show/NCT03048357. 16775447

NCT03211910 {published data only}

16775448

NCT03211910. Sacral Savers: study of prevention and enhanced healing of sacral and trochanteric ulcers. ClinicalTrials.gov/show/NCT03211910. 16775449

NCT03351049 {published data only}

16775450

NCT03351049. An RCT on support surfaces for pressure ulcer prevention. ClinicalTrials.gov/show/NCT03351049. 16775451

Nixon 1998 {published data only}

16775452


ISRCTN43076542. Pressure sore risk in the operating department. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN43076542. 16775456

Ooka 1995 {published data only}

16775458


Osterbrink 2005 {published data only}

16775460


Ozyurek 2015 {published data only}

16775462


Park 2017a {published data only}

16775464


Rae 2018 {published data only}

16775466


Reddy 2006 {published data only}

16775468


Reddy 2008 {published data only}

16775470


Ricci 2013a {published data only}

Ricci 2013b {published data only}

16775474

Rithalia 1995 {published data only}

16775476

Russell 1999 {published data only}

16775478

Russell 2000b {published data only}

16775481

Russell 2000c {published data only}

16775483

Russell 2003a {published data only}

16775485
Russell 2003b {published data only}

16775487

Santy 1994 {published data only}

16775489
Santy JE, Butler MK, Whyman JD. A comparison study of 6 types of hospital mattress to determine which most effectively reduces the incidence of pressure sores in elderly patients with hip fractures in a District General Hospital. Report to Northern & Yorkshire Regional Health Authority 1994. 16775490

Santy 1995 {published data only}

16775491

Scheffel 2011 {published data only}

16775493

Schultz 1999a {published data only}

16775495
Schultz AA. Study results: prediction and prevention of pressure ulcers in surgical patients. Advances in Wound Care 1998;11(3):11. 16775497

Scott 2000 {published data only}

16775498

Scott-Williams 2006 {published data only}

16775500
Scott-Williams S, Lummas AC. Perioperative pressure ulcer assessment and prevention efficacy study of a multilayered pad for the operating room. Ostomy/Wound Management 2006;52(4):110-1. 16775501
Serraes 2018 {published data only}
16775502

Shakibamehr 2019 {published data only}
16775504

Sharp 2007 {published data only}
16775506
Sharp A. Pilot study to compare the incidence of pressure ulceration on two therapeutic support surfaces in elderly care. In: 17th Conference of the European Wound Management Association; 2007 May 2-4; Glasgow (Scotland). 2007:Oral presentation 114, 73.

Shi 2018a {published data only}
16775508

Smith 2013 {published data only}
16775510

Stannard 1993 {published data only}
16775512
Stannard D. Commentary on the role of support surfaces and patient attributes in preventing pressure ulcers in elderly patients. AACN Nursing Scan In Critical Care 1993;3(6):2-3. 16775513

Sterzi 2003 {published data only}
16775514
Strauss 1991 {published data only}

16775516


Takala 1994 {published data only}

16775518


Takala 1996 {published data only}

16775520


Tewes 1993 {published data only}

16775522


Vanderwee 2005 {published data only}

16775524


Van Leen 2011 {published data only}

16775526


Van Leen 2013 {published data only}

16775528

Van Leen M, Hovius S, Halfens R, Neyens J, Schols J. Pressure relief with

Van Leen 2018 {published data only}

16775530

NTR4557 . Is lowering of shear and friction forces (cost)effective for prevention of pressure ulcers? trialregister.nl/trial/4435. 16775531


Van Rijswijk 1994 {published data only}

16775533


Vermette 2012 {published data only}

16775535


Vyhlidal 1997 {published data only}

16775537


Wallace 2009 {published data only}

16775539


Whittingham 1999 {published data only}

16775541


Yao 2018 {published data only}

16775543

References to studies awaiting assessment

Chaloner 2000 {published data only}

16775545

Gardner 2008 {published data only}

16775547

Henn 2004 {published data only}

16775549

Knight 1999 {published data only}

16775551

Mastrangelo 2010b {published data only}

16775553

Melland 1998 {published data only}

16775555

Additional references

Baumgarten 2009


Borenstein 2009


Borenstein 2017


Cipriani 2013


Clark 2011


Cullum 2016


Deeks 2019


Demarré 2015


Eldridge 2019

EPUAP/NPIAP/PPPIA 2019


Espejo 2018


Essex 2009


Fletcher 2015


Glanville 2019


Gorecki 2009


Gorecki 2013


GRADEpro GDT [Computer program]

GRADEpro GDT. Version accessed 30 September 2019. Hamilton (ON):
Gray 2018


Guest 2018

Guest JF, Fuller GW, Vowden P, Vowden KR. Cohort study evaluating pressure ulcer management in clinical practice in the UK following initial presentation in the community: costs and outcomes. BMJ Open 2018;8(7):e021769. [PMID: 30049697]

Guyatt 2008


Guyatt 2011


Herdman 2011


Higgins 2003


Higgins 2017


Higgins 2019


**Hróbjartsson 2012**


**Kirkham 2018**


**Lefebvre 2019**


**Li 2019**


**Nguyen 2015**


**NICE 2014**


**NPIAP 2016**


**NPIAP S3I 2007**

Ouzzani 2016


Page 2019


Parmar 1998


Peryer 2019


Peters 2008


Review Manager 2020 [Computer program]


Riley 2011


Salanti 2012


Salanti 2014

Schoonhoven 2007


Schulz 1995


Schünemann 2019


Shi 2018b


Shi 2018c


Theisen 2012


Thompson 1999


Tierney 2007


Ware 1992

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36).

World Health Organization 2019


Wounds International 2010


References to other published versions of this review

Shi 2020


Figures and tables

Additional tables

<table>
<thead>
<tr>
<th>Table 1</th>
<th>All reported adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study ID</td>
<td>Alternating pressure (active) air surfaces</td>
</tr>
<tr>
<td>Nixon 2019</td>
<td>Related and unexpected serious adverse events: 0</td>
</tr>
<tr>
<td></td>
<td>Expected adverse events/ serious adverse events: 163/1017</td>
</tr>
<tr>
<td></td>
<td>The proportion of deaths: 82/1017, 8.1%</td>
</tr>
<tr>
<td></td>
<td>Re-admission rates: 82/1017, 8.1%</td>
</tr>
<tr>
<td></td>
<td>Fall rates: 152/1017, 14.9%</td>
</tr>
<tr>
<td>Rosenthal 2003</td>
<td>See comment</td>
</tr>
<tr>
<td>Sauvage 2017</td>
<td>• Serious adverse events: 2 deaths, a massive septic shock with acute pulmonary oedema and a decompensation of an insulin-dependent diabetes.</td>
</tr>
</tbody>
</table>
20 adverse events, including 2 discomforts.

Table 2
Support-surface-associated patient comfort results reported in the included studies

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Results</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparison: alternating pressure (active) air surfaces compared with reactive air surfaces</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cavicchioli 2007</td>
<td>Dropouts due to discomfort and/or not agreeing to use the assigned modality in alternating low pressure: 5 of 86</td>
<td>Dropouts due to discomfort and/or not agreeing to use the assigned modality in continuous low pressure: 4 of 84</td>
</tr>
<tr>
<td>Finnegan 2008</td>
<td>Comfortable: 11/15 Uncomfortable: 2/15 No view: 2/15</td>
<td>Comfortable: 4/18 Uncomfortable: 7/18 No view: 7/18</td>
</tr>
<tr>
<td>Jiang 2014</td>
<td>More than the median (score of 4): 68/462 Less than the median (score of 4): 394/462</td>
<td>More than the median (score of 4): 68/482 Less than the median (score of 4): 414/482</td>
</tr>
<tr>
<td>Price 1999</td>
<td>Mean 60 (SD 25) for 26 individuals in NIMBUS II</td>
<td>Mean 67 (SD 18) for 24 individuals in Repose</td>
</tr>
<tr>
<td>Comparison: alternating pressure (active) air surfaces compared with another type of alternating pressure (active) air surfaces</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ballard 1997</td>
<td>5 of 10 (50.0%) participants responded that the Debut mattress was more comfortable than their normal bed</td>
<td>6 of 10 (60.0%) participants responded that the Nimbus mattress was less comfortable than their normal bed</td>
</tr>
<tr>
<td>Demarre 2012</td>
<td>Withdrawing due to discomfort in Multi-stage group: 11/298 (3.7%)</td>
<td>Withdrawing due to discomfort in Single-stage: 16/312 (5.1%)</td>
</tr>
<tr>
<td>Grindley 1996</td>
<td>10 responded Nimbus II is more comfortable and 2 responded Pegasus Airwave is more comfortable. 4 responded no preference</td>
<td>10 responded Nimbus II is more comfortable and 2 responded Pegasus Airwave is more comfortable. 4 responded no preference</td>
</tr>
<tr>
<td>Nixon 2006</td>
<td>Alternating pressure air mattress: 186/982 (18.9%)</td>
<td>Alternating pressure air overlay: 230/989 (23.3%)</td>
</tr>
</tbody>
</table>
Refused to be nursed on Nimbus II due to discomfort: 4 patients (10.3%).

Refused to be nursed on Pegasus Airwave due to discomfort: 20 (51.3%).

Refused to be nursed on Quattro DC2000: No data.

Significant differences between the 3 mattresses in relation to comfort (one-way analysis of variance $F = 18.28$, $P < 0.01$). Quattro DC2000 more comfortable than Nimbus II and Pegasus Airwave ($P < 0.01$ in both cases). Data prior to cross-over of the n-of-1 trial were not available.

Patients’ opinions on the comfort aspects of Dyna-Form Mercury Advance: all 3 slept well.

Patients’ opinions on the comfort aspects of Softform Premier Active: all 3 slept well.

Patients rated perceptions of their comfort upon the mattress and their overall opinion of the support surface using Likert-type scales.

Six of ten patients responded to the comfort questionnaire.

Only one arm has data (18/22 completed the questionnaire).

### Table 3

**Pressure ulcer incidence results reported in studies that compared different types of alternating pressure (active) air surfaces**

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Results</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demarre 2012</td>
<td>Alternating pressure (active) air surfaces (Hill-Rom ClinActiv)</td>
<td>• Proportion of participants developing a new pressure ulcer: $17/298$ (5.7%)</td>
</tr>
<tr>
<td></td>
<td>• Time to pressure ulcer development: median time 5.0 days (IQR 3.0 to 8.5)</td>
<td>• Proportion of participants developing a new pressure ulcer: $18/312$ (5.8%)</td>
</tr>
<tr>
<td></td>
<td>Alternating pressure (active) air surfaces (Hill-Rom Alto mattress)</td>
<td>• Time to pressure ulcer development: median 8.0 days (IQR 3.0 to 8.8)</td>
</tr>
<tr>
<td></td>
<td>• Proportion of participants developing a new pressure ulcer: $4/50$ (7.7%)</td>
<td>• Proportion of participants developing a new pressure ulcer: $RR 1.00$ (95% CI 0.26 to 3.78).</td>
</tr>
<tr>
<td>Gray 2008</td>
<td>Alternating pressure (active) air surfaces (hybrid air surfaces: Softform Premier Active Mattress)</td>
<td>• Proportion of participants developing a new pressure ulcer: $RR 0.99$ (95% CI 0.52 to 1.88).</td>
</tr>
<tr>
<td></td>
<td>Alternating pressure (active) air surfaces</td>
<td>• Time to pressure ulcer development: Mann-Whitney U-test = 113, $P = 0.182$ for median time to ulcer incidence; Kaplan Meier plot reported (log-rank Chi² = 0.013, df = 1, $P = 0.911$); HR 0.96 (95% CI 0.50 to 1.87) estimated by the review authors using the methods of Tierney 2007.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>Pressure Surface Type</th>
<th>Proportion of Participants Developing a New Pressure Ulcer</th>
<th>Time to Pressure Ulcer Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hampton 1997</td>
<td>Alternating pressure (active) air surfaces (hybrid air surfaces: Cairwave Therapy System)</td>
<td>Proportion of participants developing a new pressure ulcer: 0/36 (0.0%)</td>
<td></td>
</tr>
<tr>
<td>Nixon 2006</td>
<td>Alternating pressure (active) air surfaces (mattresses)</td>
<td>Proportion of participants developing a new pressure ulcer: 101/982 (10.3%)</td>
<td>Time to pressure ulcer development: see comments</td>
</tr>
<tr>
<td>Rafter 2011</td>
<td>Alternating pressure (active) air surfaces (hybrid air surfaces: Dyna-Form Mercury Advance)</td>
<td>Proportion of participants developing a new pressure ulcer: 0/5 (0.0%)</td>
<td>Proportion of participants developing a new pressure ulcer: RR 0.20 (95% CI 0.01 to 3.35)</td>
</tr>
<tr>
<td>Taylor 1999</td>
<td>Alternating pressure (active) air surfaces (hybrid air surfaces: Pegasus Trinova)</td>
<td>Proportion of participants developing a new pressure ulcer: 0/22 (0.0%)</td>
<td>Proportion of participants developing a new pressure ulcer: RR 0.20 (95% CI 0.01 to 3.94)</td>
</tr>
<tr>
<td>Theaker 2005</td>
<td>Alternating pressure (active) air surfaces (hybrid air surfaces: KCI TheraPulse bed with low-air-loss feature)</td>
<td>Proportion of participants developing a new pressure ulcer: 3/30 (10.0%)</td>
<td>Proportion of participants developing a new pressure ulcer: RR 0.53 (95% CI 0.15 to 1.94)</td>
</tr>
</tbody>
</table>

IQR - interquartile range

Proportion of participants developing a new pressure ulcer: summary estimate not estimable due to the lack of data.

Proportion of participants developing a new pressure ulcer: RR 0.96 (95% CI 0.74 to 1.24).

Time to pressure ulcer development: log-rank test P = 0.759; HR 0.96 (95% CI 0.73 to 1.26) estimated by the review authors using the methods of Tierney 2007.
Figure 1
Study flow diagram
1624 records identified through electronic searches (including 1164 from electronic databases and 460 from trial registries) + 6 additional records identified through other sources (including scanning the reference lists of 14 relevant systematic reviews identified in database searches; tracing relevant trial registry records) = 1412 records after duplicates removed.

1412 records screened

1178 records excluded

(1) 140 studies with 165 full-text articles excluded, with reasons:
- Irrelevant and ineligible interventions (e.g. other beds or mattresses, heel suspending devices, cushions; 53 studies)
- Ineligible study design (e.g. non-RCT, reviews, commentary articles; 52 studies)
- Studies focused on the treatment rather than prevention of pressure ulcers (20 studies)
- Incorrect randomisation and non-randomised methods (eight studies)
- Studies with ineligible outcomes (e.g. the breakdown of flaps after operations, interface pressure; four studies)
- Clinical trials that were withdrawn (two studies)
- Ineligible participants (healthy subjects; one study)

(2) Eight duplicates identified in...
Figure 2
Risk of bias summary: review authors’ judgements about each risk of bias item for each included study
<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation (selection bias)</th>
<th>Allocation concealment (selection bias)</th>
<th>Blinding of participants and personnel (performance bias): All outcomes</th>
<th>Blinding of outcome assessment (detection bias): All outcomes</th>
<th>Incomplete outcome data (attrition bias): All outcomes</th>
<th>Selective reporting (reporting bias)</th>
<th>Other bias</th>
</tr>
</thead>
</table>

Cochrane Wounds Group, Shi, Shi, Dumville, Cullum, Rhodes, Jamali... https://archie.cochrane.org/sections/documents/view?version=2105051...
Figure 3
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies

Analysis 1.1
Comparison 1: Alternating pressure (active) air surfaces compared with reactive foam surfaces, Outcome 1: Proportion of participants developing a new pressure ulcer

Analysis 1.2
Comparison 1: Alternating pressure (active) air surfaces compared with reactive foam surfaces, Outcome 2: Time to pressure ulcer development

Analysis 1.3
### Comparison 1: Alternating pressure (active) air surfaces compared with reactive foam surfaces, Outcome 3: Health-related quality of life

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Alternating pressure (active) air surfaces</th>
<th>Foam surfaces</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>1.3.1 90-day EQ-5D-5L</td>
<td>Nixon 2019</td>
<td>0.52</td>
<td>0.21</td>
<td>118</td>
<td>0.52</td>
</tr>
<tr>
<td></td>
<td>Subtotal (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td>Test for overall effect: Z = 0.00 (P = 1.00)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.3.2 90-day PU-QoL-UI</td>
<td>Nixon 2019</td>
<td>0.69</td>
<td>0.13</td>
<td>107</td>
<td>0.69</td>
</tr>
<tr>
<td></td>
<td>Subtotal (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td>Test for overall effect: Z = 0.00 (P = 1.00)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Analysis 2.1

#### Comparison 2: Alternating pressure (active) air surfaces compared with reactive air surfaces, Outcome 1: Proportion of participants developing a new pressure ulcer

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Alternating pressure (active) air surfaces</th>
<th>Reactive air surfaces</th>
<th>Risk Ratio</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Beeckman 2019</td>
<td>18</td>
<td>154</td>
<td>8</td>
<td>154</td>
</tr>
<tr>
<td>Cavicchilò 2007</td>
<td>2</td>
<td>86</td>
<td>1</td>
<td>84</td>
</tr>
<tr>
<td>Finnegan 2008</td>
<td>0</td>
<td>19</td>
<td>0</td>
<td>21</td>
</tr>
<tr>
<td>Jang 2014</td>
<td>5</td>
<td>512</td>
<td>6</td>
<td>562</td>
</tr>
<tr>
<td>Malbrán 2010</td>
<td>2</td>
<td>8</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Sideranko 1992</td>
<td>5</td>
<td>20</td>
<td>1</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Total (95% CI)</td>
<td>799</td>
<td>849</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heterogeneity: Tau² = 0.01; Chi² = 4.11, df = 4 (P = 0.39); I² = 3%</td>
<td>Test for overall effect: Z = 1.61 (P = 0.11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Analysis 2.2

#### Comparison 2: Alternating pressure (active) air surfaces compared with reactive air surfaces, Outcome 2: Time to pressure ulcer development

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>log[Hazard Ratio]</th>
<th>SE</th>
<th>Weight</th>
<th>Hazard Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beeckman 2019</td>
<td>0.81</td>
<td>0.39</td>
<td>100.0%</td>
<td>2.25 [1.05, 4.83]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>100.0%</td>
<td>2.25 [1.05, 4.83]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td>Test for overall effect: Z = 2.08 (P = 0.04)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Analysis 3.1

#### Comparison 3: Alternating pressure (active) air surfaces compared with reactive water surfaces, Outcome 1: Proportion of participants developing a new pressure ulcer

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Alternating pressure (active) air surfaces</th>
<th>Reactive water surfaces</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
</tr>
<tr>
<td>Andersen 1982</td>
<td>7</td>
<td>166</td>
<td>7</td>
</tr>
<tr>
<td>Sideranko 1992</td>
<td>5</td>
<td>20</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Total (95% CI)</td>
<td>186</td>
<td>172</td>
</tr>
<tr>
<td>Heterogeneity: Tau² = 0.00; Chi² = 0.78, df = 1 (P = 0.39); P = 0%</td>
<td>Test for overall effect: Z = 0.44 (P = 0.66)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences: Not applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Analysis 4.1
### Comparison 4: Alternating pressure (active) air surfaces compared with reactive fibre surfaces, Outcome 1: Proportion of participants developing a new pressure ulcer

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Alternating pressure (active) air surfaces</th>
<th>Reactive fibre surfaces</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conine 1990</td>
<td>39</td>
<td>93</td>
<td>45</td>
<td>76.7% 0.88 (0.64, 1.21)</td>
</tr>
<tr>
<td>Daechsel 1985</td>
<td>4</td>
<td>16</td>
<td>4</td>
<td>5.4%  1.00 (0.30, 3.32)</td>
</tr>
<tr>
<td>Stapleton 1986</td>
<td>11</td>
<td>32</td>
<td>12</td>
<td>17.9% 0.97 (0.50, 1.89)</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>141</strong></td>
<td><strong>144</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>0.90 (0.68, 1.19)</strong></td>
</tr>
</tbody>
</table>

Heterogeneity: $\tau^2 = 0.00$, $\chi^2 = 0.11$, $df = 2$ ($P = 0.95$); $I^2 = 0$

Test for overall effect: $Z = 0.75$ ($P = 0.46$)

Test for subgroup differences: Not applicable

### Analysis 5.1

Comparison 5: Alternating pressure (active) air surfaces on operating tables and subsequently on ward beds compared with reactive gel surfaces on operating tables followed by foam surfaces on ward beds, Outcome 1: Proportion of participants developing a new pressure ulcer

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Alternating pressure (active) air surfaces</th>
<th>Reactive gel surfaces</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aronovitch 1999</td>
<td>1</td>
<td>112</td>
<td>7</td>
<td>35.6% 0.13 (0.02, 1.07)</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2</td>
<td>98</td>
<td>7</td>
<td>64.4% 0.29 (0.06, 1.37)</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>210</strong></td>
<td><strong>205</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>0.22 (0.06, 0.76)</strong></td>
</tr>
</tbody>
</table>

Heterogeneity: $\tau^2 = 0.00$, $\chi^2 = 0.35$, $df = 1$ ($P = 0.55$); $I^2 = 0$

Test for overall effect: $Z = 2.39$ ($P = 0.02$)

Test for subgroup differences: Not applicable